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Abstract 
Multi-drug resistant tuberculosis is a major global health problem. Viet Nam is 14th among 27 
MDR-TB high burden countries with an estimated about 5,100 MDR-TB cases among notified 
TB cases per year. Management ofMDR-TB in Viet Nam is one of the main objectives of the 
TB control programme. This thesis provides an understanding of the current situation of 
MDRlXDR-TB in Vietnam and its control policies focusing on case finding strategy, targeting 
groups for MDR-TB screening. MDR-TB contacts, one of the high risk groups recommended 
by the WHO is a focus of this thesis. The thesis presents screening practices of household 
contacts of TB patients, feasibility of TB contact investigations, and to identify challenges and 
solutions for a successful implementation of an efficient contact investigation among MDR-TB 
patients in Viet Nam. 
Since 2009, the programmatic management of drug resistant tuberculosis (PMDT) was piloted 
in Viet Nam following the development of 2009 country MDR TB guideline. A year after the 
WHO updated guideline was disseminated, the country revised its guideline and SOP to be in 
line with WHO's recommendations and contextualized to local capacity·and resources. The 
PMDT has· been rolled out and scaled up in the country. However, lack of resources, limited 
communication on policy changes to lower level, unable to provide screening to all risk 
groups, inadequate capacity to perform diagnosis of mono and poly resistant TB and second-
line DST have posed significant challenges for the NTP to implement their policy. 
This study found that only about 30 % MDR TB cases was detected through the PMDT 
system. The possible reasons we identified were: (1) delay in fully rolling out PMDT policies 
and limited capacity of the system, mostly due to inadequate resources, (2) operational factors, 
and (3) neglecting high risk groups during MDR-TB screening, particularly close contacts of 
MDR TB patients. Noteworthy, the NTP strategy relies on "passive case finding" while the 
proportion of household contacts of smear-positive tuberculosis patients screened for TB under 
the current passive screening approach of the Vietnam National TB program is very low 
compared with prevalence of TB among contacts in high burden countries, particularly for 
contacts under 5 years of age. Although screening of close contacts of MDR-TB patients is 
recommended by the NTP of Viet Nam, this is generally not done. Therefore, a different 
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approach is needed. This study applied Social network Analysis (SNA), which is a more 
comprehensive approach than traditional contact tracing. However, with SNA of 99 MDR-TB 
index patients we were not able to detect new MDR-TB cases. The fact we found no new 
MDR-TB cases may be explained by reduced fitness of MDR-TB and the short follow up time 
of our study of 6 months. 
The results of this study suggest that there are several interventions that could improve the 
PMDT program in Viet Nam. Firstly, the National TB control Program should standardize and 
decentralize training on PMDT and provide staff with updated information on policy changes 
through proper communication channels. Capacity on MDR-TB diagnosis and treatment 
should be strengthened. PMDT should expand ambulatory care of MDR-TB treatment and 
expand risk group for MDR-TB screening. MDR TB case finding could be strengthened by 
provision of information and education of close contacts of MDR-TB patients, with special 
attention to children; and to perform more research on how active contact investigations should 
be done for MD-TB to have the best yield. The NTP should allocate more resources to MDR-
TB control, particularly well-trained staff 
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Chapter 1. INTRODUCTION 
1.1 What is tuberculosis? 
Tuberculosis (TB) is an infectious disease caused by closely related acid-fast bacteria known as 
the Mycobacterium tuberculosis complex (MTB) [1]. The causative agent of tuberculosis was 
discovered by the Nobel laureate Robert Koch who published on it in 1882[2]. The most 
common MTB pathogens that cause human disease are M tuberculosis and M africanum[3]. 
TB can occur in any part of the body, but occurs mainly in the lungs in 90% of the 
symptomatic cases (pulmonary TB). After inhalation, the bacteria cause a primary infection in 
the lungs, from which the bacteria disseminate to other organs through hematogenous 
spread[4-6]. Following a primary infection, most adults (90-95%) do not develop disease when 
infected with M tuberculosis, this is known as latent TB infection (LTBI)[7]. Approximately 
5-10% of adults infected with MTB develop symptomatic or active TB[7][8], most commonly 
in the first two years after infection [4][6] (Figure I-I).However, the risk of tuberculosis 
development may vary among different settings[9]. There is an increased risk of developing 
TB in immune compromised individuals, including but not limited to: people infected with 
human immunodeficiency virus (HIV)[lO-P], the very young or elderly [13], poor nutrition 
status [14], diabetes[6][I5], alcoholics[16], and use of immunosuppressive drugs [5][17]. LTBI 
can become active TB (reactivation) in patients with immunosuppression[8]. 
TB bacilli are transmitted through the air as they are expelled into the air in small airborne 
droplets (0.5 to 5.0 Ilm in diameter) by pulmonary TB patients when they cough or sneeze and 
subsequently inhaled by close contacts (Figure I-I).Individuals with close contact to 
pulmonary TB patients, for instance family members, are at risk of infection with MTB, 
depending on duration of exposure and density of bacilli in the air[6][I8]. Patients with LTBI 
do not transmit infection. As mentioned earlier, TB usually involves the lungs, however, other 
organs may be involved in extrapulmonary TB (EPTB). EPTB is more common in HN 
patients[5][I9] and in infants[20], and accounts for 50% to 60% of all TB among patients with 
Acquired Immune Deficiency Syndrome (AIDS)[5][2I]. 
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Figure 1-1. Phases of tuberculosis infection: Latent TB infection and active TB 
(source: http://www.nature.com/nri/joumal/v5/nS/fig tab/nri 1666 F l .html) 
. 
. , 
.' 
I latent TS I I Active TS I 
TB is airborne and can establish primary infection in the lung. Hematogeneous spread may occur approximately 
three weeks after unimmunized individuals are first infected with detectable DNA of MTB in various organs. liz 
about 90%-95% of individuals, the infection reliwins latent (LTBI) and remains latent f or decades. LTBI can be 
reactivated when all individual is immunosuppressed, particularly through infection with HIV. [22] 
1.2 How is TB diagnosed? 
Diagnosis of TB depends on whether we are dealing with latent or active TB, and in case of 
active TB, which organs are affected. Below I briefly summarize the diagnosis of TB for the 
different circumstances. 
1.2.1 Active TB 
TB is a clinical syndrome that can be identified either by bacteriologically confinned and/or 
based on clinical criteria only [23][24]. A bacteriologically confinned TB case is diagnosed by 
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positive result in smear microscopy examination, culture or World Health Organization 
(WHO)-approved rapid diagnostics (WRD). Clinically diagnosed TB is based on clinical 
judgment with a decision to initiate TB treatment [24].Diagnosis of active TB starts with 
clinical assessment and is followed by diagnostic testing. Clinical symptoms suggestive for TB 
need to be assessed [5] with special focus on risk groups for TB such as TB contacts, HIV 
patients, lung disease, and health care workers [25]. Pulmonary TB presents with persistent 
cough, sometimes with hemoptysis, fever, dyspnea, chest pains, weight loss, and night sweats 
[4][5][26][27]. For EPTB, clinical manifestations depend on the organs affected by TB, with 
most commonly the following organs: pleura, lymphatic system, urogenital system, 
osteoarticular, and meningeal [28-33]. However, active TB can also be asymptomatic [34].In 
presumed cases of TB, diagnosis for TB can be made by direct sampling of sputum or infected 
tissue for microscopy, also chest X-ray and detection of MTB by micrqbiological culture or 
molecular techniques[5][35][36].Tuberculin skin test (TST) can be used as an additional test in 
the diagnostic process for TB in children, however can not be used in case of BCG-
vaccination, which is commonly used in Asia[5][13][37]. As regards of sample for testing, 
.induced sputum or gastric lavage may be collected if it is difficult to obtain sputum, for 
instance in small children and also HIV infected people who have difficulties in expectorating 
sputum [13]. 
To diagnose pulmonary TB, microscopic examination of a sputum smear following a staining 
procedure in which the TB bacilli retain the color of the stain after an acid wash, is performed. 
TB bacilli are therefore also referred to as acid-fast bacilli (AFB; Figure 1-2). This staining 
procedure is called a Ziehl-Neelsen stain. Among people presumed to have TB this has been 
the basic diagnostic test for TB worldwide. Microscopy has a limited sensitivity by the 
threshold of detection, which is 5,000 - 10,000 bacilli per milliliter of sputum[38]. The 
sensitivity of the sputum smear ranges from 20% to 80% in adults with pulmonary TB 
[39][40]. 
Also fluorescent staining methods like auramme can be used to detect mycobacteria in 
samples[39][41]. Conventional fluorescence microscopy takes less time and is more sensitive 
than Ziehl-Neelsen. However, it is more costly. Less expensive light-emitting diodes (LED) 
have developed and are recommended by the WHO to replace conventional fluorescence 
microscopy and can be easily implemented and used in resource-limited settings. LED 
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microscopy increases sensitivity by approximately 5% compared toZiehl-Neelsen and 
conventional fluorescence microscopy[39]. LED has equal specificity. compared to direct 
Ziehl-Neelsen microscopy and fluorescence microscopy[39]. 
As TB bacilli replicate slowly, it can take up to 4-6 weeks for a culture to become positive on 
solid media, and about 2 to 3 weeks in liquid culture media [42]. In addition to shorter 
turnaround time, liquid culture is more sensitive than solid culture[43].Recently, rapid and 
sensitive molecular technologies have been used to diagnose TB. So far, WHO endorses only 
line probe assays (LPA) and the Xpert MTB/RIF as two molecular technologies for the 
genotypic DST to detect TB[ 44]. Molecular LPAs can detect resistance to rifampicin and 
isoniazid and Xpert MTB/RIF to rifampicin only [45]. However, available LPAs can be used 
on AFB smear-positive sputum specimens or on M tuberculosis cultured isolates only, and 
they are recommended to be used at the high level laboratories such as central laboratories [44]. 
The Xpert MTBIRIF is more simple to use as the process to perform the test (from specimen 
preparation, amplification to detection) has been integrated into a single machine and is fully 
automated. Xpert MTB/RIF uses three specific p:imers and five unique molecular probes that 
can both detect TB specific Deoxyribonucleic acid(DNA) and rifampicin resistance (see 
below). In 2013, WHO recommended Xpert MTBIRIF to be used as a replacement test for 
smear microscopy and can be used to support diagnosis of TB in children and HIV infected 
people. For replacement of conventional microscopy to be the initial diagnostic test for TB, 
. Xpert MTB/RIF has a pooled sensitivity of 88% and a pooled specificity of 99%[46]. 
For presumed cases of EPTB, also Xpert MTBIRIF [46] or sputum smear, TB culture and chest 
X-ray are used. Additional samples are collected depending on the location of EPTB. For 
example, cerebrospinal fluid (CSF) will be collected in case of presumed TB meningitis or 
pleural fluid in case of possible ple~ral TB [36]. In20 13, the WHO advised to use the Xpert 
MTBIRIF test in preference to conventional diagnostics in case of testing cerebrospinal fluid; 
however the use ofXpert MTB/RIF for pleural fluid is currently not recommended [46]. 
19 
Figure 1-2. Acid-fast bacilli in sputum smear 
(source:http://phil.cdc.govIPHIL_Images120040615/d094324845a24eb3a7bfeOdlf8e4a637/5_1 
ores.jpg) 
1.2.2 Latent tuberculosis infection (LTBI) 
In LTBI, the bacillus is generally not directly detected. Therefore, diagnosis of latent TB 
depends on the existence of a TB specific hast response test[8]. Available immunological tests 
for LTBI include: tuberculin skin test (TST) and interferon-gamma release assays (IGRAs)as 
well as other measures of host response [5][36]. These tests, however, cannot differentiate 
L TBI from tuberculosis disease. Therefore, active TB needs to be excluded, whereby all 
diagnostic tests should be negative. The diagnosis LTBI becomes more likely with a positive 
immune response and a history of a TB contact. Depending on the country specific resources, 
the priority to systematically test for LTBI among risk groups who are more likely teo develop 
active TB need to be considered [8]. 
1.2.3 Drug resistance testing 
The TB bacilli can become resistant to one or more anti-TB drugs used. If it is resistant to at 
least isoniazid and rifampicin, the two most powerful anti-TB drugs, it is classified as 
multidrug-resistant tuberculosis (MDR-TB). In case of MDR-TB plus additional resistance 
to any fluoroquinolone, and at least one of three second-line injectable drugs (capreomycin, 
kanamycin and amikacin), it is defined as extensive drug resistant TB (XDR-TB). Drug 
resistance can emerge and spread due to poor treatment of TB and due to transmission to 
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people who are in contact with MDR-TB patients [44]. Drug susceptibility testing (DST) of 
TB is an important aspect of TB management. 
DST indicating the sensitivity of the strain to anti TB drugs, can be performed by either 
phenotypic or genotypic methods. Phenotypic methods are based on growing bacilli in the 
presence of anti-TB agents[35][44]. Phenotypic methods can detect drug resistance without 
considering the molecular mechanism of drug resistance. It can be performed in liquid or on 
solid media by direct or indirect methods. The direct test deals with the specimen while 
indirect test uses a strain already isolated from a specimen[44]. Conventional phenotypic DST 
on solid or liquid culture has been used to detect susceptibility to first and second line anti TB 
drugs. 
Different from phenotypic methods, genotypic DST detects genetic mutations related to 
resistance to specific TB drugs. Recently, rapid tests (LPA to detect rifampicin and isoniazid 
resistance; Xpert MTB/RIF to detect rifampicin resistance) have become available. The 
sensitivity and specificity of Xpert MTBIRIF is 95% and 98%, respectively when it is used to 
detect rifampicin resistance[ 46]. As not all genetic mutations conferring resistance are known, 
molecular techniques have their limitations. Cun:ently, phenotypic DST techniques are 
recommended to detect second line drug(SLD) resistance. Molecular tests for fluoroquinolones 
and second line injectable drugs are available and in accordance with WHO guidance can be 
used as a rule-in test for treatment regimens specifically designed to deal with MDR TB with 
additional resistance to SLD. However, genotypic SLD DST is not yet endorsed by WHO as a 
replacement for phenotypic SL DST[44]. 
1.3. Treatment of tu berculosis 
1.3.1 Treatment of L TBI 
Preventive therapy for LTBI aims to prevent people with latent TB infection from development 
of active TB (reactivation). There are several LTBI treatment options: 6-9 months isoniazid, 
3-4 months isoniazid with rifampicin, 3 months isoniazid and rifapentene,and 3-4 months 
rifampicin alone [8]. These treatment options are not recommended for those who have been in 
close contact with MDR-TB due to risk of resistance. There is controversy about whether 
preventive therapy should be provided to close contacts of MDR-TB and which drugs should 
be used. So far the experience and evidence of treatment for LTBI in contacts of MDR-TB is 
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limited and it is not recommended to routinely treat them with second-line anti-TB drugs at this 
time [44]. 
As regards of LTBI treatment in close contacts of MDR-TB patients, currently there are two 
systematic reviews that analyzed the use of second line anti TB drugs in MDR-TB contacts to 
prevent disease development. The reviews used data from January 2004 to April 2011and 
included 19 references and 3 studies with a total of 1195 patients. One study in the reviews 
showed that no TB developed either from contacts who were treated or the untreated with 
prophylaxis, while other two studies reported non-significant risk differences of developing 
active TB disease (4% ; 95%CI: -3 to 12, and 5%; 95%CI: -2 to 11). In addition, evidence 
from these three studies was considered as low quality due to limitations in study design, 
inconsistencies among the results and methodology. The evidence from the reviews therefore is 
not sufficient to decide whether or not to apply preventive treatment for contacts of MDR-TB 
and warrant more research, preferably clinical trials[47]. A more recent prospective 
observational study in Micronesia showed that no contacts of MDR-TB patients who received 
preventive treatment with a fluoroquinolone developed MDR-TB disease, while 3 of 15 
contacts who did not receive prophylaxis developed MDR-TB disease[ 4.8]. 
1.3.2 Treatment of TB 
TB is treated by taking a combination of different drugs with multiple targets (figures 1-3 and 
1.4). This should prevent monotherapy reduce the likelihood of spontaneous mutations arising 
and thus emergence and amplification of drug resistance. According to the WHO, standardized 
treatment regimens are designed for different patients groups including (i) new patients who 
are supposed or known to be susceptible TB, (ii) previously treated TB patients and (iii) multi-
drug resistant TB patients (MDR-TB). There are 5 groups of anti-TB drugs recommended by 
the WHO for treatment ofTB [23] (table 1-1). 
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Table 1-I.WHO categorization of anti-tuberculosis drugs. 
Group 1 First-line oral drugs Rifampicine (R), isoniazid (H), pyrazinamide (Z), 
ethambutol (E), Rifabu,tin(Rtb), Rifapentine (Rpt) 
Group 2 Injectables Streptomycin (S), Kanamycin (Km), 
Amikacin(Am), capreomycin (Cm) 
Group 3 Fluoroquinolones Levofloxacin (Lfx) , moxifloxacin (Mfx), 
gatifloxacin (Gfx) 
Group 4 Oral bacteriostatic drugs Pro/ethionamide (Pto, Eto), cycloserine (Cs), 
terizidone (Trd), Para-aminosalicylic acid 
(PAS),Para-aminosalicylate sodium (PAS-Na) 
Group 5 Drugs with limited data on Bedaquiline (Bdq), Delamanid (DIm), linezolid 
efficacy and/or long term (Lzd) , Clofazimine (Cfz), amoxicillinlclavulanate 
safety in TB treatment (Amx/Clv), Imipenemlcilastatin (IpmlCln), 
Meropenem (Mpm),High-dose isoniazid, 
. 
Thioacetazone(T), clarithromycin (Clr),' 
Treatment for new TB patients (drug susceptible cases) 
New pulmonary TB patients are recommended to receive a six-month regimen containing 
rifampicin: 2HRZE/4HR (see Table 1-1 for guide to which letter corresponds to what drug; the 
numbers refer to duration in months. Brackets around a combination of drugs indicates the 
drug is combined in a fixed dose combination tablet. The figure behind a drug indicates the 
number of weekly doses, if the drug is not taken daily). The optimal dosing frequency is daily 
throughout the treatment course. However, intermittent frequency (three times per week) of 
2HRZE/4(HR)3 or 2(HRZE)3/4(HR)3 may be provided if direct observed treatment (DOT) is 
ensured, the patient is negative for HIV or not living in an HIV prevalent setting [23]. 
Isoniazid, rifampin, ethambutol, and pyrazinamide are used for two months during the 
intensive phase, followed by isoniazid and rifampin for four months during the continuation 
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phase (Table 1-2). In settings with high levels of isoniazid resistance, ethambutol is 
recommended to add to continuation phase to prevent possible monotherapy of rifampicin [23]. 
Table 1-2. Standardized regiment for TB treatment for new and previously treated 
cases[23]. 
(See Table 1-1 for guide to which letter corresponds to what drug) 
Category Intensive phase Continuation phase 
New patients 2HRZE 4 HR, or 
4 HRE (if high levels of 
isoniazid resistance) 
Previously treated patients 2HRZES/l HRZE SHRE 
(Medium or low risk of MDR-TB, 
conventional DST is used) 
Previously treated patients . Empirical MDR regimen to be revised based on 
. 
DST results 
(High risk of MDR-TB, conventional 
DST is used) 
Treatment for previously treated TB patients 
Previous TB treatment may suggest possible drug resistance[ 49]. Therefore, these patients 
should be tested by DST to at least isoniazid and rifampicin before the start of treatment to 
detect drug resistance and revise the regimen accordingly. If rapid DST is available, the results 
should be used to guide treatment. For settings that use non or conventional DST only, 
treatment with second line anti TB drugs is recommended for high risk patient for MDR-TB 
(treatment failure cases), and the so called retreatment regimen is started with first line drug 
regimen (2HRZES/IHRE/SHRE) for medium or low risk group patients (relapse and treatment 
after lost to follow up cases, table 1-2)[23] 
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Treatment of extrapulmonary TB 
EPTB and pulmonary TB can be treated with the same regimens[23]. However, for TB 
meningitis, it is recommended to extend the treatment to 9-12 months [50][51] and 
streptomycin should be used instead of ethambutol. For bone or joint TB a 9-months treatment 
duration is recommended [51]. Corticosteroids are recommended to use as adjuvant therapy for 
TB meningitis and pericarditis [52][53]. 
Figure 1-3. First line treatment for drug susceptible TB. 
(source:https:llwww.niaid.nih.gov/topics/tuberculosis/UnderstandinglWhatIsTB/ScientificIllust 
rations/pages/firstlineillustration.aspx) 
Cell Wall Synthesis 
ATP Synthesis 
Treatment of multi-drug resistance TB 
According to the WHO[44], there are 2 types of treatment regimes for MDR-TB patients 
including (i) standardized treatment based on regional resistance data whereby all patients in a 
defined patient group receive the same regimen designed based on drug resistance survey 
infonnation, (ii) individualized treatment designed based on the individual patient's previous 
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TB treatment history and DST results. Standardized regImens are recommended over 
individualized regimens due to unavailability or unreliability of DST results for specific drugs 
in most countries and the long turnaround time for culture based DST. The combinations of 
these two designs may be used. There are four principles to the design ofMDR-TB treatment: 
(i) use at least four drugs certain to be effective; 
(ii) prevent the use of drugs with potential for cross-resistance; 
(iii) do not use toxic drugs; 
(iv) use the most potent drugs 
The combination of effective drugs with different targets is preferred (Figure 1-4). Choosing a 
second line injectable agent is the first step in building the regimen. Pyrazinamide is 
recommended to be used in the intensive phase. Drugs from WHO 'group 5' are only added if 
the target of four drugs cannot be reached otherwise. The duration of the intensive phase is 
eight months and the total treatment duration is 20 months for most newly diagnosed MDR-TB 
patients. Duration is modified based on the patient's response to treatment. Total length of 
treatment should be at least 12 I?onths past the culture conversion, but not less than 20 months. 
Patients previously treated with MDR-TB regimen are recommended to receive treatment for 
at least 24 months[44]. 
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Figure 1-4. Possible Effective Treatments for MDR-TB 
(source:https://www.niaid.nih.gov/topics/tuberculosisiUnderstanding/WhatIsTB/Scientificlllust 
rati ons/pages/m ul tidru gresi stan ti 11 ustration. asp x ) 
Cell Wall Synthesis 
ATP SynthesiS 
Thioamides, lmd Cycloserine inhibit cell wall synthesis. PAS inhibits DNA precursors synthesis; . 
Fluoroquinolones inhibit DNA gyrase; Cyclic Peptides and Aminoglycosides inhibit Mycobateriu1l1 
tuberculosis protein synthesis. 
1.4 Drug targets and mechanisms of resistance 
Background 
Drug resistance is caused by mutations in specific gene encoding either the drug target or the 
enzymes involved in drug activation[54][55]. These mutations may occur by mutations, 
insertions or deletions of nucleotides of specific genes resulting in modification of drug target, 
block pro-drug activating enzyme, or destroy drug action by increasing the targeted gene 
products [54][55]. Resistance may also involve decreases in permeability and/or increase in 
efflux leading to decrease in drug accumulation[55] [56]. 
There are two types of drug resistance distinguished including intrinsic resistance and acquired 
resistance. Intrinsic drug resistance concerns the natural characteristics of the MTB making it 
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resistant to many kinds of antimicrobial agents. M. tuberculosis bacilli have a lipid rich cell 
wall with a low permeability limiting uptake of small molecule, particularly hydrophilic, drugs 
into the cell. But passive diffusion is only partly responsible for uptake of drugs by the cell. 
The intracellular concentrations of drugs also depend on influx and efflux systems through the 
cell wall. Influx is operated through porins and drug efflux via efflux pumps. Mutation in 
regulators of the efflux pump gene can result in an increased efflux of drugs, lowering the 
concentration in the cell and hence its activity [56]. An example of intrinsic resistance due to 
efflux pumps is tetracycline. Another natural resistance mechanism is the production of 
extended-spectrum Beta-Iactamases (ESBL) that inactivate beta-Iactam antibiotics[57][58]. 
Intrinsic resistance greatly limits the arsenal of drugs that can be used to treat TB. 
Acquired drug resistance is caused by spontaneous mutations that are selected through 
incorrect treatment, like only using a single drug, rather than combinations [55][59][60]. 
Treatment for TB with serial monotherapy may lead to stepwise acquired drug resistance to 
different drugs and thus multiple drug-resistance TB (MDR-TB). For that reason, combination 
of anti-TB drugs in treatment regimen is recommended [55]. The probability of acquiring 
. resistance from spontaneous mutations varies between first line anti-TB drugs from 10_8 to 10-
6[61].Mutation rates can vary between different lineages [62][63]. The risk or"a resistance 
mutations is decreased if multiple drugs are used together as it reduces the probability of 
selecting for resistance to below 10-18 per cell division [55]. 
Resistant mycobacteria can subsequently be transmitted to other hosts and cause primary 
resistance [60]. The transmission of MDR-TB strain from MDR-TB patients to their contacts 
can drive MDR-TB epidemic. Over time, selected resistance strains can replace the population 
of susceptible TB strains due to selective pressure from treatment [ 64]. Diagnosis and treatment 
delay, or less effective treatment of MDR-TB increase transmission of TB strains due to a 
prolonged infectious period [65][66]. 
Below follows a brief description of key resistance mechanisms ofTB drugs. 
Rifampicin: Rifampicin is a bactericidal drug and considered together with isoniazid to be the 
basis of short-course TB treatment. Rifampicin 'kills' the TB cell by inhibiting protein 
synthesis [44][55][67]. The target of rifampicin is the beta-sub unit of ribonucleic acid (RNA) 
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polymerase encoded by gene rpoB. Mutations in this gene can lead to changes in the structure 
of RNA polymerase, consequently leading to the decrease in drug affinity for its target and 
development of resistance[55][60]. Most rifampicin resistant strains are also resistant to other 
, 
drugs, mainly isoniazid, and therefore rifampicin resistance can be used as a marker for MDR. 
Isoniazid: Isoniazid is a pro-drug that needs to be activated by catalase/peroxidase, encoded by 
katG. The most important targets of the activated drug are enzymes for mycolic acid synthesis 
(enoyl reductase encoded by inhA), thereby inhibiting mycolic acid synthesis, a key component 
of the MTB cell wall. Several mutations in the katG gene giving rise to resistance may interfere 
with catalase/peroxidase activity thereby compromising virulence. However, the most 
important katG mutation at 315 doesn't affect this activity nor virulence, which is why it is 
successful. Mutation in KatG can result in a loss of catalase/peroxidase activity and isoniazid 
will not be sufficiently activated [55]. Mutations in inhA or its promotor region and other genes 
can also lead to isoniazid resistance [68]. The frequency of various mutations conferring 
resistance to isoniazid vary according to the genotypes of MTB with geographical differences 
in their distribution as a result [69].Mutation in KatG was considered to be more frequent in 
resistant strains [70] and associated with high-le.vel resistance to Isoniazid, while mutation in 
inhA is likely associa·ted with low level resistance to isoniazid[71][72]. Isoniazid resistance is 
considered at low level when there was> 1 % growth of MTB in the presence of 0.2 J.1g1mL of 
INH. High level Isoniazid resistance is classified when there is > 1 % growth of MTB in the 
presence of 1 J.1g/mL of INH. In addition to the most common mutations in kat G and inhA, 
mutation in many other genes are associated with INH resistance such as ahpC, kasA and 
NDH[55][72]. 
Pyrazinamide: Pyrazinamide is a pro-drug that activated by the enzyme 
pyrazinamidase/nicotinamidase coded by the pl1cA. The pro-drug passively diffuses into the 
MTB cell where it is converted to the active metabolite pyrazinoic acid[72]. This drug is most 
effective during the early stage of therapy before inflammation has subsided and is able to kill 
dormant mycobacteria[73]. The target of this drug is not fully clear. The possible mode of 
action of pyrazinamide involves the role of pyrazinoic acid to inhibit membrane transport. This 
causes inefficient efflux pump whereby pyrazinoic acid would be accumulated inside and kill 
the cell[72]. It possibly includes inhibition of mycobaterial fatty acid synthetase enzyme in 
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replicating baci1li[74], and disruption of Adenosine triphosphate (ATP) synthesis[75] 
interfering with the function of a ribosomal protein[76]. Several point mutations in the 600 
base-pair pncA gene may lead to pyrazinamide resistance[77]. Alternative resistance 
mechanism of this agent includes defects in transportation of the agent into the MTB cell due 
to changes in porins[78]. 
Ethambutol: This drug inhibits enzyme arabinosyl transferase, which helps to synthesize the 
major cell wall polysaccharide arabinogalactan. Resistance to this agent is a multi step process 
involving genes in the embA, embB and embC cluster. There is evidence that mutations in 
codon 306 of the embB gene leads to resistance to ethambutol. This mutation also predisposes 
the MTB cell to develop resistance to several other drugs, thereby generating multi drug 
resistant strains [79]. 
Streptomycin: The mode of action of this aminoglycoside drug is to inhibit ribosomal protein 
S 12 and thereby inhibiting protein synthesis. It was the first drug to be used in TB treatment 
and initially used as monotherapy, resulting in high resistance levels to this drug. Resistance is 
determined by mutation in the rrs and rpsL gene resulting in alterations in the streptomycin 
binding site[55]. 
Fluoroquinolones: The target of this drug is DNA gyrase, encoded by the genes gyrA and 
gyrB. DNA gyrase catalyzes the supercoiling of. DNA and is essential for efficient DNA 
replication, transcription, and recombination. Fluoroquinolones can bind to DNA gyrase and 
inhibit its activity with cell death as a result [55][60][72]. Mutations in these genes cause 
changes in DNA gyrase, and fluoroquinolone is unable to bind to this target. 
Second line injectabIes: The second line injectable drugs commonly used to treat MDR-TB 
are kanamycin, amikacin that belong to amino glycoside antibiotics and capreomycin that 
belong to cyclic peptide antibiotics. The targets of kanamycin and amikacin are the enzymes 16 
rRNA (encoded by gene rrs) and aminoglycosidase acetyltransferase (encoded by gene eis) 
[55][60][64]. Targets of capreomycin are the enzymes:16S rRNA encoded by rrs gene and 
rRNA-methyltransferase encoded by tlyA[55][60][64]. These enzymes catalyze protein 
synthesis. Kanamycin, amikacin and capreomycin attack its targets to inhibit protein synthesis 
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and kill the cell. Mutations in these genes change its product (enzymes) and as a result are not 
recognized by second line injectable drugs to be inhibited. Cross-resistance between 
kanamycin and amikacin has been reported [80][81]. However, they are not considered to be 
, 
fully cross resistant [82]. 
Cycloserine: The target of this drug is not exactly defined. Cycloserine can block the activity 
of D-alanine to inhibit the peptidoglycan synthesis[72]. In addition, it can interfere the process 
to convert from L-alanine to D-alanine by inhibition of D-alanine racemase (AlrA)[83]. Some 
studies showed that resistance to cylcoserine is caused by overexpression of alrA[84] or 
mutation in gene cycA encoding for the D-alanine transporter[85]. 
Para-Amino Salicylic Acid (PAS): Thus far the target of this drug is not clearly defined [72]. 
It Supposedly interferes with folate synthesis. One study showed that mutations in the thyA 
gene[86], another study identified mutations in laiC related with PAS resistance [87]. 
However, other mechanism may result in resistance to PAS since only less than 40% of 
resistant strains had mutations in thyA[88]. 
. 
Ethionamide: Ethionamide is a pro-drug that is· activated by monooxygenase[72]. This 
enzyme is encoded by the ethA gene which is regulated by transcriptional repressor encoded by 
the EthR gene. When activated, it inhibits the enoyl-ACP reductase enzyme and interfere the 
mycolic acid synthesis to kill the cell [89]. Mutations in etaAlethA, ethR and inhA genes cause 
ethionamide cannot be activated, with ethionamide resistance as a result[90]. 
Clofazimine: Clofazimine belongs to the WHO group 5 drugs recommended by the WHO to 
include in the treatment regiment for MDR-TB and XDR-TB patients [44]. The mechanism of 
action of this drug is not exactly defined [72]. The outer membrane of MTB may be the target 
of this drug [91]. A study showed that mutations in the reference strain H37Rv, regulator 
Rv0678 caused an overexpression of efflux pumps resulting in resistance to clofazimine[92]. 
Linezolid: This drug is also one of the WHO group 5 drugs recommended by the WHO for 
treatment of drug resistant TB [44][72]. It kills the cell by binding the the 50S ribosome 
subunit inhibiting protein synthesis [83]. Resistance to linezolid is considered to relate to 
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mutations in 23S rRNA[93], mutation T460C III rplC[94], and involvement of efflux 
pumps[95]. 
Bedaquiline: Bedaquiline is a newly developed anti TB drug. It has completed phase II 
clinical trials, but not phase III. This drug is recently included by the WHO belonging to group 
5 drugs for MDR-TB treatment with interim policy guidance provided, to be used under 
conditional approval [44][96]. It has a novel mechanism of action by inhibiting the ATP 
synthase ofMTB, which is encoded by atpE gene[97]. The most common mutation that causes 
resistance to bedaquiline is in the atpE gene[98]. However, only about 30% of resistant 
mutants had mutations in the atpE gene, other possible mechanisms of resistance is yet 
unknown[99]. 
Delamanid: This drug is also recently included in the group 5 drugs for treatment of MDR-TB 
by the WHO and is undergoing phase III clinical trials. The mechanism of action is to inhibit 
the mycolic acid synthesis [44][100]. Resistance mechanisms need to be elucidated [101]. 
1.5 Pathways of drug resistant TB 
Two pathways are considered to cause the development of drug-resistant TB, including: 
acquired drug resistance and primary drug resistance. There are multiple factors involved in 
these pathways (Figure 1-5). 
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Figure 1-5. Pathways of drug resistant tuberculosis 
Source: C.ompanion handbook to the WHO guidelines for the programmatic management of drug-resistant 
tuberculosis 
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Acquired drug resistance is caused by poor treatment quality leading to the selection and 
stepwise amplification of mutant resistant strains (see above 'mechanism of drug resistance'). 
Factors that contribute to poor treatment outcomes include: (i) inappropriate treatment due to 
lack of treatment guidelines and training, poor patient education and treatment support, poor 
management of treatment response and adverse drug reaction, (ii) inadequate drug quality and 
supply due to stock out of drugs, unqualified drugs and poor storage conditions, (iii) poor 
patient's adherence to treatment. Cross cutting factors that contribute to both pathways leading 
to the spread of drug resistant TB include health system weakness and risk factors and social 
detenninants. Week health services for diagnosis and treatment of TB involve insufficient 
financial resources, poor political commitment, mismanagement of supplies including 
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medicines and diagnostics commodities; and a poor functioning health information system. 
People who belong to vulnerable groups (HIV, drug abuse, alcoholism) or have poor 
socioeconomic condition have poor access to health care service and have higher risk of drug 
resistance development [44]. 
Primary drug resistance occurs when a person becomes infected with a drug-resistant TB 
isolate, transmitted by an infected donor, and develops active TB. Existing drug-resistant TB in 
the community without proper treatment causes high drug-resistant TB prevalence and 
transmission of drug-resistant TB [44]. Environmental conditions are considered to influence 
the transmission of drug resistant TB, including poor ventilation, crowding, poor infection 
control measures (especially in closed settings) can facilitate TB transmission. 
1.6 The epidemiology of tuberculosis and multi drug resistant tuberculosis in the world 
and control measures 
1.6.1 The epidemiology of TB and MDR-TB in the world 
Tuberculosis (TB) is a major global health problem and ranks as the second leading cause of 
death due to infectious diseases after HIV/AIDS. It is reported by the WHO that there are 
approximately 9 million new TB cases annually and 1.5 million people die because of 
TB[102]. The majority (56%) of TB cases live in South-East Asia and the Western Pacific 
region. About 80% of TB patients worldwide are detected in just 22 high TB burden countries. 
Globally, MDR-TB incidence is estimated to be 3.5% among new TB cases and this proportion 
has been stable for recent years. It is estimated that approximately 500,000 MDR-TB cases 
emerge each year worldwide and between 5% and 7% of them develop XDR-TB [102]. 
1.6.2 Guidelines, framework and control measures for TB drug resistance recommended 
by the WHO 
In 1997, the first report on drug resistance of tuberculosis (TB) in 35 countries revealed 
widespread drug resistance. The report recommended a more proactive approach to address 
multi-drug resistant tuberculosis (MDR-TB). As a result, the 'directly observed treatment-plus 
(DOT-plus) for MDR-TB" for directly observed treatment short course therapy (DOTS) 
approach for general TB control was established in 1999, followed by the Green Light 
Committee (GLC) in 2000. This GLC, hosted by the WHO, provides technical assistance and 
support to countries in accessing second line TB drugs. The first Guidelines for establishing 
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DOTS-Plus pilot projects for management of multidrug-resistant tuberculosis were published 
in 2000 and provided guidance for implementation for treatment of MDR-TB with second line 
anti-TB drugs. The 2006 WHO MDR-TB guidelines were to be in, line with the 'Stop TB 
Strategy' (launched in 2005) which integrates management of MDR-TB into comprehensive 
national TB control plans [103]. 
In 2006, XDR-TB emerged, particularly in countries with a high burden of HIV in combination 
with poor TB treatment outcomes[104]. Therefore, a more effective response from both health 
officials and medical practitioners was required. As a result new guidelines were drafted in 
2008 that required countries to enhance access to TB culture and drug susceptibility testing for 
all presumed drug resistant tuberculosis (DR-TB) cases. The guidelines additionally provide 
guidance for management ofXDR-TB, DR-TB and HIV[105]. 
In response to the 62ndWorld Health Assembly's resolution (WHA62.15, adopted in 2009) 
calling on Member States to develop a comprehensive management framework for drug-
resistant TB, the 2011 WHO guidelines for the programmatic management of drug resistant 
tuberculosis (PMDT) addresses. critical questions concerning case finding and treatment 
strategies[10o]. To assist countries in implementing WHO policies, the Companion Handbook. 
Was developed in 2014[44]. The current WHO framework for management of drug resistance 
tuberculosis includes five essential components: (1) sustained political commitment, (2) 
rational case finding strategy, (3) appropriate treatment strategy, (4) uninterrupted supply of 
.. quality assured anti-tuberculosis drugs, and (5) standardized recording and reporting systems. 
Based on the pathways leading and factors contributing to drug resistant TB, five principle 
ways were recently recommended by the WHO (in 2014) to control drug resistant TB [44], 
including: 
(i) early diagnosis and quality treatment for drug-susceptible TB; 
(ii) early diagnosis and quality treatment for drug-resistant TB. Specific interventions 
for early diagnosis of drug resistant TB is to ensure appropriate diagnostic 
technologies to screen among risk groups including household contacts; 
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(iii) adequate infection control measures to minimize the risk of TB transmission in the 
populations, to be implemented at every level of heath care facility to household 
level; 
(iv) well functioning health systems. It is recommended for the TB control programme 
to be integrated with other public health programmes for sharing of resources and 
joint activities; 
(v) Targeting risk factors and social determinants as identified. 
1.6.3 Policy for contact management 
Tuberculosis contacts are· defined as people who have close contact with infectious TB 
patients. They are recommended by the WHO to be actively and systematically investigated to 
detect TB infection and active TB and should be included in the national TB control 
programme (NTP) [18]. This systematic screening involves clinical assessment, testing and 
examinations or other procedures as needed. For children, tuberculin skin testing with purified 
protein derivative is also recommended. If active TB is not detected in the initial investigation, 
the close contact should be monitored[107]. This allows for early diagnosis and treatment to 
minimize the transmission iI1 the community [18]. Depending on available resources, contact 
investigations can be performed for all index cases or only targeted to priority categories of 
index cases such as patients who have MDR-TB or XDR-TB, HIV co-infection, or who are 
young children [107]. TB in a child <5 years of age indicates that the infection likely was 
transmitted by hislher household members and warrants further investigation to find the source 
of infection, rather than find the secondary cases who were infected by the child[lS]. 
Close contacts of MDR-TB and XDR-TB should be investigated using the same procedures as 
for contacts of drug-sensitive cases but more 'aggressively'. MDR-TB contact investigation 
should be integrated into the programmatic management of drug resistant TB (PMDT). Not 
only information about the contacts, information regarding the places that index patients 
resided or visited should be collected to investigate the risk of transmission in those sites [18]. 
In addition to the assessment and examination provided as for contacts of drug-susceptible TB, 
sputum investigation among contacts of MDR-TB need utilization of DST, ideally rapid 
diagnostic method such as Xpert MTB/RIF[44][18].In the settings that rapid DST is not 
available, close contacts of MDR-TB patients with clinical manifestation for TB should be 
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directly enrolled in empiric MDR-TB treatment to reduce mortality and transmission of drug 
resistance [44]. While the purpose investigation among contacts of drug-susceptible TB is for 
detection and treatment of both LTBI and active TB, investigation of MDR-TB contacts will 
focus on diagnosis and treatment of active TB [44]. 
1.7 Introduction to Viet Nam and its healthcare system 
1.7.1 General information on health and health system 
, 
Viet Nam is located in South East Asia region with a population of 91 million in 2014. Viet 
Nam is divided into 63 provinces and cities. The provinces and cities are divided into districts, 
which are subdivided into communes. There are 54 different ethnic groups housed in Viet 
Nam; among these, the Kinh people are predominant (accounting for 86.2% of the whole 
population). Any health program is more difficult by increasing distances from the big cities to 
the remote areas. Health services are weaker in the rural areas where 70% of the population 
lives [ 108] [109]. 
The health status of people in Viet Nam has improved significantly over the last few decades. 
Level of basic health indicators are higher compared with that in other countries with equal 
income per capita; such as, life 'expectancy at birth, maternal mortality ratio, infant and child 
mortality rate, child malnutrition rate, and malaria morbidity and mortality[109]. The average 
life expectancy of the Vietnamese people increased considerately from 72.9 in 2010 to 73.1 in 
2013 (Table 1-3)[109-112]. During 2001-2008, the infant mortality rate fell sharply from 30%0 
to 15%0 [104]. This rate gradually declined from 2010-2013 [109-112]. The mortality rate of 
under-five fall from 58%0 in 2001, to 27.5%0 in 2005 and 25.0%0 in 2009 [104], it continued to 
decreased from 23.8%0 to 23.l%0 during 2010 and 2013[109-112]. However the TB prevalence 
and HIV prevalence has not decreased. 
Currently, TB ranks third in the list of important communicable diseases in Viet Nam[l09]. 
Although the annual number of reported new HIV was considered to decline gradually, the 
cumulative indicators did not decrease due to unpredictable trends in risk factors for HIV such 
as injecting drug use and commercial sex work[1l4]. HIV prevalence in adults is 
approximately 0.24 %, which is similar with that for Malaysia and Indonesia, but lower than 
for Thailand and Cambodia[115]. Disparities in health status between regions and between 
I 
Population groups are a concern. The regions with low level of basic health indicators are those 
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with geographical difficulties to access to health services, unsafe water and high poverty 
proportion [1 09]. 
Table 1-3.Basic health indicators achieved by the national health program from 2010-
2013 (source: Health Partnership Group, Joint annual health review 2011-2014) 
Indicators 2010 2011 2012 2013 
Population size (million) 86.9 87.8 88.8 89.7 
Average life expectancy (years) 72.9 73.0 73.0 73.1 
Infant mortality rate (%0) 15.8 15.5 15.4 15.3 
Under -five mortality rate 23.8 23.3 23.2 23.1 
HIV/AIDS prevalence rate (%) 0.21 0.22 0.237 0.242 
1.7.2 Epidemiology of TB and drug resistant TB 
Viet Namis ranked Ith among 22 high burden countries with TB, and 14th among 27 countries 
with a high burden of MDR-TB. Viet Nam was one of the first high-burden countries to 
achieve the WHO target of detecting 70% of all new sputum smear-positive cases arising each 
year, and of treating 85% of the detected cases successfully since 1997[116][117]. While TB 
incidence in Viet Nam was predicted by mathematical models to decline about 11% (range 8-
12)[118] if the target was achieved, the notification rate of new smear-positive TB showed no 
decline from 1997-2006[119].The question for the Viet Nam NTP regarding the accuracy of 
the WHO estimation was answered by the result from a national TB prevalence survey 
conducted in 2006-2007. It was shown that the prevalence of TB was l.6 times as high as 
previously estimated, revealing that many cases remain undiagnosed[27]. 
The Fourth National Anti-Tuberculosis Drug Resistance Survey (DRS) in Viet Nam showed an 
increasing trend of MDR-TB among new and previously cases compared with the three 
previous drug resistance surveys conducted in Viet Nam in 1996, 2003 and 2005. The MDR-
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TB rate increased from 2.3% in 1996-1997 to 2.7% in 2005 and 4.0% in 2011 among new 
cases[120]. 
In 20l3, the incidence of TB in Viet Nam is estimated at 144 per 100,000 population per year 
and the estimated prevalence is 209 cases per 100,000 population. The mortality rate· of TB 
(exclude HIV+TB) is reported at 19 per 100,000 population[102]. The proportion ofTB cases 
with resistance to any drug was 32.7% and 54.2% among new and previously treated cases, 
respectively. Resistance levels of streptomycin (30.0%) and isoniazid (22.4) were higher than 
rifampin (6.7 %) and ethambutol (4.5 %) resistance levels. The proportion of TB cases with 
MDR-TB among new and retreatment cases is estimated to be 4% (95%CI 2.5-5.4) and 23% 
(95%CI 16.7-29.9), respectively, with approximately 6% among TB cases co-infected with 
HIV [102][120]. These proportions are equal to the levels in the countries with high burden of 
MDR-TB (4.2%, 95%CI 2.1-6.2 and 21%, 95%CI 12-30, respectively), but slightly higher 
than the global proportions (3.6%, 95%CI 2.l-5.land 20.2%, 95%CI l3.3-27.2, 
respectively)[17]. According to the TB drug resistance survey conducted in Viet Nam from 
2011-2012 showed that the estimated proportion of XDR-TB among MDR-TB is 5.6% 
(unpublished data). There.are estimated to be about 5,100 MDR-TB and 290XDR-TB cases 
among notified TB cases per year. 
1.7.3 The framework and policy of Viet Nam for drug resistance management 
Viet Nam started to develop the plan for controlling MDR-TB in 2007 and this plan was 
approved by the GLC to be implemented in the period 2007-2011[121]. In 2008, the first 
guidelines for programmatic management of DR-TB in Viet Nam was developed, which 
adopted the WHO recommended five-component frame work [122]. Case finding and 
treatment strategies programmatic management of drug resistant of Viet Nam was updated in 
line with the WHO recommendation in a step-wise manner. Viet Nam specific conditions 
regarding capacity for diagnosis and treatment of drug resistant TB, financial and human 
resources, were taken into consideration. Regarding case finding strategies used in Viet Nam, 
We refer to chapter 2 of this Thesis (MDR-TB control policies and practices in Viet Nam for 
case finding strategy). 
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Treatment strategy 
In accordance with the WHO guidelines, Viet Nam adopted the standardized treatment regimen 
based on results of the 3rd national drug resistance survey data for MDR-TB patients. Based on 
the WHO recommended principles, the treatment design selected drugs including Ethambutol, 
Pyrazinamide, Kanamycin (or Capreomycin if Kanamycin is intolerable), Levofloxacin, Pro-
Ethionamide, Cycloserines (PAS if Cycloserine is intolerable). As regards of treatment 
duration, to be in line with the most updated WHO recommendation in 2014[44], the current 
treatment guideline adopts 8 and 20 months for intensive phase and total duration of treatment 
for newly diagnosed MDR-TB patients, respectively. This recommendation was based on a 
meta-analysis which included more than 9000 treatment episodes for MDR-TB patients [106]. 
The analysis found that the adjusted relative risk for cure peaked at a treatment duration 
between 7.1 and 8.5 months, and between 18.6 and 21.5 months for intensive phase and whole 
treatment course, respectively. However, only observational studies without randomized 
controlled trials were included in this meta-analysis, so the quality of evidence can be 
considered as low [106]. 
1.7.4 The structure and organisation of the national TB control programme of Viet Nam 
The network and organization of Viet Nam NTP and function of TB units by levels 
Regarding the organization of the health care sector in Viet Nam, there are four administrative 
levels that form of a four-tiered pyramid. On top is the Ministry of Health (MOH), the highest-
level authority in the health sector. The second tier is the provincial Department of Health 
(DOH) that provides health services for the population at the provincial level. The next level is 
the District Health Centers (DHC), responsible for health care activities in the districts and 
their communes. The fourth tier consists of the Commune Health Centers (CHC) that serve 
people in the communities. Administrative directions are operated in the top-down order from 
the MOH, province, district to communal levels. In Viet Nam, private health care facilities are 
common, especially in larger cities. In the 23 provinces that have private-public health services 
mixed in TB control (PPM), there are 26,648 private health care facilities available[123]. 
Similar to the general health care sector, the TB program is also organized by four levels in 
Viet Nam. The top level is the central (national TB control programme), followed by 
provincial TB programme, district TB units and communal health post. The TB programme at 
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the central level is located in three sites including (i) the National Lung Hospital (NLH) in 
Hanoi, (ii) the National Lung Hospital of 74 (NT.74) in Vinh Phuc province and (iii) the 
National Lung Hospital of 71 (NT.71) in Thanh Hoa province. The central TB programme is 
administratively under direction of the MOH, and technically provides direction to provincial 
, 
TB programmes. Likewise, the provincial TB programmes are administratively under 
management of the DOH, and provide technical management to the district levels. From 
district to communal levels, the TB program is fully integrated in the primary care system. The 
district level provides both administrative and technical direction to the communal level 
(Figure 1-6). 
The PMDT is fully integrated into the NTP. The infrastructure of the TB control network is 
also used for PMDT implementation (Figure 1-6) [114]. As a result, the PMDT has four 
different levels: central, provincial, district and communal level. 
Figure 1-6.0rganizational structure of the TB programme in Viet Nam. 
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At the central level, the PMDT task force has been formed as one of the technical groups under 
the official directive of the NTP Director. The main function of the central PMDT task force is 
to develop action plans, mobilize funding, ensure sufficient diagnostics and treatment supplies, 
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supervIse and monitor the implementation and progress of PMDT, provide training and 
technical assistance to peripheral levels. At provincial levels, the main function is to provide 
diagnosis, treatment, case management and follow up. However, the actual PMDT varies 
between provinces due to differences in staffing, diagnostic and treatment capacities. A 
province can have a treatment center, a treatment site, a diagnosis center, a diagnosis site or a 
cultural laboratory based on the following definitions: 
The treatment center is defined as a facility having bed capacity to hospitalize local 
MDR-TB patients and patients from surrounding provinces. 
Treatment site is a facility having bed capacity to hospitalize MDR-TB patients resided 
in the province only. 
Adjacent province is referred to a province having no bed capacity to hospitalize MDR-
TB patients. Its responsibility is to provide ambulatory treatment after patients 
discharged from treatment centers in other provinces 
Diagnosis center is a laboratory with capacity to perform DST for first and second line 
anti-TB drugs. 
Diagnosis site is a laboratory with capacity to· perform Xpert MTB/RIF to detect 
rifampicin resistance. 
Culture laboratory is a facility approved by the NTP to perform culture to follow-up the 
treatment ofMDR-TB patients. 
In case a province has no hospitalization capacity for MDR-TB patients, patients are referred to 
an adjacent province with this capacity. 
The number of provinces with a PMDT center increased from 1 to 45 provinces between 2009 
and 2015. The network expansion for PMDT regarding treatment and diagnosis system is 
presented in Table 1-4. 
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Table 1-4. Network expansion of the Viet Nam PMDT between 2009 and 2015. 
2009 2010 2011 2012 2013 2014 2015 
Total PMDT provinces 1 6 20 35 35 41 45 
, 
Treatment center 1 6 6 10 10 10 10 
Treatment sites 17 19 24 
Adjacent provinces 14 25 8 12 11 
Diagnosis center 2 2 2 2 2 2 2 
Diagnostic sites for PMDT 14 25 40 (*) 60 (**) 
Culture laboratory for PMDT 1 6 17 19 19 19 19 
(*) located in 31 PMDT provinces; (**) pI.an to procure additional 20 Xpert machines to have 
60 machines by the end of 20 15 to cover 45 PMDT provinces 
At the district level, the PMDT is managed by the district TB unit (DTU), which is the basic 
unit in the PMDT network. The main function of DTU is to identify presumed MDR-TB and 
transfer sputum samples for diagnosis, provide treatment with direct observation for patient 
when they discharge the provincial hospital, supervise treatment supporters at communal level. 
At the commune level, the PMDT is managed by commune health staff They are involved to 
support patients during ambulatory treatment, clinically assess to identify presumed TB and 
MDR-TB including symptomatic contact and refer them for screening[122]. 
As far as the involvement of the private sector is concerned, at the moment, the collaboration 
between the NTP and private sectors is being implemented for detection and treatment of 
. general TB patients, and not for MDR-TB patients specifically. The PMDT have requested the 
private sector to comply with national guidelines in treatment ofMDR-TB and to reportPto the 
NTP for cases enrolled and treatment outcome. Thus far the private sector does not comply 
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fully in reporting MDR TB cases. However, of those reported, the treatment outcome data 
show a very high default rate of up to 75% in 2011 in Ho Chi Minh city[124]. 
The TB laboratory network and system in Viet Nam 
It is recommended by the WHO that the essential laboratory services for PMDT should involve 
both mycobacteriology and clinical laboratories. Mycobacteriology laboratories are required to 
be able to identify M tuberculosis and perform DST to at least rifampicin and isoniazid. They 
also should have culture capacity for monitoring patient's response to treatment. The target is 
to have at least one culture laboratory per 5 million population [44][125]. The laboratory 
infrastructure in Viet Nam for PMDT is organized in the WHO recommended pyramid 
structure (Figure 1-7). Level I is for peripheral laboratories located in district level. The main 
function of these laboratories is doing smear microscopy while Xpert machines are only 
provided in some districts in Ho Chi Minh City and Hanoi. So far there are 979 microscopy 
units available including 730 units located in districts, 249 units located in general hospitals 
and in prison health units (equal to district level). There are only 6 Xpert machines available in 
the district level. Level II is for intermediate laboratories l?cated in the provincial level. In 
addition to capacity to perform smear in all laboratories, level II laboratories compose of 
diagnosis sites (equipped with Xpert machines) and culture laboratories responsible for doing 
culture (solid and liquid) to monitor patient's response to treatment (culture conversion). 
The laboratory network, especially in level II was expanded over time to meet the increasing 
requirements for PMDT. The population of Viet Nam in 2014 was reported at about 90 million, 
and there are 19 culture laboratories for PMDT so far to meet the WHO requirement (refer to 
the table 1-7 for number of diagnosis sites and culture laboratories). Level III laboratories 
(diagnosis centers) have DST capacity in addition to functions of levels I and II. There were 
two level III laboratories, one is the national reference laboratory located in National Lung 
Hospital (Hanoi) and one is the regional laboratory located in Pham Ngoc Thach hospital in Ho 
Chi Minh City. These two laboratories can do molecular testing, conventional DST to first line 
and second line TB drugs. 
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Figure 1-7. Laboratory organizational structure of the NTP in Viet Nam. 
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The policy of Viet Nam is to ensure quality of diagnosis and treatment monitoring of drug 
resistant tuberculosis in all TB laboratories. The infrastructure should be sufficient for 
performing sputum microscopy, culture and DST with proper bio-safety. However, the policy 
for clinical laboratory development is not mentioned in any guidelines for TB or PMDT. 
Services for this basic examination were set up by provincial health departments or TB 
hospitals themselves, and not by the NTP. In PMDT implementing sites, clinical laboratory 
services are considered to fulfill the minimum required testing for treatment evaluation. 
Two level III laboratories have the link with the supranational laboratory in Adelaide, 
Australia, the Institute of Medical & Veterinary Science (IMVS), for DST proficiency testing. 
These level III laboratories also have responsibility for smear microscopy external quality 
assurance (EQA), monitoring and supervision of culture laboratories. In 2012 the guidelines to 
ensure the quality control of a culture laboratory were developed with a check list for culture 
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laboratory supervision[125]. However, quality assurance system for culture in accordance with 
these guidelines has not been practiced adequately, and the completed checklist after 
supervision visits were not analyzed for strength, weaknesses of culture laboratory system in 
the country yet. So far there is no established EQA programs specific for Xpert MTB/RIF. To 
ensure the best performance of Xpert MTB RIF, Viet Nam has a yearly plan for calibration of 
Xpert machines and a contracted maintenance services. 
1.7.5 Resources for PMDT in Viet Nam 
The mid-term development plan for the period 2007-2011[126] and 2011-2015[127] included 
PMDT activities and were submitted and approved by the Global Fund to Fight AIDS, TB and 
Malaria (GF ATM). About 40% of this funding source was allocated for PMDT annually to 
conduct its activities from 2009- 2015 (Table 1-5). Approximately 90% of the PMDT is 
supported by the GF ATM. Other sources have also supported the PMDT including (i) 
government for first line drugs (FLDs) as part of composition for MDR-TB treatment regimen, 
(ii) budget from the President's Emergency Plan for AIDS Relief (pEPF AR) under the 
TBCARE project for human resource development, technical assistance and some facility 
upgrading activities. 
The average cost for one MDR-TB case detected and treated in Viet Nam is approximately 
USD 3,500including USD 2,000 for SLD, as opposed to aboutIOO USD required for first line 
drugs to treat a susceptible case[128]. About ninety percent of PMDT budget is for SLD, the 
other cost is for detection, training and case management. Budget allocated to case finding 
activities includes procurement of consumables (material for sputum packaging, test kits and 
reagents), cost for sputum refferal, and reimbursement for testing. For the period 2016-2017, 
the PMDT increased the capacity to provide diagnosis and treatment' for an additional 5,400 
MDR-TB patients. To prepare for funding sustainability in the future, the NTP has sent an 
official request to provincial authorities and local TB control programmes, to develop their 
own strategic plan to mobilize more local financial support for TB control including PMDT for 
the period from 2016-2020. 
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Table 1-5. GFATM funding for the NTP and PMDT from 2009-2015 
Year 2009 2010 2011 2012 2013 2014 . ~OIS 
PMDT 
, 
Budget 
(US D) ISI,110 1,478,723 3,703,731 4,011,090 4,684,019 6,867,387 8,286,033 
Total amount 
for NTP 
(USD) 3,332,387 4,018,737 10,344,00S 10,749,894 13,103,832 12,992,319 16,863,747 
% PMDT 
budget 4.S3% 36.80% 3S.81% 37.31% 3S.7S% S2.86% 49.14% 
The total number of personnel engaged in TB control in the Viet Nam is: 19,174 healthcare 
workers (2.21110,000 inhabitants). The number of staff working for TB at provincial, district 
and communal level are 5,116 (0.59 1 10,000 inhabitants), 3,475 (0.4 1 10,000 inhabitants) and 
11,840 (l.37/1O,000 inhabitants), respectively[129]. 
1.7.6 Indicators to monitor and evaluate the PMDT 
Indicators developed by GF ATM in collaboration with Stop TB Department and the Stop TB 
Partnership for monitoring MDR-TB management were adopted by Viet Nam's PMDT and 
used in this thesis. This set of indicators cover the main activities of PMDT including 
diagnosis, enrollment, treatment outcome and supply management for MDR-TB[130]. The list 
of these indicators is presented in Chapter 2. 
1.8 Outline of the thesis 
Viet Nam is a country with a high TB burden and management ofMDR-TB in Viet Nam is one 
.. of the main objectives of the TB control programme. Viet Nam started treatment for MDR-TB 
since 2009 and scaled up the network to manage MDR-TB to 45 provinces by 2015. The 
number of MDR-TB detected and enrolled on treatment increased over the past six years from 
100 patients to 1500 patients per year. Viet Nam increased the utilization of rapid diagnostic 
testing since 2012 to detect MDR-TB. In parallel, Viet Nam improved the supply chain 
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management system to access SLD to treat detected MDR-TB patients[124][128].Viet Nam 
should use these increased capacities to optimize the early detection of patients, and proper 
treatment to decrease the source of infection and diminish the amplification of drug resistance. 
This thesis, therefore, assesses current case finding strategies for TB and MDR-TB in Viet 
Nam to find targets to improve case finding to enable the NTP to detect more MDR-TB cases 
sooner. 
The first objective of this research is to assess MDR-TB control policies and practices in Viet 
Nam, with a special focus on case-finding strategy to see what the challenges are and how it 
can be improved. The second objective is to assess screening practices among a high risk group 
for MDR-TB including household contacts and other MDR-TB presumptives.Currently, the 
contacts are recommended by the NTP to go for screening whenever they have TB presumed 
symptoms. This passive case finding may not identify the MDR-TB cases who do not go for 
screening, or diagnose MDR-TB at a too late stage when the patients are seriously ill. The third 
objective of this thesis is to evaluate whether social-network analysis, an active approach for 
screening among contacts of MDR -TB cases in Viet Nam can improve MDR-TB case 
detection. The outline of the different chapters is as follows: 
- Chapter 2 presents the main outcomes of the assessment for MDR-TB control policies and 
practices in Viet Nam for case finding strategy. 
- Chapter 3 describes screening practice of household contacts of smear positive tuberculosis 
patients in Viet Nam. 
- Chapter 4 describes screel!ing practices among MDR-TB presumptive cases in areas of Viet 
Nam with PMDT. 
- Chapter 5 presents the results of the contact tracing by Social Network Analysis (SNA) to 
enhance Multi-Drug Resistant Tuberculosis Case Finding in Hanoi in Viet Nam. 
- Chapter 6 provides a general discussion of the findings described in this thesis and 
suggestions to improve case finding strategy of MDR-TB as well as for further research. 
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2.1 Background 
Multidrug resistant TB (MDR-TB) is a major public health concern that posed the challenges 
to the effective TB control programme globally. The disease is caused by the emergence of 
strains that are resistant to the most important anti TB drugs including rifampicin and isoniazid. 
This occurs ~hen antibiotics are improperly used for drug-susceptible TB patients, poor drugs 
supply and also caused by transmission of bacteria in the community[I][2]. In 2013, there were 
480,000 people developed MDR-TB in the world[3]. 
After the first WHO guideline for Programmatic Management of Drug Resistant Tuberculosis 
(PMDT) in 2006, management of drug resistant TB in Viet Nam started to gain attention. As a 
result, the management of MDR-TB has been included in the national TB control program 
since 2007 with several policies and guidelines being developed to strengthen the management 
of MDR-TB in the country. Funding for the PMDT has increased over time, with investments 
from both government and international donors reaching nearly 8,000,000 USD in 2015. 
The first pilot of the PMDT was piloted in 2009 in Ho Chi Minh city in a cohort of 100 MDR-
.TB patients with a treatment success rate of 73%. From 2010 onwards, the PMDT has 
gradually expanded its coverage to 45 provinces in 2015, with PMDT policies being updated 
over time in line with newly released WHO guidelines and contextualized to Viet Nam. Along 
with policy changes, Viet Nam has continuously increased the number of MDR-TB patients 
with a treatment success rate of approximately 70%, higher than other low and middle income 
countries (LMIC) with rates from 44-58%[3][4][5]. 
The number of 948 MDR-TB cases detected and treated annually under the existing PMDT, 
however, far fall short of the total estimated number of MDR-TB cases of 5,100 [3]. Before 
expanding PMDT coverage, an assessment of the current MDR-TB policy and practices is 
needed to come with recommendations to improve MDR-TB control. A systematic review 
illustrated that important gaps and discrepancies exist for many countries in their MDR-TB 
. guidelines measured against WHO-recommended interventions for PMDT[6]. In this chapter 
the MDR-TB control policies and practices in Viet Nam with a special focus on case-detection 
are evaluated. We also assess how MDR-TB control policies in Viet Nam have developed over 
time in response to updates in WHO guidelines. 
6S 
2.2 Methods 
We conducted a review of key policies, guidelines and reports related to the PMDT, the 
development process of guidelines and operational documents for PMDT in Viet Nam. To 
assess PMDT policy development and implementation we did systematic interviews of key 
informers of TB health staff at both central and provincial levels. Furthermore, PDMT 
performance was assessed by analyzing selected indicators using the Monitoring and 
Evaluation Toolkit from Global Fund to fight AIDS, Tuberculosis and Malaria (GFATM, table 
2-1). 
Reviewed policies, guidelines and reports included: (i) WHO guidelines for PMDT from 2008-
2014, (ii) national PMDT guidelines of Viet Nam developed by the National Tuberculosis 
Control Programme (NTP) to specify the case finding and treatment strategy for drug resistant 
TB (iii) standard operational procedures (SOPs) for PMDT (iv) official letters by the NTP to 
inform policy changes during PMDT implementation, and (v) annual progress reports of the 
NTP. The PMDT guidelines and operational documents for PMDT in Viet Nam were 
compared to those developed by WHO by each topic to assess the comprehensiveness and 
timeliness. Dates of publications were recorded to allow for assessing chronology of policy 
changes. In case of discrepancies, reasons for these were sought for in the documents or 
through contacting involved policy makers. 
Indicators for both diagnosis and treatment of MDR-TB are used in this study to assess the 
implemented policies. Seven indicators developed by GFATM in collaboration with WHO's 
Global TB Programme and the Stop TB Partnership were used, including: diagnosis, 
enrollment, treatment outcome and supply management for MDR-TB[7]. Data to construct 
these indicators were collected from the routine surveillance system of the NTP from 2009-
2015. All PMDT provinces provide quarterly reports to the NTP of the tested presumptive 
MDR-TB cases (individuals considered at high risk for MDR- TB) per different risk 
categories, number of notified MDR-TB cases, the number of MDR-TB patients enrolled on 
treatment, culture conversion at six months, and stock on hand of anti-TB drugs. Treatment 
success rate was reported annually and is defined as the proportion of patients started on 
treatment who had cure or treatment completed as the outcome. Quality assurance for drug 
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susceptibility testing was assessed by proficiency testing conducted by Institute of Medical and 
Veterinary Science (IMVS), Adelaide, Australia on a yearly basis. 
Table 2-1. PMDT Indicators recommended by GFATl\f (in collaboration with WHO's 
Global TB Programme and the Stop TB Partnership) and adoption status by the Viet 
NamPMDT 
1 
2 
Category 
Indicator 
Quality assurance for drug susceptibility testing. Improving 
Definition: Laboratories showing at least 90 percent proficiency for diagnosis 
isoniazid and rifampicin drug susceptibility testing among the total 
number of laboratories that undertake drug susceptibility testing 
during the reporting period (number and percentage). 
Number of IB cases with result for drug susceptibility testing. 
Definition: Number of IB cas~s with results for diagnostic drug 
susceptibility testing for MDR-IB among those eligible for drug 
susceptibility testing according to national policy during the 
specified period of assessment (number and percentage) 
Detection 
3 Number of confirmed MDR-IB cases enrolled on MDR-IB Enrollment 
4 
5 
--
treatment regimen. 
Definition: Number of laboratory-confirmed MDR-IB cases 
enrolled on second-line anti-IB treatment during the specified 
period of assessment (number) 
Delay in start of MDR-IB treatment. 
Definition: Ihe duration in days between the date of MDR 
confirmation (DSI results showing resistance to both isoniazid and 
rifampicin in the MDR-treatment register) and the date when the 
patient started a prescribed second-line drug regimen as per the 
MDR-treatment register. 
Culture conversion at six months. 
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Enrollment 
Interim results 
6 
Definition: MDR-TB cases initiated on a second-line anti-TB 
treatment who have a negative culture at the end of six months of 
treatment during the specified period of assessment (number and 
percentage) 
Treatment success rate. 
Definition: Laboratory-confirmed MDR-TB cases successfully 
treated (cured plus completed treatment) among those enrolled in 
second-line anti-TB treatment during the year of assessment 
(number and percentage) 
Final outcome 
7 Reporting units with stock-outs of first-line and second-line anti- Procurement 
TB drugs. and supply 
Definition: Reporting units (districts or basic management units) management 
reporting no stock-out of second-line anti-TB drugs on the last day 
of the quarter (number and percentage) 
2.3.Results 
2.3.1 Development and dissemination of guidelines and operational documents for PMDT 
In this study, we reviewed all guidelines for PMDT developed by WIIO in 2008, 2011 and 2014. 
The WHO guidelines were compared to the following documents of the Viet Nam PMDT: Viet 
Nam PMDT 2009 guidelines, PMDT SOPs published in 2012, and all reports and official letters 
issued by the NTP to inform policy changes during 2009-2015. The national mid-term plan for 
TB program for the period 2007-2011 and 2011-2015 were also reviewed. Key findings are 
presented below. 
Management ofMDR-TB was included for the first time in the mid-term plan of the National TB 
Control Program (NTP) in the period 2007-2011 as one among six objectives for TB control[8]. 
A task force on MDR-TB was established with support from KNCV Tuberculosis Foundation to 
develop a plan for PMDT implementation in the period 2007-2011 [9]. The plan was approved by 
Green Light Committee (GLC) in 2007and funded by the GFATM to pilot in 110 Chi Minh city 
and expanded to other sites. 
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In 2009, when the PMDT started, the first national guideline for PMDT was published based on 
the 2008 WHO guidelines[lO]. A Committee was formed by the NTP to develop this guideline. 
The development of this guideline involved NTP staff from central levels, TB doctors from 
Pham Ngoc Thach hospital who were in charge of supervision of Southern provinces, and 
technical consultants (from Royal Netherlands Tuberculosis Foundation- KNCV) for review and 
comments. The NTP coordinators played a role of secretariat and prepared the draft version of 
the guidelines. The guideline was contextualized to Viet Nam which was based on the five 
components of the DOTS strategy and limited diagnosis and treatment capacity of the NTP 
system. Priority was given to the highest risk groups for screening, and an ambulatory model of 
care for case management after patients discharged from hospitalization was utilized. It was 
approved by the NTP executive board in 2009 and disseminated to the TB units in the same year. 
To ensure consistency during implementation among all PMDT sites, a draft SOP was developed 
and piloted in Ph am Ngoc Thach hospital, Ho Chi Minh city. Results of the pilot was used to 
develop a standardized SOP for management of TB patients nationwide[ 11]. The SOPs were 
endorsed by the NTP in 2012 and printed and distributed to all implementing sites. This set of 
SOPs .consisted of nine operational and· technical documents including (a) procedures for 
diagnosis of drug resistant TB accompanied by the procedure for using Xpert MTBlRtF; (b) 
Sputum collection, storage and transportation; (c) consultation, registration and management for 
MDR-TB patients; (d) patient referral from district TB unit to treatment center; (e) treatment for 
MDR-TB patients at treatment unit in hospitalization phase; (g) adverse drug reactions 
management and reporting during MDR-TB treatment; (h) patient referral from treatment center 
to district TB units; (i) treatment, monitoring and management of outpatients; and (k) drug 
management for MDR-TB patients. 
During the period 2009-2015, the PMDT policies in Viet Nam for case finding and treatment 
strategy were updated to follow the revisions of the WHO guidelines of 2011 and 2014. 
Approved changes were disseminated through 17 instruction letters from the central level to the 
provincial and district TB units over 2009 - 2013 and through yearly PMDT training courses. All 
PMDT sites were trained annually on general management of PMDT, clinical management of 
MDR-TB, recording and reporting, and laboratory perfonnance. In 2013, interviews with TB 
staff at PMDT sites using an interview guide were conducted privately to investigate about 
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training provided to staff, their knowledge and awareness about PMDT. Reports from each 
interview were made and these revealed that the policy changes were not understood clearly due 
to lack of awareness about the updated policy and lack of standardized PMDT training modules 
[12]. To address this issue, the NTP revised the SOPs in 2014 and developed standard PMDT 
training modules, conducted more trainings and supervisions to all levels, and strengthened the 
communication by utilization of teleconferences to discuss about policy changes and 
consultation for clinical management. 
In 2011, the mid-term plan for the NTP for the period 2011-2015 was developed and approved 
by Ministry of Health (MOH), which included PMDT as important component[13]. This plan 
was consolidated with other health programs to form a targeted national health program with 
secured funding approved by the Prime Minister in 2012. In the national health program, it is the 
goal to control the transmission of MDR-TB and increase the access for the population to MDR-
TB management services from 25% in 2011 to 55% in 2015[13]. In January 2014, MDR-TB was 
emphasized in a resolution adopted by the Prime Minister to strengthen the implementation of 
activities towards reaching the Millennium Development Goals (MDGs)[14]. For the attainment 
of stronger political commitment for TB control, the National Strategic ·Plan for the NTP towards 
2020 and vision to 2030 was approved by the Deputy Prime Minister in March 2014. 
Comprehensive solutions were set to achieve the set goal including policy, advocacy, technical 
and financial solutions. It was expected that the NTP will keep MDR-TB under control at the 
rate of 5% among new TB cases along with policies to monitor the trend of MDR-TB and TB-
drugs adverse reactions[15]. 
2.3.2 Case finding strategy and policy changes over time 
Case finding for drug-resistant TB is the process for identifying MDR-TB presumptive patients 
(individuals considered at high risk for MDR- TB) to diagnosing and reporting MDR-TB cases 
detected. Eight components of case finding strategy are assessed: (1) targeting risk groups, (2) 
strategies for the use of Drug Susceptibility Testing (DST), (3) use of second-line susceptibility 
testing, (4) management of specimens and results, (5) case finding in pediatric patients, (6) case 
finding in HIV infected patients, (7) case-finding of patients with mono- and poly-drug 
resistance, and (8) case finding for extra-pulmonary tuberculosis. Comparisons of the WHO and 
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Viet Nam Guidelines of MDR-TB case finding strategies are presented in table 2-2. The WHO 
guidelines of 2008, 2011, and 2014 are compared with the Viet Nam policies in 2009-2011, 
2012-2013, and 2014-2015, respectively because it took at least one year for Viet Nam to 
develop and revise the policies after the three WHO publications. Table 2-2 illustrates that since 
2008, the WHO guidelines include a wide range of risk groups, recommend rapid DST with 
molecular tests and second line DST to diagnose XDR-TB. However, Viet Nam did not 
immediately adopt all WHO recommendations (Table 2-2). Due to limited resources, Viet Nam 
could only focus on a limited number of risk groups that gradually expanded since 
implementation of Xpert MTBIRIF testing. 
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Table 2-2. Comparison of the WHO and Viet N am Guidelines of MDR-TB case finding 
strategies 
Guidelines contents WH02008 WHO 2011 
IVN 2012-2013 
WHO 2014 
IVN 2014-2015 
Targeting 
risk groups 
Strategies 
for the use of 
DST 
IVN 2009-2011 
WHO All risk groups for DR-TB No update 
are mentioned. 
More attention to contact 
investigation. 
No update 
VN Mainly focus on limited Stepwise extending -Guidelines for 
number of very high risk to include more risk contact management 
groups groups -Screening among 
WHO Strong encouragement of Rapid test is 
DST for all patients with recommended over 
increased risk for MDR-TB conventional DST 
More emphasis on the role 
of rapid test for early case 
detection 
VN Hain test (Line probe assay 
to detect rifampicin and 
isoniazid resistance) . and 
conventional DST were 
used 
Use Xpert MTB/RIF 
more widely as the 
screening test while 
using Hain test less 
among MDR-TB risk 
groups 
new cases in some 
provinces in 2014 
Update for 
interpretation of rapid 
test result 
Update the 
interpretation of Xpert 
MTB/RIF in 2014 
Use of WHO SL DST to MDR-TB SL DST to all MDR- Conventional DST is 
recommended second-line patients at increased risk TB patients 
susceptibility I-:-:::-:--+-=£~or=-:X=-==D:..::R.:...-...:.T-=B:-____ ~~-:--;-_____ t--:--:-::-:-:-_-:---:--_______ 
testing (SL VN Only for non-converters* Include some more -Additional for close 
DST) after six months of MDR- categories of contacts of XDR-TI3 
Case finding 
in pediatric 
patients 
TB treatment patients** to be patients in 2014 
WHO Tuberculin test, smear, 
chest Xray, culture and 
DST are recommended. 
TB can be clinically 
diagnosed without 
bacteriological evidence. 
VN Mentioned in guidelines, 
but not in practice 
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tested from 2013 - Stepwise to give SL 
DST to all rifampicill 
resistance from 2015 
The use of rapid test 
is recommended 
Started to use Xpert 
MTBIRIF for TB and 
DR-TB diagnosis in 
Children with a single 
Xpert MTB/RIF-
negative should have 
further diagnostic 
testing 
Update guideline fof 
diagnosis in chiidrell 
when XpertMTBIRI~ 
children negative in 2014 
Case finding WHO DST at the start ofTB Rapid test is Stronger emphasis on 
inHN treatment in all HN recommended over the role of rapid test to 
infected patients conventional DST' detect rifampicin 
patients Use rapid diagnostic resistance and the 
techniques if possible need of SL DST for 
Implement XDR-TB XDR-TB diagnosis 
diagnosis inhigh prevalent 
setting 
VN Mentioned in guidelines, Started to use Xpert XDR TB diagnosis for 
but not in practice MTBIRIF for TB and MDR-TB or 
DR-TB diagnosis in rifampicin resistance 
HIV infected patients with HN from 2015 
Case-finding WHO Recommended strategies to Rapid DST followed No update 
of patients detect mono and poly by further DST and 
with mono- resistant TB during the clinical evaluation 
and poly- course ofMDR-TB 
drug diagnosis 
resistance VN Not available Rifampicin resistance Rifampicin resistance 
diagnosed by Gene separate from MDR 
Xpert MTBIRIF TB by further Hain 
testing among 
rifampicin resistance 
. from 2015 
Case finding WHO Not clearly developed Not clearly EPTB-DR can be . 
for extra developed diagnosed by Xpert 
Pulmonary MTBIRIF or 
tuberculosis conventional DST 
(EPTB- VN Not available Not available Start to use Xpert 
MDR-TB) MTBIRIF in non-
respiratory specimens 
* People whose sputum culture had not converted from positive to negative 
** Including retreatment cases (relapse or treatment failure), treatment after default, HIV 
positive TB patients, household contacts of MDR-TB cases, and TB presumptive patients with a 
history of TB drug use for more than 1 month. 
Targeting risk groups 
The WHO Guideline of 2008 identified the following risk groups for MDR-TB: retreatment 
patients, close contacts of known MDR-TB patients, patients who remain smear positive at 
month 2 or 3 of short-course chemotherapy with first line anti-TB drugs, people who were in an 
institutiQn with high risk of MDR-TB, individuals infected with HIV. It was recommended for 
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each country to identify the risk groups based on patient's history and epidemiological data of 
drug resistance in the country. Intensive investigations of contacts with MDR-TB and especially 
XDR -TB cases should be conducted to increase early detection of MDR-TB cases. Viet Nam 
had no data available on drug resistance for the different patient groups, and as a result it was 
decided for the 2009 PMDT guideline to include all WHO recommended risk groups. However, 
only patients with a history of treatment such as failure cases, non-converters of the retreatment 
regimen and chronic cases were given priority in Viet Nam and the remaining categories were 
ignored due to limited resources. Management of MDR-TB contacts was not established yet at 
the time. MDR-TB contacts were advised to self-refer for TB testing in case of symptoms 
suggesting TB. 
From 2012, with the introduction of Xpert MTBIRIF in Viet Nam, additional risk groups for 
MDR-TB screening were included: retreatment cases (relapse or treatment failure), treatment 
after loss to follow-up for more than two months, HIV positive TB patients, household contacts 
of MDR-TB cases, and TB presumptive patients with a history of TB drug use for more than 1 
month. Despite this expansion of risk groups, many presumptive MDR patients were missed for 
screening until 2013 (refer to indicators for PMDT performance for more detail). 
In 2014, Viet Nam revised the PMDT guideline according to the WHO Companion Hand Book. 
Contact management was also incorporated where symptomatic contacts of MDR-TB would be 
registered, followed up and evaluated by health staff systematically. Since 2015, in addition to 
the risk group expansion, Viet Nam will also start to screen for MDR-TB among new smear-
positive TB cases (started in 14 provinces with high burden ofMDR-TB). 
Strategy for drug susceptibility testing (DST) 
The second version of WHO guidelines (2008) recommends performing DST for at least 
isoniazid and rifampicin for all patients at increased risk for MDR-TB. However, patients from 
very high risk groups (for example failures ofretreatment regimen or chronic cases) are allowed 
to be enrolled to MDR-TB treatment without DST if resources for DST are limited. From 2009 
to 2011, rapid tests (Line probe assay -LPA, Hain test) were used to diagnose MDR-TB among 
failure cases of first-line treatment and for non-converters (after 3 months) of retreatment cases. 
Failure of retreatment cases and chronic cases were put on MDR-TB treatment without Hain test. 
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The third WHO guidelines in 2011 recommended the use of rapid molecular DST rather than 
conventional testing or no testing. From 2012, Xpert MTBIRIF was expanded to replace Hain 
tests in Viet Nam. Xpert MTBIRIF is currently used widely as the first screening test to detect 
rifampicin resistance for all PMDT sites. The Hain test is only, used at the National Reference 
laboratory and Pham Ngoc Thach hospital, mainly for patients who self referred for TB 
diagnosis. 
The fourth WHO guidelines in 2014 updated the interpretation of molecular test results 
accounting for the patient risk category. According to this recommendation, if the Xpert 
MTBIRIF assay detects rifampicin resistant TB in patients considered at high risk for MDR-TB, 
no confirmatory testing needs to be performed. This is because for these cases the positive 
predictive value for RIF resistance is considered sufficiently high[ 16]. Only in low risk 
individuals, confirmatory testing is recommended using another phenotypic or another genotypic 
test. Further DST for isoniazid and second line drugs is recommended to adjust the empirical 
second line treatment regimen according to the DST results. Viet Nam requires confirmatory 
testing if rifampicin resistance is d,etected among low risk groups. However until 2014, due to 
limited resource,. no further DST was provided prior to treatment. Patients will be tested for 
second line TB drugs only if their sputum does not convert after 4 months of MDR-TB 
treatment. From 2015, the NTP plans to stepwise manage XDR TB and use Hain test for first 
line drugs and DST for second line drugs to patients with rifampicin resistant TB detected by 
Xpert MTB/RIF. 
Use of second line DST in case-finding and diagnosing XDR-TB 
As per the second WHO guidelines of 2008, patients at risk for XDR-TB or at risk for failure of 
MDR-TB treatment should receive DST for injectable agents and fluoroquinolones. Those at risk 
are: failure of MDR-TB treatment, close contact of XDR-TB or contact of patients who failed 
from MDR-TB treatment, patients who have evidence of progressive disease after 4 months of 
second-line treatment, patients having persistent positive smear or culture ,after 8 months or more 
of treatment. For XDR-TB in a high prevalence setting, second line drug (SLD) DST may be 
used for all MDR-TB who are HIV positive. The third WHO guidelines (2011) and the 
Companion Handbook (2014) recommended using second line DST for all MDR-TB patients, or 
at least for patients with risk factors for XDR-TB. In Viet Nam, from 2009-2012, without 
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experience and capacity for XOR-TB diagnosis and treatment, the policy for this period was only 
to perform OST for patients whose sputum did not convert after six months of MOR-TB 
treatment. This policy was intended to monitor XOR-TB as no drugs for XOR-TB treatment 
were available at the time. From 2013, with the improvement in technical capacity to perform 
second line OST, more categories of patients were added for testing including (i) rifampicin 
resistance with previous SLO use, (ii) MOR-TB treatment non-converters, and (iii) random 10% 
of rifampicin resistant cases, even though still no treatment for XOR-TB was available. Since 
2014, Viet Nam included close contacts of XOR-TB patients for testing. Currently, Viet Nam 
performs OST for second line drugs: kanamycin, capreomycin, amikacin and ofloxacin. As of 
2015, it is Viet Nam NTP policy to start managing and providing treatment for XOR-TB at small 
scale (three provinces: Ha Noi, Ho Chi Minh City, and Can Tho) to draw lesson learned, and 
later on to expand to the rest of the country. 
Case finding in pediatric patients 
The second WHO guideline recommended using tuberculin testing, sputum smear examination, 
chest X-ray, culture and OST for MOR-TB diagnosis in children. Children with TB suggestive 
symptoms who are close contacts of MDR-TB patients can already start MDR-TB treatment 
even if they are smear and culture negative. This strategy for children is mentioned in the 
Vietnamese guidelines but was not put into practice until 2009 due to limited diagnostic capacity 
for culture and OST and absence of mechanisms of managing contacts. Since 2012, Xpert 
MTBIRIF has been used in Viet Nam to detect TB and rifampicin resistance TB in children with 
TB presumptive and/or at increased risk for MOR-TB in line with WHO guidelines from 2011. 
Case finding in IIIV infected patients 
The second WHO guideline (2008) recommends that DST (either rapid or conventional) should 
be performed at the start of TB treatment in HIV co-infected patients. Patients can be enrolled 
into MDR-TB treatment empirically without OST confirmation. The Companion Hand Book 
recommends that all TB-HIV co-infected patients, besides rapid DSTtest, should also be tested 
for second-line anti-TB drug resistance in case of DR-TB. Similar to the policy for MDR-TB 
case finding in children, OST for TB-HIV patients is mentioned in the PMDT guidelines of Viet 
Nam since 2009[10]. However it was not implemented between 2009-2011 due to limitations in 
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diagnostic capacity for culture and DST. Although there was no policy to provide DST for HIV 
infected patients in this period, HIV testing was provided to TB and MDR-TB patients in Viet 
Nam. The indicator set by the NTP for the period 2013-2015 is to provide HIV tests for 65% to 
90% of all TB patients. This indicator was set for HIV testing among TB patients in general and 
did not prioritize patients with presumptive MDR-TB. Until 2014, 72.5 % of TB patients were 
tested for HIV[l7]. From 2012, Viet Nam started to use Xpert MTBIRIF to detect rifampicin 
resistance in HIV infected patients. However, second line DST is not yet performed when 
rifampicin resistance is detected due to limited capacity for diagnosis and treatment ofXDR-TB. 
Case-finding of patients with mono- and poly-drug resistance 
In 2008, WHO recommended to identify cases of mono- and poly-drug resistance (resistance to 
one or more anti-tuberculosis drugs but not to both isoniazid and rifampicin) by DST. Due to 
limited resources for diagnosis and treatment of DR-TB, it was NTP's policy in the period 2009-
2011 to focus on MDR-TB only. 
The NTP uses Xpert MTBIRIF since 2012 to detect rifampicin resistant TB. However, isoniazid 
susceptibility testing.is not performed in rifampicin resistant TB due to limited resources. As of 
2015, it is the NTP policy to provide the Hain test to detect isoniazid resistance in rifampicin 
resistance cases detected by Xpert MTBIRIF. Additionally, if rifampicin resistance is not 
detected among patients who failed or relapsed from retreatment regimen, conventional DST to 
four first line drugs including streptomycin, isoniazid, rifampicin, etambutol (SIRE) will be 
performed to detect mono or poly resistance. 
Drug-resistant TB case finding among extra-pulmonary TB 
Until the second and the third WHO guidelines in 2008, 2011, case finding for extra-pulmonary 
(EPTB) MDR-TB has not been clearly developed. The Companion Hand Book (2014) 
recommends that drug-resistant extra-pulmonary TB can be diagnosed by Xpert MTB/RIF or 
conventional DST. To diagnose meningitis rapidly, it is recommended to use Xpert MTBIRIF in 
cerebrospinal fluid specimens due to the severity disease in these patients. Therefore in 2014, 
Viet Nam updated their guideline to also use Xpert MTBIRIF in non-respiratory specimens to 
diagnose EPTB, particularly TB meningitis. 
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2.3.3 PMDT performance 
Six among the seven indicators to monitor MDR-TB programs developed by the GFATM have 
been adopted by Viet Nam over time. At the start few indicators were adopted due to time 
constraints and lack of an adequate health management information system. Currently only one 
indicator (delay in start of MDR-TB treatment) has not been adopted due to time constrains. 
PMDT indicators achieved during the period 2009-mid 2015 are presented in the table 2-3 
below. 
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Table 2-3. Measurements of PMDT indicators for performance framework (PF) 
from 2009-2015 
Mid-
2009 2010 2011 2012 2013 2014 
Indicators 2015 
Quality assurance for Target (%) 100 100 100 100 100 100 100 
drug susceptibility Achievement 
1 100 100 100 100 100 NA NA 
testing (%) 
% of presumptive Not Not Not Not 
Target (%) 28 40 55 
MDR-TB patients with set set set set 
result for isoniazid and 
2 Achievement 
rifampicin susceptibility NA NA 14.4 20.4 31.2 82.5 NA (%) 
testing· 
Target 100 250 698 900 916 1502 2200 
Confirmed MDR-TB (number) 
cases enrolled on MDR- 101 97 578 713 943 1532 
3 TB treatment regimen Achievement NA 
Number(%) 
(101) (39.8) (82.8) (79.2) (102.9) (102) 
MDR-TB cases on Target (%) NA NA 65 70 75 75 75 
MDR-TB treatment 
regimen with negative Achievement 
4 (%) 77 75 73 74 57 67 NA culture by six months 
Target (%) 75 75 75 75 75 75 75 
5 Treatment success rate Achievement 
(%) 73 78 72 70 NA NA NA 
Reporting units with no Not Not Not Not Target (%) 100 100 100 
stock-outs of first-line set set set set 
and second-line anti-TB Achievement 
6 100 100 •• •• 100 100 NA 
drugs: (%) 
(*)Xpert MTB/RIF is used since 2012 to replace Hain test, so INH susceptibility results were not 
available for this indicator from 2012. 
(**) stock out reported, no exact numbers known; (NA): not available 
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The first indicator on quality assurance shows that between 2009-2013, two reference 
laboratories participated in DST proficiency testing and had an optimal score. Proficiency testing 
was not done in 2014 due to renovations. 
The second indicator determining the proportion of presumptive MDR-TB patients that have a 
DST result was not included in the monitoring and evaluation plan until 2013. Data to calculate 
this indicator was available since 2011 and showed that the proportion of patients with DST 
performed increased from 14% in 2011 to 85% in 2014. The steep rise was mainly due to the 
introduction of Xpert MTBIRIF rapid test system. 
The third indicator is to measure the number of confirmed MDR-TB cases enrolled in MDR-TB 
treatment regimen. The performance showed a favorable achievement compared with the target 
except for 2010 due to a delay in the drug supply. 
The fourth indicator to evaluate how many MDR-TB cases have converted to negative culture 
after six months of treatment has been included in the monitoring plan since 2011. The data was 
already collected by the NTP since 2009 to evaluate patient's response to treatment. Between 
2009 and 2012, 75% of MDR-TB patients culture converted by six months of treatment. It 
decreased to 57% and 67% for a cohort of patients in 2013 and 2014. 
The fifth indicator for MDR-TB treatment success rate is evaluated 48 months after start of 
treatment. The target for this indicator was set to the WHO target of 75% for treatment success. 
Viet Nam achieved 73% and 78% of patients treated successfully between 2009 and 2010. 
However, the outcome of cohort 2011 and 2012 showed a decreased to 72% and 70%. 
The sixth indicator concerns the drug supply to ensure treatment for MDR-TB patients. It was 
not included in the monitoring plan between 2009 and 2010. Available reports do show that no 
stock outs occurred in this period. Between 2011 and 2012, stock outs ofSLDs were reported by 
several sites, but no details are available. Since 2013 no stock outs of SLD have been reported. 
2.4. Discussion and recommendations 
In general the development process of guidelines and operational documents for PMDT in Viet 
Nam goes through a process of problem identification, stakeholder involvement, consideration of 
resources, an official approval and subsequent delivery of policy documentation to implementing 
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sites. There is a considerable delay in the development of SOPs which took three years since 
implementing PMDT. 
Most WHO recommended MDR TB risk groups are included for screening in Viet Nam policies. 
Since 2013, 35 provinces with the highest number of MDR-TB, accounting for approximately 
85% of all MDR-TB for the whole country, are covered by PMDT. Untill2013 the proportion of 
MDR TB presumptive tested (indicator 2) accounted for about 30%, and increased to 85% in 
2014 to cover eligible presumptive MDR-TB cases as per national guidelines. This increase can 
be explained by an improved training and communication strategy for PMDT in 2014 based on 
an assessment in 2013 (submitted for publication). 
Screening new smear positive TB cases for MDR-IB is one way to increase the MDR-IB case 
detection rate and in line with the global strategy of testing in new TB cases[18]. However this is 
too costly as it is currently estimated that the proportion of MDR-TB among new TB cases is 
approximately 4%, and 23% among previously treated TB cases in Viet Nam [3]. Therefore, as 
far as new IB cases are concerned, Viet Nam will target high risk groups for MDR-IB, 
including new IB cases in institutions with high risk of MDR-J:B such as prisons and hospitals. 
In order to manage contacts of MDR-IB cases systematically, Viet Nam willfollow contacts 
more closely to early MDR-IB diagnoseand exclude them from chemoprophylaxis as offered to 
contacts of susceptible IB cases[l]. It is desirable for the PMDI to have better epidemiological 
data on MDR-IB by risk groups and by geography to target case finding and make better use of 
limited resources in the future. 
Viet Nam has continuously followed the most updated versions of WHO TB policy changes. 
Viet Nam introduced Xpert MTB/RIF to test presumptive MDR-TB cases one year after the 
WHO recommendation (2011), and now also uses this test to diagnose extra-pulmonary DR-TB. 
. For detection of mono and poly resistance to drugs other than rifampicin in a limited resource 
setting, it is appropriate to use conventional DSI among patients who were previously treated 
with the retreatment regimen but are not resistant to rifampicin as detected by Xpert MIBIRIF. 
Given that the MDR-IB rate in Viet Nam is about 80% among failure cases [19]and that Xpert 
MTBIRIF has only 95% sensitivity[l6], it would be beneficial to start these patient on empirical 
MDR-TB treatment awaiting phenotypic DST results .. In order to detect more mono and poly 
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drug resistance, Viet Nam should consider performing first line DST in any TB patient who has 
been previously treated but has no resistance to rifampicin by Xpert MTBIRIF. There is a high 
proportion of resistance to drugs other than rifampicin in Viet Nam: 44.2% for streptomycin and 
44.7% for isoniazid among previously treated patients[20]. Treatment of undetected mono and 
poly resistant TB patients using standardized short-course chemotherapy can increase the risk of 
further acquired resistance including MDR-TB, and thus needs to be avoided[I][2]. Viet Nam is 
therefore recommended to detect to mono and poly drug resistant TB properly and for resistant 
cases provide treatment with modified see or even second line drugs to prevent drug resistance 
amplification[2]. 
Susceptibility testing for isoniazid, fluoroquinolones and second-line injectable drugs is not 
performed on rifampicin resistant TB isolates to direct treatment. Not doing this may result in 
that the potent drug isoniazid is not administered to about 5% (or even higher if we take into 
account low-level INH resistance) of patients with TB resistant to rifampicin but susceptible to 
isoniazid[20]. SLD DST is needed to provide appropriate treatment to XDR-TB patients and 
patients who have fluoroquinolone resistant strains which are estimated to comprise 5.6% and 
16.7% ofMDR-TB patients in Viet Nam, respectively, according to a preliminary report from a 
TB drug resistance survey conducted in 2011-2012 (unpublished data). It is expected that as of 
20 IS Hain testing for first line drugs and SLD DST will be introduced in a stepwise manner for 
all rifampicin resistant strains detected by Xpert MTB RIF. 
Regarding case-finding and diagnosing XDR-TB, due to limited capacity and experience in 
XDR-TB treatment, the policy of using second-line DST to diagnose XDR-TB is only intended 
for monitoring and evaluation and not for treatment, which is clearly undesirable. Fortunately, 
this issue will be addressed as of 2015. As susceptibility to older and newer generation 
fluoroquinolones varies[2], it is recommended to perform DST specifically for the 
fluoroquinolones used in the PMDT programme. Viet Nam will likely prioritize second line DST 
in HIV patients with rifampicin resistant TB. 
Indicators of PMDT performance from 2009-20 IS suggest that the increase in the screening of 
presumptive MDR-TB cases to detect more MDR-TB cases has affected the quality of case 
management. With the expansion ofPMDT coverage (from 1 to 45 sites) and the increased target 
set for the number of cases to enroll for treatment (from 100 to 2200 patients), the conversion 
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and treatment success rates have decreased and are below the national set target of 75%. 
According to the NTP, the decrease in conversion rate from 77% to 57% -67% may be explained 
by lack of follow up cultures performed, and the increase in the proportion of patients still 
positive at month 6 (at risk of failure to treatment) which were included in denominator to 
calculate the indicators[17][21-23]. However, reasons for loss to follow up are unknown and 
patients lost to follow-up may be still infectious or even have drug resistance amplified and 
continue to transmit drug resistant TB to the community. The success rate achieved by Viet Nam 
is still overall higher compared to other LMIC countries [3]. However, the decrease in treatment 
success rate from 73-78% to 72-70% may be explained by the increase in those lost- to -follow 
up from 6-7% to 12% (both success and lost-to follow up cases were included in the denominator 
to calculate treatment outcome indicators)[17][21-23]. Poor links between provincial TB 
programs and district TB units along with unsupervised therapy while expanding PMDT may 
have lead to this situation[24]. Currently, the indicators used by Viet Nam are only for MDR-TB 
management. To monitor the detection and treatment of XDR-TB, Viet Nam should include 
more indicators as recently recommended by the WHO[2]. The insufficient capacity for PMDT 
to deal with the considerable MDR-TB cohort expansion is also .reflected in the drug supply 
system. The stock outs during 2011-2012 were due to inadequate capacity for SLD management 
system to adapt the increasing number of patients [21][22]. 
Furthermore, regular policy changes are not communicated well to implementing sites resulting 
in policies not being implemented well. There is a need for the NTP to utilize standardized 
training modules and, possibly, distance learning tools to save resources. A clear implementation 
process needs to be put in place to ensure the right people receive the right information and this 
should be monitored and evaluated. 
2.5. Conclusion 
Our study reviewed WHO initiated MDR-TB policy as well as the adaptation and 
implementation of these policies in Viet Nam, with a special focus on case finding strategy. The 
study found that the policies for MDR-TB case finding in Viet Nam have been developed and 
revised in line with the WHO guidelines over time, with participation from key experts in the 
country. To address the issue of limited resources, priority was first given to people at highest 
risk to acquire MDR-TB, subsequently expanding to include almost all WHO recommended 
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targeting groups for DST. From 2012-2015, Viet Nam rapidly implemented Xpert MTBIRIF to 
detect TB and rifampicin resistance in MDR-TB presumptive cases. 
However, inadequate communication of policy changes have led to inadequate knowledge 
among NTP staff on policy implementation. In addition, lack of resources posed significant 
challenges for the NTP to implement their policy, such as delays in management of MDR-TB 
contacts and in diagnosis of mono and poly resistant TB, as well as inadequate performance of 
second-line DST to diagnose XDR-TB. 
While PMDT has been established since 2009 with policies updated following WHO's 
recommendations, numbers of MDR-TB cases have enrolled to treatment have remained limited 
compared with the estimated number of MDR-TB cases among notified TB patients. This is due 
to the focus of MDR-TB screening being on certain high-risk groups rather than on new TB 
cases. Expansion of risk groups for MDR-TB screening is key to increasing the detection of 
MDR-TB cases. However, in order to ensure high quality of policy implementation as PMDT is 
being scaled up, the NTP should standardize and decentralize training on PMDT and improve the 
communication about PMDT policies while sustaining and strengthening the quality of case 
management and treatment. 
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Abstract 
Background: Close contacts of tuberculosis (TB) patients are at increa~ed risk of developing 
tuberculosis. Although passive contact screening guidelines are incorporated in the national TB 
control program, currently it is unknown how frequent close contacts are screened for TB in 
Vietnam. This study assesses current contact screening practices in Vietnam and determines the 
proportion of household contacts screened of newly registered TB patients. 
Method: Survey of household contacts of smear-positive TB patients (index patients) registered 
for treatment in 2008 in three Vietnamese cities. Households were interviewed in 20 I 0 about 
screening for TB since treatment registration date of the index patient. 
Results: We interviewed 4,118 household contacts of 1,091 identified index cases. Contact 
screening mainly relied on self-referral by household contacts. Of the 4,118 household contacts, 
474 (11.5%) self-referred for TB screening, while this screening proportion was only 5.5% 
among contacts under 5 years old (16/293). Sputum examinations were performed in 374 
(78.9%) of the screened contacts. Contact screening identified 27 cases of pulmonary TB (0.7%; 
or 656 cases/IOO,OOO contacts), of which 2.0 were detected by sputum smear. . 
Conclusions: The low proportion of household TB contacts screened for TB illustrates the 
limitations of passive contact screening as currently practiced in Vietnam. Children under 5 years 
of age are particularly neglected with this approach. Active contact screening with fixed follow-
up times of close contacts of newly diagnosed TB patients should be considered in Vietnam, 
particularly in case of young children and drug-resistant TB. 
Key words: Tuberculosis, contact screening, case finding, Vietnam 
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3.1 Introduction 
The World Health Organization (WHO) reported that the detected proportion of incident global 
tuberculosis (TB) cases is below the WHO target of70% [1]. One of the proposed solutions is to 
improve the case detection rate by active and systematic screening all household contacts of 
pulmonary TB patients, since they are considered to be at increased risk for TB infection [2, 3]. 
Although contact investigation is already a priority of tuberculosis control programs in many low 
burden and resource replete countries [4], in high burden and resource deplete areas contact 
screening for TB is often not performed due to the high workload and costs [5]. The recently 
issued International Standard for Tuberculosis Care states that contact investigation is an 
important activity and warrants more effort to ensure that persons in close contact with infectious 
TB patients are evaluated and managed [6]. 
Vietnam currently ranks 12th out of 22 countries with a high burden of TB [1]. The annual 
notification rate of new smear-positive pulmonary TB to the National TB Program (NTP) in 
recent years is about 57-58/100.000 population [7], but only accounts for 56% of new TB cases 
that occur annually. The remaining 44% are not diagnosed and/or diagnosed but not reported to 
the NTP [8]. In order to increaS'e TB notification, the NTP utilizes both passive and active case 
finding strategies [9]. However in practice, due to lack of specific instructions for active case 
finding and insufficient resources, active case finding is rarely done. For most of the Vietnamese 
population, the NTP strategy relies on "passive case finding". Passive case finding needs people 
to self-report with TB symptoms to primary health centers, and are then screened by sputum 
smear. This passive case finding strategy makes use of mass media to inform the general 
population about TB so that they can self-refer when symptomatic. For household contacts of 
infectious TB patients, a similar strategy exists as for the general population. The only difference 
is that TB patients and their contacts get direct information and instructions from health staff 
regarding when the household contacts need to come for screening. We refer to this strategy as 
"passive contact screening". 
This passive contact screening strategy is incorporated in the NTP guidelines and meets the 
minimum requirements for contact investigation as recommended by the WIIO [10]. The 
requirements include: provide health education to TB patients and their household contacts, 
household visits and check for symptomatic contacts, perform sputum smear in case of 
90 
prolonged cough. Health education is performed either at the health facility, where patients come 
to take drugs, or at home when health staff visits patients. The health education includes 
instructions when to seek screening, with additional instructions for children <5 years such as 
fever for more than two weeks or failure to thrive as their symptoms may be aspecific. 
There are no data on current contact screening practices in Vietnam, while these data are 
essential for managing the program. Therefore, we conducted a retrospective cohort study of 
household contacts of patients with newly diagnosed TB in three large cities in order to assess 
whether they follow the NTP guideline on the following aspects: (1) screening of symptomatic 
household contacts, (2) screening of children <5years, and (3) type of screening tests performed. 
3.2 Materials and Methods 
3.2.1 Study design and setting 
We conducted structured interviews within the households of newly diagnosed TB patients who 
Were registered for treatment with the NTP in 2008. The interviews were conducted between 
October and December 2010 in nine randomly selected districts of three large cities in Vietnam, 
three districts per each city: Hanoi, 110 Chi Minh City, and Da Nang. This study" was approved 
by the research committee of the National Lung Hospital in Hanoi. Informed consent was 
obtained from TB patients and subsequently from their household contacts. 
A standardized questionnaire was used to evaluate the contact screening practices of household 
Contacts of TB patients. The interViews were conducted by local health staff of the TB program. 
The survey was done in the evening during working days and during daytime in weekends. In 
case of absence on 2 visits, the household was considered 'lost to follow-up'. The questionnaire 
sought information from the patients and their household contacts about the TB screening 
instructions received at the time of treatment and whether the instructions were followed. Index 
patients and household representatives were asked about the occurrence of prolonged cough 
among household contacts since the diagnosis ofTB in the index case and whether these contacts 
Went for screening or received advice from health staff regarding screening. Primary caregivers 
provided the answers concerning children. 
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3.2.2 Study population and definitions 
The study population consisted of smear-positive TB patients registered for treatment in 2008 in 
one of the 9 districts mentioned above (index patients), satisfying at least one of the following 
criteria: (1) >1 smear- positive samples (from two different sputum specimens), or (2) one 
smear-positive sample and an abnormal chest Xray (CXR) consistent with TB, or (3) a positive 
culture with or without positive smear. For the survey we included household contacts of notified 
TB cases. The following definitions were used: 
• Household contact: an individual that shared the same house with the index case for a period 
of at least 3 months leading up to the time of diagnosis of the index case. 
• Screened household contacts: a household contact who attended a public or private health 
facility for TB screening in the interval (days) between the day treatment was started of the 
index case and the interview date of the household. 
• Secondary case: a household contact who was diagnosed to have TB in the interval (days) 
between the day start of treatment of the index case and the day of interview of the household. 
• Prolonged cough: unexplained cough of more than two weeks duration occurring between the 
start of treatment of the index case and the interview of the household. 
3.2.3 Data collection and analysis 
The data were collected through the NTP district coordinators. The staff of commune health 
stations conducted the household interviews after study specific training was provided. Data 
were entered into Microsoft Access software, and exported to SPSS (version 17.0) for analysis. 
Data quality was monitored by cross-checking 10% of the data entered in to the database against 
the original paper-based questionnaire. Descriptive statistics, including frequency, median, 
interquartile range (IQR), proportion and 95% confidence intervals (95% CIs), were performed 
where appropriate. Proportions were compared using the chi-squared test. P-valucs below 0.05 
were considered significant (two-sided). 
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3.3 Results 
3.3.1 Demographic and clinical characteristics of study population 
We interviewed the household contacts of 1,09111,215 (89.8%) smear-positive TB patients 
registered in 2008 in the nine selected districts. Households of 124 index TB patients (10.2%) 
did not participate in the study because of the death of the index case, absence at the time of 
interview, or having moved to another address. 
Demographic and clinical characteristics of index TB patients and their household contacts are 
described in Table 3-1. The male-to-female ratio was approximately 3:1. Of the 1091 index 
patients, 90 (8.2%) were IIlV positive and 77 (7.1%) had a history of drug abuse. Of 4118 
household contacts, 293 (7.1 %) were children under 5 years of age at the time of the interview, 
and 142 had prolonged productive cough at any time between registration of index patient and 
the interview (3.4%; 95% CI 2.9-4.0%; Figure 3-1). Of 1,091 index patients, 1,017 (93.2%) 
stated that none of their family members, other than the index case, had ever had a diagnosis of 
TB. 
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Table 3-1. Characteristics of study population 
Category Characteristics n % 
Index TB patients 
Sex Male 816 74.8 
Female 275 25.2 
Age <5 0 0.0 
5- 14 0 0.0 
15-24 136 12.5 
25-34 178 16.3 
35-44 234 21.4 
45-54 231 21.2 
55-64 139 12.7 
>=65 173 15.9 
Household contacts 
Age <5 293 7.1 
5- 14 631 15.3 
> 15 3194 77.6 
Household contacts who went for TB screening 
Sex Male 170 35.9 
Female 304 64.1 
Age <5 16 3.4 
5- 14 31 6.5 
>15 427 90.1 
Household contacts with smear examination 
Sex Male 132 35.3 
Female 242 64.7 
Age <5 2 0.5 
5- 14 13 3.5 
> 15 359 96.0 
Secondary TB cases detected from contacts (any test) 
Sex Male 13 48.1 
Female 14 51.9 
Age <5 1 3.7 
5- 14 2 7.4 
> 15 24 88.9 
Secondary TB cases detected from contacts (positive smear) 
Sex Male 11 55.0 
Female 9 45 .0 
Age <5 0 0.0 
5- 14 2 10.0 
> 15 18 90.0 
* TB tuberculosIs 
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Figure 3-1. Flow chart of tests taken for household contacts of smear-positive TB patients 
in three cities of Vietnam, 2008-2010. 
Prolonged cough 
n=142 
Not screened 
n=39 
I I 
Screened 
n=103 
I 
No Xray done 
I 
Household contacts ofTB patients 
n=4118 
I I 
Cough unknown or no cough 
n=3976 
I I 
Screened Not screened 
n=3605 
n=371 
I I 
Xray No Sputum 
diagnostics n=11 smear 
Sputum Missing 
smear done data diagnostics 
done 
n==4 
Abnormal consistent 
with TO, n=4 
3.3.2 Household screening 
n=88 
Positive smear 
n=17 
Positive smear 
n=20 
• n=286 
Positive smear 
n=3 
n=65 n=13 
Abnormal consistent 
with TO 
n=3 
. done 
n=7 
the median number of household contacts per index patient was 3.8 (IQR: 3 - 5). During the 
interval between the registration of the index case and the interview, at least one household 
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contact was screened for 335/1,091 (30.7%; 95% CI: 28.0-33.4%) index patients. A total of 
474/4,118 (11.5%; 95% CI: 10.5-12.5%) of all household contacts sought TB screening, 
including 16/293 (5.5%; 95% CI: 2.9-8.1 %) contacts aged under 5 years (Figure 3-2). The rate of 
screening was higher (p-value <0.05) among those with prolonged cough (103/142; 72.5%; 95% 
CI: 65.2-79.9%) than among those without prolonged cough andlor cough unknown (371/3976; 
9.3%; 95% CI: 8.4-10.2 % Figure 3-1). Detailed information regarding the examinations 
performed was available for 461/474 (97%) individuals who went for TB screening. Smear 
examination was done for 374/461 contacts (81.1 %), 76 (16.5%) contacts only had CXR and 11 
(2.4%) had neither sputum nor CXR examination (Figure 3-1). Of 103 contacts with prolonged 
productive cough who were screened, 88 were tested by direct sputum smear examination 
(85.4%; 95% CI: 78.6-92.3%), 11 (10.7%; 95% CI: 4.7-16.6%) only by CXR and 4 (3.9%; 95% 
CI: 0.2-7.6%) had no specific TB testing. There was no significant difference in the proportion of 
contacts that went for TB screening by smear grade of the index case (p value =0.23, Table 3-2). 
Figure 3-2. Venn diagram for screening of household contacts of smear-positive TB patient 
in three cities of Vietnam, 2008-2010. 
Contacts had sputum 
c 
exam 
All ages (< 5 ys).· n- .H4 (2) 
TB ease detectedd 
All ages « 5 ys). n:27 (1) 
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Houlehold contact,· 
All ag s « 5 ys). r4U8 (291) 
Contacu went for TB 
screening b; 
All If}8S « 5 ys) ' n-474 (16) 
Table 3-2. Screening for contacts grouped by sputum grade of index patients 
Positivity Contacts Secondary 
No of Contacts went' 
grade of No of per cases with 
Index for screening 
index contacts index positive 
cases8 
patient n(%) 
smear; n(%) case 
3+ 144 563 3.9 75 (13.3) 3 4.0% 
2+ 183 699 3.8 75 (10.7) 3 4.0% 
1+ 610 2249 3.7 265 (11.8) 9 3.4% 
Scanty 154 607 3.9 59 (9.7) 5 8.5% 
Total 1091 4118 3.8 474 11.5% 20 4.2% 
aBased onlhe International Union Against Tuberculosis and Lung Disease (IUA TLD)-recommended 
grading oJsputum smear microscopy results 
Just 103 (21.7%) symptomatic contacts that went for screening had prolonged productive cough, 
and the remaining 371 (78.3%) had no prolonged cough ~nd/or cough unknown. 39 contacts with 
prolonged cough did not go for screening. Reported reasons for not going for screening included: 
busy earning a living, feeling better after self-medication with over-the-counter drugs, and afraid 
of un affordable treatment cost. 
Among the 4,118 household contacts, 27 secondary TB cases were detected (detection rate: 0.7% 
Or 656 patients/IOO,OOO contacts), of which 13 were male. One TB case was detected among 
children under 5 years of age (Table 3-3). 20 contacts with TB were diagnosed by positive 
Sputum smear and 7 by CXR (Figure 3-1). There is a significant difference in proportion ofTB 
detected between contacts with prolonged cough vs without prolonged cough or unknown 
(P<O.OO I, table 3.3). 
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Table 3-3. TB case detected among contacts of smear positive TB patients 
Contact by characteristic 
Types 
All household contact 
Contacts with 
prolonged cough 
Contacts without 
prolonged cough or 
cough unknown 
Children under 5 years 
of age 
number 
4118 
142 
3976 
293 
474 374 
103 88 
371 286 
16 2 
* Includes contacts who came to public or private health facility for screening 
27 
21 
6 
1 
**Either with smear- positive or smear-negative tuBerculosis detectedfrom contacts 
TB=tuberculosis 
Smear 
positive 
TB 
cases 
detected 
20 
17 
...... 
c 
c 
C 
V 
3 ~ 
o 
The index patients had a median duration of2 days (IQR: 1-4 days) from diagnosis to treatment. 
The median duration from treatment registration of the index case to screening of contacts was 
29 days (IQR: 9-65 days), and for TB positive contacts this was 97 days (IQR: 37-316 days). 
Most index patients (n=722; 66.2%) were aware that any adult contact with prolonged cough 
should go for TB screening. Sixty-nine (6.3%) index patients thought screening was not required 
for household contacts and only 68 (6.2%) were aware of the risks for children under 5 years of 
age in their household. 
3.4 Discussion 
This study shows that with the current system of passive contact screening for T8, -10% of all 
household contacts are screened, and just 5.5% of children under 5 years of age. These rates are 
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low and need to be improved as studies show that up to 22% of household contacts in high 
prevalence countries have TB [5]. The low proportion of household contacts screened is likely a 
consequence of the passive nature of the strategy, which mainly relies on typical clinical 
symptoms being experienced by the contact and persons seeking appropriate health care on their 
own initiative [11]. In this study, several contacts did not go for TB screening even when they 
experienced prolonged cough. Reported reasons for this are related to unawareness about the 
need for screening and fear of costly diagnosis and treatment. Although the vast majority of TB 
patients (66%) knew about the need for investigating contacts, one-third were not aware that 
contacts with prolonged cough need to be screened. Furthermore, very few of the TB patients 
(6.2%) knew that young children need to be screened in case of suspect symptoms, and as a 
result children under 5 years of age are usually ignored. There is a need to evaluate the 
effectiveness of health education materials and methods being used in the NTP to optimally 
utilize them so that contact tracing can be performed more effectively. 
Currently the NTP only focuses on contacts that self-report to a health facility with a persistent 
productive cough for at least 2 we~ks [9, 12]. A large TB prevalence survey in 2006-2007 in 
Vietnam revealed that 47% of TB cases had other sympto}11s than cough or only chest X ray 
abnormalities [8]. Thus half of the patients may be missed if the program only focuses on cough. 
Another issue that may contribute to under-diagnosis is the method of screening for Tll. 
According to the Vietnam NTP guidelines, direct smear examination is the main diagnostic test 
provided for people who present themselves at a health facility with symptoms suggestive of Tll. 
However, in this study, 15% of TB contacts with a prolonged productive cough who went for 
screening were not examined by sputum smear. 
In order to improve Tn case detection, systematic contact investigations need to be considered 
for implementation in low income and middle income countries with endemic TB levels [13]. 
The potential yield of TB cases from contact investigation in high- and low-incidence settings 
has been reviewed previously [4, 5]. In a meta-analysis, the prevalence of TB among all 
household contacts is estimated to be 3.1 % [4]. In high-prevalence countries, up to 22% of 
household contacts have active tuberculosis [5]. Furthermore, in settings with high proportion of 
IIIV-positive TB cases, active screening among household contacts yields nine times more TB 
cases as compared to passive case finding [14]. Recently, programs are starting to utilize 
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resources for targeted screening of contacts of MDR-TB patients, HIV positive contacts and 
children [15]. 
This study has several limitations. We collected data over a limited time period (from index 
patients registered for treatment in 2008 up to the time of the interview in October to December 
2010. Also the retrospective nature of this study may result in recall bias. We may have therefore 
missed TB disease among contacts that either developed disease after our study or may nor recall 
correctly. As the questions were simple and straightforward on a major health issue in the 
household, we believe we were able to minimize recall bias. Furthermore, several studies have 
shown that the highest proportion of TB cases among contacts are detected in the first two years 
after exposure and therefore we think only few may have developed disease after our study [4, 
16]. 
Furthermore, it is difficult to conclude whether the detected TB cases among contacts went for 
screening due to the health education provided to them at the time of the index case diagnosis or 
due to other reasons. However, as most TB cases among contacts were diagnosed relatively 
sho!'tly after the diagnosis and treatment of the index case (-3 months) we believe that the 
majority went for screening as a result of instructions provided to them at the health education. 
Another limitation is that no rural areas were included in this study and our findings only apply 
to urban areas. There may be better screening practices in urban areas due to higher education 
levels and knowledge about TB, better access to health facilities and more resources for IB 
diagnostics. 
Another limitation was that the assessment of NTP guidelines regarding contact screening was 
done by health staff, who are also part of implementing these NTP guidelines (Le. TB unit staft). 
This may have biased the results. However, the interviewers were trained in survey techniques 
and were instructed not to be concerned about 'right' or 'wrong' answers. Furthermore, the study 
progress was supervised by two independent supervisors (Fe and HW). Since the results are not 
supportive of the current program, we believe we have been successful in minimizing bias. 
3.5 Conclusions 
This study shows that the proportion of household contacts of smear-positive tuberculosis 
patients screened for TB under the current passive screening approach of the Vietnam National 
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IB program is very low compared with prevalence of IB among contacts in high burden 
countries. Better health information and instructions need to be provided to contacts of IB 
, 
patients to improve their health seeking behavior in case of possible IB symptoms, with a focus 
on vulnerable groups like HIV -positive contacts, contacts of drug resistant IB cases and contacts 
under 5 years of age. Special attention is needed to provide guidance when to seek IB screening 
for children. Contact investigation should be conducted more actively and systematically starting 
by recording the contacts information for management and follow-up. Active contact tracing of 
close contacts of newly diagnosed IB patients should be considered in Vietnam, particularly in 
case of young children and drug-resistant lB. Studies that assess how this can be efficiently done 
are required. 
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Abstract 
Background: Vietnam is ranked 14th among 27 countries with high burden of multi drug-
resistant tuberculosis (MDR-TB). In 2009, the Vietnamese government issued a policy on MDR-
TB called Programmatic Management of Drug-resistant Tuberculosis (PMDT) to enhance and 
scale up diagnosis and treatment services for MDR-TB. Here we assess the PMDT performance 
in 2013 to determine the challenges to the successful identification and enrollment for treatment 
ofMDR-TB in Vietnam. 
l\fethods: In 35 provinces implementing PMDT, we quantified the number ofMDR-TB 
presumptive patients tested for MDR-TB by Xpert MTBIRIF and the number of MDR-TB 
patients started on second-line treatment. In addition, existing reports and documents related to 
MDR-TB policies and guidelines in Vietnam were reviewed, supplemented with focus group 
discussions and in-depth interviews with MDR-TB key staff members. 
Results: 5,668 (31.2%) of estimated 18,165 MDR-TB presumptive cases were tested by Xpert 
MTBIRIF and second-line treatment was provided to 948 out of 5, 1 00 (18.7%) of MDR-TB 
patients. Those tested for MDR-TB were 340/3,224 (10.5%) ofTB-IIIV co-infected patients and 
290/2,214 (13.1 %) of patients who remained sputum smear-positive after 2 and 3 months of 
category I TB regimen. Qualitative findings revealed the following challenges to detection and 
enrollment ofMDR-TB in Vietnam: insufficient TB screening capacity at district hospitals 
where TB units were not available and poor communication and implementation of policy 
changes. Instructions for policy changes were not always received, and training was inconsistent 
between training courses. The private sector did not adequately report MDR-TB cases to the 
NTP. 
Conclusions: The proportion ofMDR-TB patients diagnosed and enrolled for second-line 
treatment is less than 20% of the estimated total. The low enrollment is largely due to the fact 
that many patients at risk are missed for MDR-TB screening. In order to detect more MDR-TB 
cases, Vietnam should intensify case finding ofMDR-TB by a comprehensive strategy to screen 
for MDR-IB among new cases rather than targeting previously treated cases, in particular those 
With IIIV co-infection and contacts of MDR-IB patients, and should engage the private sector in 
PMDI. 
}(ey words: Multi drug resistant tuberculosis, detection, treatment, Vietnam 
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4.1 Introduction 
Multidrug-resistant tuberculosis (MDR-TB) is a global health concern as treatment is prolonged, 
costly, and less effective compared to that of drug-susceptible TB. Globally, there are about 
450,000 MDR-TB patients reported with an estimated 170,000 MDR-TB-related deaths 
annually. Regarding the TB and MDR-TB epidemiology in Vietnam, the country is ranked 12 nd 
among 22 high burden countries with TB, and 14th among 27 countries with a high burden of 
MDR-TB. The incidence of TB in Vietnam is estimated at 144 per 100,000 population per year 
and the estimated prevalence is 209 cases per 100,000 population [7]. There are estimated to be 
about 5100 MDR-TB cases among notified TB cases per year. The proportion of TB cases with 
MDR-TB among new and retreatment cases is estimated to be 4 and 23 %, respectively, with 
around 6 % among TB cases co-infected with HIV [7]. A preliminary report from a TB drug 
resistance survey conducted in Vietnam from 2011-2012 showed that the estimated proportion 
ofXDR-TB among MDR-TB was 5.6 %. Of the MDR-TB patients, 16.7 % showed resistance to 
fluoroquinolones (ofloxacin), 1.1 % to amikacin, 5.6 % to kanamycin, and 5.6 % to capreomycin 
(unpublished data). 
In 2009, the· Vietnamese government issued a policy on MDR-TB following. WHO 
recommendations to enhance and scale up diagnosis and treatment services for MDR-TB [11]. It 
is based on the five essential control components that constitute the already implemented DOTS 
strategy for drug-susceptible TB. These components include: sustained political commitment, 
rational case finding, short-course treatment, an uninterrupted drugs supply, and standardized 
recording and reporting [8]. Since a pilot project in Ho Chi Minh City in 2009, diagnosis and 
treatment services for MDR-TB have become available in 35 of all 63 provinces by 2013. The 
programmatic management of drug-resistant tuberculosis (PMDT) is more complex than for 
susceptible TB as it requires greater human, financial and technical resources [8]. Between 2009 
and 20 II the Vietnam PMDT program had a success rate, defined as MDR-TB patients who 
completed treatment and were cured, of approximately 75 %. This rate is high compared to many 
other countries reporting rates of 44--58 % [5][6]. Despite that the treatment outcome may 
depend on drug resistance patterns, this high success rate does reflect good compliance with the 
treatment regimen in Vietnam [10]. The current standard second-line regimen is kanamycin, 
capreomycin, levofloxacin, cycloserine, protionamide, and para-aminosalicyclic acid (PAS). 
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However, the number of MDR-TB patients detected and enrolled to second-line treatment is low 
compared to the expected number among notified TB cases, based on national drug susceptibility 
data [4]. This means that only a few of the MDR-TB patients, get diagnosis and the 
recommended treatment. This can partly be explained by the fact that Vietnam did not have 
nation-wide PMDT coverage by 2013, and drug susceptibility testing was not yet done for all 
notified TB cases. However, PMDT was fully implemented in major cities by 2010, where just 
30-50 % of the total estimated MDR-TB patients were enrolled for second-line treatment. This 
finding lead us to assess the proportion of MDR-TB patients enrolled out of the estimated 
number of MDR-TB in all PMDT areas of Vietnam in 2013 to determine the challenges to an 
efficient PMDT implementation and to provide recommendation to improve the PMDT 
enrollment. 
PMDT includes five steps from diagnosis to treatment for MDR-TB patients:(I) identification of 
presumptive MDR-TB cases (individuals considered at high risk for MDR- TB) according to 
case definitions, (2) referring presumptive cases for diagnosis, (3)drug resistance testing, (4) 
obtaining informed consent from p~tients for treatment, and (5) enrollment of diagnosed MDR-
TB patients to treatment. In this assessment, we used the data reported by the national TB control 
program to focus on three of these steps: identification of presumptive MDR-TB cases, drug 
resistance testing, and enrollment of diagnosed MDR-TB patients for treatment. Qualitative 
investigation was used for assessment of steps (2) and (4) and additionally to support the 
findings and their interpretation for the other steps. 
4.2 Materials and Methods 
By 2013,35 provinces had implemented the PMDT and participated in the MDR-TB enrollment 
assessment. Thirty-one provinces were selected by the NTP to implement PMDT based on their 
Prior MDR-TB case-load and case management capacity. The remaining four provinces with a 
low MDR-TB case-load were selected as they had a high IIIV prevalence. All 35 provinces were 
provided access to diagnostic equipment for intensified case finding using the Xpert MTBIRIF 
(Xpert) assay, a within-cartridge real-time peR assay that detects M. tuberculosis as well as 
mutations in the rpoB gene conferring resistance to rifampicin in clinical specimens [15]. The 
selected provinces are required to provide PMDT treatment services in case MDR-TB patients 
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are diagnosed. For the assessment, we reviewed all existing reports and documents related to 
MDR-TB policies and guidance since 2009 through December 2013. 
A presumptive MDR-TB case requiring testing was defined as belonging to at least one of the 
risk groups as defined in the NTP guidelines (see Appendix 1). In order to calculate the 
proportion of those screened for MDR-TB, we divided the number of tested presumptive MDR-
TB cases by the number of presumptive MDR-TB cases estimated using annual data reported by 
each province to the NTP (stepl). All PMDT provinces provide quarterly reports to the NTP of 
the number of Xpert MTBIRIF tests done and the number of MDR-TB cases detected. We used 
the 2013 Xpert MTBIRIF data for assessing the number of presumptive cases screened per risk 
category (step 3). 
For national estimation of MDR-TB, we used the number of all notified IB cases per province 
and applied the result of the most recent national DRS in Vietnam (year 2011-2012). Eligible 
cases to be enrolled in the DRS were smear-positive IB patients (both new and previously 
treated IB patients) registered for treatment in the selected clusters during the period of 
recruitment (bem:een June and December 2011). Ihe DRS showed prevalence of MDR-IB 
among new and previously treated cases of 4.0 % and 23.0 %, respectively [7]. Ihis allowed us 
to estimate the expected number of incident MDR-IB cases in all provinces irrespective of 
detection by the NIP. We used the standard errors from the MDR-IB prevalence as estimated in 
the DRS to calculate confidence intervals for the proportion of MDR-IB patients enrolled for 
second-line treatment in this study. The proportion with 95 % confidence intervals (95 % CI) 
was estimated for the number of MDR-IB patients enrolled for second-line treatment among (i) 
the estimated number of MDR-IB cases in the whole country and (ii) the estimated number of 
MDR-TB cases in the 35 PMDT provinces (step 5). 
Ihis review was followed by focus group discussions (FGD) in face-to-face workshops, which 
encompassed five separate one-day sessions with approximately 30 key provincial IB staff 
members (for all PMDI steps including steps 2 and 4). FGD were used to discuss the PMOi 
program, challenges to implementation and potential solutions. Five groups were invited froOl 
eight different geographic areas (see Appendix 1). IB staff included provincial prograOl 
managers, program officers with expected knowledge of the local overall situation and staff 
responsible for implementation of PMDI in their province. Guidance was provided for FGD 
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facilitators who had previous FGD discussion experience and knowledge of the NTP. 
Discussions were continued until saturation was reached before facilitators moved to a new 
topic. FGD summaries were checked and agreed upon by all participants to be finalized for 
content analysis later on. The sessions were not audio recorded and transcribed due to lack of 
funds. 
Furthermore, in-depth interviews to supplement the focus group discussions was conducted by 
the same group of interviewers with eighty TB health staff at different levels of the NTP, 
including 8 central staff from PMDT team, 56 provincial staff from variety of departments, and 
16 district and commune level health staff (for all steps). The interview guide was developed and 
piloted before the interviews and included questions regarding: structure of the TB health unit at 
specific levels in the health system, training provided to staff, their knowledge and awareness 
about MDR-TB risk groups, their role and job description, and challenges encountered in PMDT 
implementation. The in-depth interview also allowed the interviewee to reflect on findings from 
the FGD. These interviews were conducted during monitoring visits in 2014 in eight randomly 
selected provinces among the 35 ~MDT provinces from three zones: four provinces were 
randomly selected from the sOl\thern zone as there exists the highest disease burden, two from 
the north and two from the centre (see Appendix 1). The interviews were conducted privately. 
During the interview and FGDs, detailed notes were taken and used subsequently to identify key 
themes. In the analysis, similarities and differences between the various interviews and FGDs 
Were looked for and summarized to identify key findings. The interviews were not recorded. 
This study was approved by the research and ethics committee of the National Lung Hospital in 
Ilanoi. Informed consent was obtained from participants in workshops and in-depth interviews. 
4.3 Results 
4.3.1 The estimated number of MDR-TB cases in Viet Nam 
Based on the notification report of the NTP in 2013 and the results of the recent national DRS, 
We estimated that in 2013 there were 5065 (95 % CI: 3355-6700) MDR-TB patients among 
102,196 notified TB cases, resulting in a proportion of 5.0 % MDR-TB among notified cases for 
the year 2013 (95 % CI: 3.3-6.6 %). These cases were mainly concentrated in the South-East, 
Mekong Delta and Red River Delta regions. The PMDT program already covered provinces with 
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an expected high number of MDR-TB cases (Figure4-1 and Table 4-1). We estimated that the 
majority 3982/5065 (78.6 %) of the national MDR-TB case-load originates in the provinces 
participating in the PMDT (Table 4-1). 
Figure 4-1. Estimated number ofMDR-TB patients among notified TB cases 
in Viet Nam, 2013 
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Table 4-1. Actual enrollment and estimated total number ofMDR-TB cases nationwide and 
in 35 Pl\1DT provinces (the numbers in brackets are for lower and upper el) 
All provinces 35 PMDT provinces ·1. estimated 
Dumber of 
Number MDR-TB 
Ser.No Region Estimated Dumber ·1. enrolled Estimated Dumber 
enrolled ·1. enrolled covered 
ofMDR-TB cases of!\1DR-TB cases 
PJ\1DT 
provinces 
I Red River 234 859 (565-1,139) 27.3 (20.5-41.4) 627 (414-830) 37.3 (28.2-56.5) 73.0% 
Delta 
2 
North-East 
0 339 (223-449) 0.0 189 (124-252) 0.0 56.0% 
3 
North-West 
0 53 (35-71) 0.0 9 (6-12) 0.0 17.0% 
-
4 
Northern 
54 466 (305-618) 11.6 (8.7-17.7) 338 (222-449) 16.0 (12.0-24.3) 72.7% 
Central 
Southern 
5 Central 84 405 (266-536) 20.8 (I 5.7-3 I.S) 304 (200-403) 27.6 (20.8-41.9) 75.2% 
Coast 
-
6 Central 0 110 (72-146) 0.0 21 (14-27) 0.0 18.8% 
I--
Highland 
7 South -Ea~t 495 1,546 (1,035-2,036) 32.0 (24.3-47.8) 1,408 (944-1,854) 35.2 (26.7-52.4) 91.1 % 
r--
8 Mekong 81 1.288 (854-1,704) 6.3 (4.8-9.5) 1,086 (720-1,436) 7.5 (5.6-11.3) 84.3% 
r-- Delta 
Total 948 5.065 (3,355-6.700) 18.7 (14.1-28.3) 3.982 (2.643-5,264) 23.8 (18.0-35.9) 78.6% 
---
4.3.2 Identification of MDR-TB presumptive cases to be tested (step I) 
In 2013, there were an estimated 18,165 cases identified as presumptive MDR-Til nationally, 
With the majority (n = 14,998) in the 35 PMDT provinces (82.6 %). There was no data available 
on the number of MDR-TB presumptive cases identified by the health staff of PMDT areas who 
were referred for screening. 
4.3.3 Testing practices per risk category by Xpert MTB/RIF and detection of MDR-TB 
(step 3) 
A. total of 32 Xpert MTB/RIF instruments were distributed among the 35 PMDT provinces. The 
estimated number of MDR-TB cases to be detected per machine per year for these instruments 
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varied by region, ranging from 9 to 338 MDR-TB cases (see Appendix 1). The instrument's 
capacity is expected to be sufficient as one instrument with four modules is able to test 
approximately 3000 MDR-TB presumptive cases to detect around 500 rifampicin resistant TB 
cases per year (see Appendix 1). 
The proportion of MDR-TB presumptive cases tested by Xpert MTBIRIF was 31.2 % 
(5668/18,165) for the whole country and 37.8 % (5668/14,998) in the 35 PMDT provinces 
(Table 4-2). In PMDT provinces, the highest proportion of MDR-TB presumptive cases tested 
was in the North-West (43/46; 93.9 %) and the Southern Central Coast (668/897; 74.5 %) 
regions. The lowest proportions were in the Central Highlands (0/69; 0 %) and the Mekong Delta 
(516/3935; 13.1 %; Table 4-2) regions. In the North-West region, all provinces together only had 
43/214 (20.1 %) of presumptive cases tested while that percentage was 43/46 (93.9 %) in the 
PMDT provinces. Among 5668 MDR-TB presumptive cases tested, 997 cases were detected as 
rifampicin resistant (17.6 %). 
Table 4-2. Percentage of presumptive MDR-TB patients tested by regions 
All provinces 35 PMDT provinces 
Number of Estimated Estimated . 
presumptive number of number of 
Ser.No Region % tested 
MDR-TB presumptive presumptive % tested 
patients tested MDR-TB MDR-TB 
patients patients 
1 Red River Delta 801 ·2,519 31.8 % 2,035 39.4 % 
2 North-East 263 1,154 22.8% 627 42.0% 
3 North-West 43 214 20.1 % 46 a 93.9% 
4 Northern Central 460 1,144 40.2% 886 51.9 % 
Southern Central 
5 668 1,117 59.8% 897 74.5% 
Coast 
6 Central Highland 0 290 0.0% 69 0.0% 
7 South-East 2,917 6,991 41.7% 6,503 44.9% 
8 Mekong Delta 516 4,736 10.9% 3,935 13.1 % 
Total 5,668 18,165 31.2 % 14,998 37.8 % 
a one PMDT province ill North - West 
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The proportions of HIV infected TB cases and new TB non-converters tested by Xpert MTBIRIF 
were 10.5 % (340/3224) and 13.1 % (290/2214), respectively (Table 4-3). Retreatment patients 
who showed no sputum conversion after 3 months of the category II regimen were tested 
frequently: 85.7 % (413/482). We estimated that 249/402 (62.0 %) of symptomatic household 
contacts of MDR-TB patients were tested. Among 249 MDR-TB symptomatic household 
contacts screened within 1 year after MDR-TB patients diagnosed, 77 TB patients were detected 
(30.9 %) including 9 TB patients resistant to rifampicin (3.6 %). We could not calculate the 
testing rate among failure cases since no data were available for the number of people tested. 
However, this rate was estimated to be at least 68.5 % because one failure case could receive up 
to two tests. 
Table 4-3. Presumptive MDR-TB patients estimated and tested by risk category in the 
Whole country and in 35 PMDT provinces of Vietnam 2013 
Estimate Estimate 
Number of % tested in 
number for number for 
Presumptive category Xpert tests PMDT 
whole PMDT 
performed areas 
. country a areas only 
Retreatment Failure 0 593 519 711 ND 
Relapse 7,059 5,673 2,641 46.6% 
Defaulters 472 376 129 34.3 % 
Other 739 662 210 31.7 % 
Non-converters at 2 New 2,713 2,214 290 13.1 % 
and 3 months Retreatment 586 482 413 85.7% 
MDR contacts 402 402 249 62.0% 
TB/HIV 3,828 3,224 340 10.5 % 
> 1 month using TB drugs 1,773 1,446 685 47.4% 
Total MDR-TB suspects 18,165 14,998 5,668 37.8% 
Q The denominator is the number of presumptive by categories that need to be tested 
b Failure is defined as sputum smear positive at 5 months or later during treatment, so one failure case 
could receive one or 2 tests (at 5 and/or 7 months). ND: not done as failure cases can be tested on 
mUltiple occasions 
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4.3.4 Enrollment to second-line treatment (step 5) 
Of 997 rifampicin-resistant cases detected, 948 (95.1 %) were enrolled for MDR-TB treatment, 
accounting for just 18.7 % (95 % CI: 14.1- 28.3 %) of the estimated 5065 MDR-TB cases in the 
whole of Vietnam (Figure4-2). The region with the highest proportion of MDR-TB patient 
enrolled for second-line treatment was the South-East region with 495/1546 (32.0 %; 95 % CI: 
24.3-47.8 %), followed by the Red River Delta with 234/859 (27.3 %; 95 % CI: 20.5-41.4 %). 
The lowest enrollments were in the Mekong Delta region: 81/1288 (6.3 %; 95 % CI: 4.8-9.5 %). 
No enrollments were reported in PMDT for North-East, North-West and Central Highlands 
(Table 4-1, Figure4-3). Also in the 35 PMDT provinces, the enrollment proportion ofMDR-TB 
cases was low: 948/3982 (23.8 %; 95 % CI:18.0- 35.9 %). The highest proportion was seen in the 
PMDT provinces in the Red River Delta with 234/627(37.3 %; 95 % CI: 28.2-56.5 %), and 
South-East region: 495/1408 (35.2 %; 95 % CI: 26.7-52.4 %) 
Figure 4-2. PMDT performance for case detection and enrollment of MDR-TB in Vietnam 
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Figure 4-3. The enrollment proportion into the second-line treatment program of MDR-TB 
. . 
cases among the estimated number of notifiable MDR-TB cases in 35 PMDT provinces in 
2013. Data are presented per socio-economic region. 
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4.3.5 Qualitative investigations (all steps) 
This section reveals the challenges to a successful diagnosis and enrollment for treatment of 
MDR-TB (Table 4-4). It was noted that TB units (i.e. small departments operating under the 
NTP that identify MDR-TB presumptive, provide TB diagnostic and first-line treatment services 
by specifically trained staff) are located mainly in district health centers. Although there is a 
policy change ongoing to have TB units also in (district) hospitals this bad not yet been 
implemented in all districts. As a result, several district hospitals, where many MDR-TB 
presumptive cases present did not have TB diagnostic facilities and hospital staff bad not been 
trained and instructed to screen patients for TB and MDR-TB. 
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Table 4-4. Obstacles to enrolling MDR-TB patients for treatment and solutions for an 
effective PMDT 
Ser. 
Obstacle 
No 
Proposed solution 
1 A set of key documents is lacking: updated The NTP is strongly recommended to 
guidelines, conCIse and clear SOPs, and ensure that key documents are prepared 
standard training modules. and circulated to appropriate staff, with 
proper training. Letters with updates 
should be discouraged, unless there is an 
urgency. 
2 Failures in identifying presumptive MDR-TB The development of consistent training 
3 
cases for screening. 
Absence of a sound referral system for sending 
sputum samples to a laboratory. 
modules in accordance with national 
guidelines and SOPs. 
A sound national referral system should 
be set up with a shipping agency who 
can do this safely. 
4 Current· Vietnam policy is to require patient to The NTP policy needs consider the 
be hospitalized at the start of treatment. adoption for ambulatory treatment with 
However, there is insufficient hospitalization community based care as also 
capacity and patients may refuse to be referred recommended by WHO [8]. Health 
to another treatment centre in another province Insurance need to support MDR-TB 
either due to distance from hometown or patients in reimbursing costs in case 
additional costs without getting health there is a need for referral to another 
insurance reimbursement. province for PMDT treatment. 
5 Temporary MDR-TB drug stock-out due to Improve drug procurement and 
procurement and distribution delay resulted in distribution system. 
patients either not enrolled for treatment or a 
delay in treatment. 
6 TB units in many districts remain located in Enforce policy to locate TB units in the 
health centers that focus on prevention, and district general hospitals. Training 
are separate from the general hospitals, which should be provided to appropriate staff 
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is discrepant from MoH policy. As individuals to ensure that TB units in the hospital 
prefer to go to the hospital rather than a have the function of both TB diagnosis 
preventive health center, it is beneficial that and treatment management. 
TB units are located in the district hospital 
where many MDR-TB presumptive cases 
presented. This will probably increase case 
finding of MDR-TB. However, the TB control 
programme still requires a function of case 
management for treatment in the communities. 
7 Poor links between the NTP and public sector Establish the collaboration between the 
and no management system for MDR-TB private sector and PMDT. Private sector 
patients in prison. There is no mechanism to should be trained to identify MDR-TB 
refer MDR-TB presumptives or MDR-TB presumptive cases and refer to the NTP 
patients from the private sector to the NTP to for diagnosis and treatment. Ensure 
be diagnosed or for treatment. The private private sector adheres to treatment 
sectors often do not notify ~DR-TB cases to guidelines for TB and MDR-TB. MDR-
the NTP. TB patients who cannot. to continue 
treatment in private sector should be 
transferred to the NTP for treatment 
continuation. Provide diagnosis and 
treatment service for MDR-TB patients 
mpnson. 
Provincial and district staff reported that they were overall not well informed about PMDT 
procedures. The first guideline for PMDT was issued in 2009 [11] and has not been updated for 
any of the multiple changes since then. The changes in policies over time had been updated 
through separate instruction letters from the central level and though yearly PMDT training 
Courses without documenting these in a clear set of guidelines. A total of 17 instruction letters to 
inform about changes have been sent out from central level to provinces between 2009 to late 
2013. However, regularly these update letters were not received by the provincial PMDT officer 
or the information was not disseminated to the relevant staff at lower levels. A further challenge 
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was regular health care staff turnover or change in health care staffs responsibilities over time. 
As a consequence, it is challenging to ensure training and skills deVelopment for all the staff 
involved in TB and MDR-TB management. 
Standard operating procedures (SOPs) for PMDT were developed and released in 2012, three 
years since the MDR-TB guideline was released. The SOPs lacked clear instructions for steps 
that need to be taken [16]. No standard PMDT training modules are available as the training and 
presentations were prepared and updated by different lecturers, based on their interpretation of 
the available guidelines and SOPs. Inconsistencies across training courses were mentioned by 
trained health staff, which generated uncertainty. In addition, the majority of district level staff 
was not trained due to lack of funding. In 2013, the majority of district staff with an assigned 
responsibility to identify presumptive MDR-TB had not been trained to identify risk groups. 
Supervision visits conducted between April and July 2014 revealed that, although all districts 
under PMDT had been trained, their focus was on retreatment cases, while non-converters 
among new cases and HIV-positive TB patients were generally neglected. 
Many TB units were unable to send sputum for test!ng by Xpert MTB/RIF as no appropriate 
financial compensation mechanisms were in place for consumable procurement and sputum 
transportation fees. Partly this was due to a delay in an award from the Global Fund. In addition 
it was not straightforward to send specimens by mail as no agreements with the postal services 
were in place, and sputum referral using health staff or public transportation were used instead. 
This may explain why in some regions with Xpert MTBIRIF capacity, like the Mekong delta 
region, the proportion tested and enrolled was limited. Finally, there had been stock outs of Xpert 
MTBIRIF test kits due to delays in cartridge forecast reporting. Although challenges were 
mentioned for sending sputum, there was always a confirmation and communication between 
referring sites and laboratory after samples had been sent. A small number of referred samples 
were rejected by the laboratory for being considered low-quality or low-volume, and requested to 
re-collect and re-send. 
For MDR-TB patients that were diagnosed, health staff mentioned that informed consent waS 
obtained for all of these patients before starting treatment. There were issues regarding enrolling 
MDR-TB patients for treatment due to lack of hospitalization capacity. It was reported that poor 
links existed between the public and private sector, as patients cannot be referred from the 
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private to the public sector to continue their treatment. Furthermore, there are no management 
systems in place to screen and treat MDR-TB patients in prison (see Table 4-4 for more details). 
4.4 Discussion 
We estimated that only one third of MDR-TB presumptive cases are screened by Xpert 
MTBIRIF in Vietnam. However, it is encouraging that 95 % of the patients who were tested 
positive for MDR-TB were enrolled for second-line treatment. The low enrollment rate is mainly 
attributable to low number of presumptive MDR-TB cases identified and subsequently tested, 
and not due to poor enrollment of patients after diagnosis. There were some inconsistencies 
between the percentage of MDR-TB presumptive cases tested in 35 PMDT provinces (Table 4-2) 
and the enrollment rate of MDR-TB (Table 4-1). While there were relative high testing 
proportion in the North-East, North-West, Northern Central and Southern Central Coast regions, . 
the enrollment proportion for treatment among number estimated were low, varying from 0 % to 
27.3 %. In other regions, the variations in enrollment rates were in line with the variations in 
percentage of MDR-TB presumptive cases tested. The reasons behind these inconsistencies were 
limited capacity for hospitalization a~d other issues as revealed by our qualitative. assessment. 
This study showed that access to Xpert MTBIRIF testing was overall sufficient for Vietnam. 
However, regions with a higher number of operational Xpert MTBIRIF instruments had a higher 
enrollment proportion compared to regions with fewer instruments, except for the Mekong River 
Delta (Figure4-3). While the burden of MDR-TB in Mekong Delta region was high, with Xpert 
MTBIRIF instruments widely available, the enrollment proportion in this region was very low: 
7.5 % (Table 4-1, Figure4-3). The reason behind the low enrollment proportion in Mekong Delta 
region is a weak system for transferring specimens for Xpert MTBIRIF testing as revealed by our 
qualitative study. In addition, procurement of test kits needs improvement to avoid stock outs, 
and redistribution of Xpert MTBIRIF instruments from the Red River Delta with 9 instruments 
""'.' 
and a low workload to the Northern Central region with just one instrument and a high workload 
may improve access to testing for risk categories. Testing coverage was nil in the Central 
Highlands region. Although this area has a relatively low number of estimated MDR-TB cases, 
facilitating a good specimen referral system for testing could increase the coverage. Main 
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challenges for effective MDR-TB diagnosis and treatment and potential solutions proposed by 
our study team for under enrollment are listed in Table 4-4. 
New TB patients whose sputum had not converted after 2 or 3 months of treatment and TB 
patients with HIV, both considered risk groups for MDR-TB, were largely neglected for 
screening and had the lowest proportions of MDR-TB screening done while they account for the 
majority of presumptive MDR-TB cases [8][11]. Since the proportion of detected rifampicin-
resistant patients among these groups in 2013 was 11.3 % [9], it is likely that a considerable 
number of MDR-TB remain undiagnosed due to inadequate screening among these groups. 
Importantly, undetected MDR-TBIHIV patients who have high mortality rates [1] [14] would 
lose the opportunity for adequate treatment. Moreover, TB-HIV patients in 2013 are 
underreported due to limited collaboration between the TB and HIV control programs [2]. 
The qualitative assessment revealed that many patients refuse treatment in units far from home. 
Other patients reported problems getting health insurance reimbursement in case they were 
referred to another province. Lack of collaboration between treatment centers and adjacent 
provinces for referring patients for treatment also contrib~ted to drop outs. Another contributing 
factor to treatment deiays and poor enrollment was the irregular delivery and stock outs of MDR-
TB treatment drugs due to procurement delays. Occasionally, patients insisted to be enrolled, but 
they had to wait for a long time to start treatment. 
This study also revealed poor links between the public and private sector. Due to absence of a 
referral mechanism between the two systems, MDR-TB presumptive were not referred from 
private sector to the NTP for diagnosis, and patients who withdrew from MDR-TB treatment in 
the private sector for financial or other reasons were unable to enroll to continue treatment in the 
public PMDT. Currently, only limited data for MDR-TB patients in the private sector are 
available, where default rates are high, up to 75 %, implying poor MDR-TB management in the 
private sector that may lead to drug resistance amplification [13]. Also MDR-TB patients in 
prisons pose a challenge as second-line treatment is not available, and no procedures for 
management ofMDR-TB patients after discharge from prison are in place. 
The current PMDT policy is that each district should have a TB unit. The Ministry of Health has 
as a policy to locate TB units in general hospitals, or in district health centers if a general 
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hospital is not present [3]. This policy is aimed at strengthening the utilization of diagnosis and 
treatment services for TB units in the district hospital, where most patients seek health care. 
However, our study found that not all district hospitals have a TB unit with TB screening 
capacity. Health staff lack proper training and MDR-TB screening skills and do not have access 
to updated guidelines/SOPs to support them in identifying patients. This results in confusion and 
limited confidence among staff to implement the PMDT properly. Inconsistencies across training 
Courses also contributed to confusion around the PMDT policies. Clear guidelines, instructions 
and training for health staff is needed to improve this. 
Our study has several limitations. To estimate the MDR-TB enrollment proportion we used two 
different data sets: the 2013 NTP report and the DRS conducted in 2011-2012. For the number 
of MDR-TB cases detected, we only used laboratory reports from Xpert MTBIRIF testing and 
we did not include reports from other tests such as line-probe assays or phenotypic drug . 
susceptibility testing. As the number of tests done by these other methods is small, less than 5 % 
with considerable overlap with Xpert MTBIRIF testing, we decided to exclude these. 
. Furthermore, as we do not know the prevalence of rifampicin resistance for each MDR-TB risk 
group we could not assess the positive pr~dictive value (PPV) of Xpert MTBIRIF separately 
among each category of presumptive MDR-TB patients. However, for most categories, the 
estimated prevalence of rifampicin resistance is relative high (around one-fourth, given the 23 % 
prevalence among previously treated patients in the DRS). In addition, recent studies from South 
Africa [12] and Brazil [17] suggest a PPV on the order of 90 % even with relatively low 
prevalence of rifampicin resistance. Therefore we do not expect that the PPV in our study will 
have been much below 90 %, and thus did not affect the results to considerable extent. 
A final limitation is that we did not involve the private sector in our study. However, our 
qualitative assessment suggests poor management of MDR-TB in the private sector and a lack of 
a good referral system between the private and public sector. This situation causes patients to be 
under screened, poorly treated, and underreported to the NTP. Better links need to be established 
between the private and public sector. 
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4.5. Conclusion 
The proportion ofMDR-TB patients enrolled for second-line treatment among the total estimated 
number ofMDR-TB cases in Vietnam in 2013 was 18.7 % (948/5065). The low enrollment was 
considered due to under-screening of MDR-TB presumptive cases, especially for HIV infected 
and new TB non-converters. Multiple reasons exist for under-screening, including: poor 
communication and implementation of policy changes, lack of involvement of general district 
hospitals, and limited resources. However, Vietnam has achieved a high proportion of enrollment 
to second-line treatment among of detected MDR-TB cases and a high treatment success rate, 
which can be considered an opportunity to mobilize resources and expand the program to detect 
and treat more MDR-TB cases. Vietnam should expand the intensified case finding of MDR TB 
by a comprehensive strategy with more focus on new detected cases, in particular those with 
HIV co-infection and contacts of MDR-TB patients. The capacity to treat new MDR-TB caseS 
will need to be increased in case the screening is improved. The private sector needs to be 
engaged in the PMDT. 
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Chapter 5. CONTACT TRACING BY SOCIAL NETWORK ANALYSIS (SNA) TO 
ENHANCE MULTI-DRUG RESISTANT TUBERCULOSIS CASE FINDINGIN HANOI, 
VIETNAM 
5.1 Introduction 
The emergence of resistance to anti-tuberculosis drugs, and particularly of multidrug-resistant 
TB (MDR-TB) is a serious public health threat and an obstacle to effective global TB control [1]. 
Inappropriate or incorrect use of anti-TB drugs, or use of poor quality medicines, weak health 
systems, social determinants are the main cause of drug resistance development and spread [2]. 
In the world, about 3.5% of new TB cases and 20.5% of previously treated cases have MDR-TB 
strains. Only 20% of estimated MDR-TB cases are reported to be on recommended treatment 
with a success rate of just 48% [3]. In this context, the Stop TB Partnership Global Plan aims that 
by 2015 at least 75% of MDR-TB cases need to be treated successfully [4] In order to achieve 
these targets, it is crucial to identify more MDR-TB cases at an earlier stage and provide optimal 
treatment. 
Viet Nam is ranked 14th among 27 high burden MDR-TB countries [2]. To meet the targets set 
in the Global Plan to stop TB, Viet Nam has approved the plan to detect and tre.at more MDR-TB 
cases, reaching 1,115 cases in 2014. As of September 2009, Viet Nam has started to implement 
Programmatic Management of Drug Resistance Tuberculosis (PMDT), the main component for 
TB control. By 2012 Viet Nam has adopted the use ofXpert MTBIRIF for detection ofMDR-TB 
cases in PMDT sites and set up mechanism to access second line drugs (SLDs) for MDR-TB . 
patients. Chapter 2 on MDR-TB control policies and practices in Vietnam of this thesis presented 
details on MDR-TB case finding strategies to meet the target. 
Despite these efforts in Viet Nam, the proportion of MDR-TB cases detected and enrolled to 
treatment annually compared with the estimated of MDR-TB cases among notified TB cases is 
low (less than 30%) [5], leaving the majority of undetected MDR-TB to persist in the 
community. The existence of drug-resistant strains in a population is an important source of 
transmission for new drug-resistant cases. In addition, the majority of MDR-TB found among 
new cases (patients who never received TB treatment before) in Viet Nam suggests that 
community based transmission an important source of new MDR-TB cases. Among the total of 
5,100 MDR-TB estimated cases, there are about 3,000 (5.8.8%) with new pulmonary MDR-TB 
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and 2,100 (41.2%) previously treated TB cases [3]. The existing MDR-TB case finding strategy 
of PMDT in Viet Nam focuses on screening drug resistance among previously treated cases, or 
patients currently on TB treatment who are non-converter, failed treatment, or relapsed and not 
among new TB cases. 
Household contacts are classified as a risk group but currently undergo a passive case finding 
approach, i.e. they are advised to seek help in when symptomatic. Data from our prevalence 
survey conducted in 2006-2007 showed that this existing passive case finding approach can only 
detect about 60% of patients, leading to the recommendation to conduct an active case finding 
approach in risk groups [6]. Our study on household contact investigation also shows a low 
proportion of contacts screened with a passive approach (Chapter 3) [7]. 
Although close contacts of MDR-TB patients are recommended by the National Tuberculosis 
Control Programme (NTP) of Viet Nam to be screened for MDR-TB [8], there is not yet a clear 
mechanism for contact tracing in Viet Nam. Recently, one study that used population-based data 
from rural Viet Nam showed that only 1 % of index cases have a TB positive household member 
and 83% of these household TB cases have a different strain of M tuberculosis compared to 
their. household members. This' finding suggests that most TB cases result from transmission 
outside the household [9]. These results are similar to those in high incidence settings in South 
Africa, and Malawi [10][11]. 
Traditional contact tracing can only identify a few instances of transmission and often only 
focuses on household contacts and little on other common contacts at for example work, school, 
or social contacts [12][13][14]. Contact investigation of only household members is not 
sufficient to identify the transmission of MDR-TB and additional approaches are needed. It is 
also recommended by the WHO that, to conduct investigation among contacts of MDR-TB and 
XDR-TB, additional information should be collected regarding description of their residence and 
other sites where transmission might have occurred [15]. 
Social network Analysis (SNA) is a more comprehensive approach than traditional contact 
tracing which includes a set of persons (nodes) and the connections (ties) among them for 
analysis of structure of disease transmission. The basic unit of analysis in SNA is the tie linking 
at least two nodes (e.g., person to person or person to place dyads). It measures the nature of 
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these connections such as work- or school-associated activity, kinship within a network [16][17]. 
These contacts and places are identified through the structure of social network based on the 
links between at least two MDR-TB cases. In identifying a probable source case and locations 
targeted for follow-up, social network analysis is supposed to be able to outperform standard 
contact tracing [18]. 
Screening for MDR-TB among contacts is an important priority for effective TB control. We 
conducted this study to assess the yield of social network investigation among contacts of MDR-
TB patients in case detection of MDR-TB in Viet Nam. Additionally we looked at feasibility of 
such an active contact investigation strategy among contacts of MDR-TB patients in Viet Nam. 
This is a preliminary analysis as the study is still ongoing. 
5.2 Methods 
We used a mixed methods approach. To analyze the detection rate of an active social network 
approach we conducted a cohort study in which we followed up close contacts and household 
contacts of MDR-TB patients over a period of at least 6 months. To look at feasibility of this 
approach, we organized a workshop to distribute semi-structured questionnaires to be self-
. 
completed by TB health staff who participated in the contact investigation activities of the study. 
The questionnaire was followed by an open discussion for to discuss experiences and challenges 
that were encountered when performing MDR-TB social network analysis. The study protocol 
Was reviewed and approved by the Science and Ethical Committee of the Viet Nam National 
Lung Hospital (Code 388/20 13/NCKH). 
5.2.1 Cohort study 
MDR-TB patients who lived in Hanoi and diagnosed as MDR-TB between October 2013 and 
April 2015 were eligible for the study. After informed consent was obtained, the predesigned and 
pilot validated case report form (CRF) was u~ed to interview MDR-TB patients to collect the 
following data: demographics, medical history, social network including their contacts and 
frequently visited places (see appendix for CRF). The interviews were conducted by trained TB 
healthcare workers as soon as MDR-TB patients were diagnosed. Completed CRFs of MDR-TB 
patients were submitted to central level as soon as completed to identify the places and contacts 
need to be investigated including checking whether similar contacts or places have been reported 
by other MDR-TB patients. 
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MDR-TB contacts were followed up at district level by the study team to undergo MDR-TB 
screening after informed consent was obtained. Eligible places (the recommended places for 
screening as described in definitions) were also accessed and investigated by provincial or 
district coordinators to identify additional contacts for MDR-TB screening using an interview 
guide. The contacts screening for TB and MDR-TB involved (i) clinical assessment to identify 
presumed TB patients and people at risk ofMDR-TB using predesigned CRF, (ii) chest X ray to 
identify presumed TB patients (abnormal chest X-ray suggested for TB) among those who were 
not presumed by clinical assessment, and (iii) microbiology (Xpert MTBIRIF) to identify TB and 
rifampicin resistant TB among those who are identified as presumed TB patients either by 
clinical assessment or chest X-ray (refer to screening steps for more detail). Contacts diagnosed 
as TB or MDR-TB cases will be treated according the current TB treatment guidelines in Viet 
Nam. MDR-TB treatment is made available free of charge in Viet Nam. Field visits to supervise 
the study implementation were conducted quarterly from central and provincial level to district 
level. 
5.2.2 Study population 
The study involved patients detected with rifampicin resistant TB (either diagnosed by Xpert 
MTBIRIF or by Hain test, the test that were being used by the NTP for MDR-TB diagnosis) and 
their eligible contacts (all ages), who were named by index patients or identified from places and 
able to give informed consent. In case the patient was unable to answer the questions, a family 
member who is expected to know the individual best, was asked to answer on hislher behalf . 
. Inclusion Criteria: The study included rifampicin resistant TB or MDR-TB patients living in 
Hanoi (all ages) who are diagnosed (either diagnosed by Xpert MTB/RIF or by Hain test) and 
put on MDR-TB treatment between October 2013 and April 2015. Additionally, their defined 
contacts (either named by patients or came from eligible places) during 3 months preceding 
MDR-TB diagnosis were also included in the study. Only participants who were willing and able 
to give informed consent for participation were selected for screening. For patients and contacts 
who are children (less than 18 years old), information was obtained from their parents Of 
responsible family members. 
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Exclusion Criteria: Cases or contacts were excluded if no informed consent was obtained. Index 
MDR-TB patients who were diagnosed and enrolled for treatment in Hanoi, but lived in other 
provinces before coming to Hanoi for diagnosis and treatment could not enter the study. Contacts 
with the index MDR-TB cases not during 3 months prior to MDR-TB diagnosis were also 
excluded. 
5.2.3 Follow up 
There were two active screening moments in this study. The first was at the time the eligible 
contacts were identified and the second at 6 months post MDR-TB diagnosis. Eligible contacts 
were recorded in a registered book to be followed up by district coordinators. The second 
screening was made by an appointment on completion of the first active screening, and followed 
by a reminder at 6 months by telephone. During the study period, study participants were asked 
to make an unscheduled visit to district TB units and contact with the district health coordinators 
if they had any symptom suggestive of TB. 
Screening steps and diagnostic testing included (see Figure 5-1): 
• Clinical assessment by trained district health coordinators to identify MDR-TB presumptive 
cases , which included: (i) "eligible contacts with productive cough for more than 2 weeks, 
which may be accompanied by other symptoms, (ii) TB patients who were on current first 
line anti-TB treatment initiated before being identified as eligible contacts of MDR-TB, (iii) 
children with failure to thrive, two weeks of fever or cough, or cervical lymphadenopathy. 
• Chest X-ray to detect additional MDR-TB presumptive cases among those who were not 
identified as MDR-TB presumptive case by clinical assessment alone. This examination was 
taken at district health facilities. MDR-TB presumptive cases were identified in case of an 
abnormal chest X-ray suggestive ofTB. 
• "" Xpert MTBIRIF testing to detect TB and rifampicin resistant TB. This was done among 
MDR-TB presumptive cases who were either identified by clinical assessment or by chest 
X-ray. Microbiological testing was done on sputum or gastric aspirates in children. 
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Figure 5-1. Recruitment and screening process among close contact of MDR-TB index patients 
Eligible contacts 
Not TB suspects by interview 
Gene Xpert MTB/RIF 
Second line drugs treatment 
Culture, DST 
TB (+)/R(-) 
First line drugs treatment 
Follow up, can repeat Xpert after 
2 months if sputum not converted 
130 
NotTB 
suspects 
Consultation 
Follow-up 
Consultation 
Follow up 
Operational definitions (see Appendix 2 for more detail) 
MDR-TB presumptive case: In this study, the MDR-TB presumptive referred to any MDR-TB 
contact with (i) clinical symptom suggested for TB or (ii) abnormal findings consistent with TB 
on the Chest X-ray (CXR) or (iii) TB patients who were on current first line anti TB treatment. 
MUItidrug-resistant tuberculosis (MDR-TB) case: defined as TB caused by strains of 
Mycobacterium tuberculosis that are resistant to at least isoniazid and rifampicin. In this study, 
patients who are tested by Gene-X-pert and are positive for rifampicin resistant TB will be also 
classified as MDR-TB (because more than 96% of rifampicin resistance in Vietnam is also 
resistant to isoniazid). 
Index MDR-TB case: rifampicine resistant or MDR-TB patient who was diagnosed and enrolled 
to treatment by routine system. 
Household contact: all household members of the MDR-TB patients, including children who 
should have been in the household at .least 4 hours a day, for at least 14 days, or a cumulative 
total average e!l{posure of at least 8 hours per week for at least 8 weeks during 3 months Jeading 
up to the time of TB diagnosis. 
Close contact: any individual apart from household members who also have frequent and 
prolonged contact with the MDR-TB patients (i) in in-house environment during 3 months 
leading up to the time of TB diagnosis, (ii) spend at least 4 hours a day, for at least 14 days, or a 
cumulative total average exposure of at least 8 hours per week for at least 8 weeks together with 
the patient in in-house environment. 
Mutual contact: a contact that is named by at least 2 confirmed MDR-TB patients. 
Mutual place: a place that is named by at least 2 confirmed MDR-TB patients. 
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High risk place: The in-house condition place where the MDR-TB index case spend an average 
of at spend at least 4 hours a day for at least 14 days, or a cumulative total average exposure of at 
least 8 hours per week for at least 8 weeks in 3 months prior MDR-TB diagnosis. 
Eligible place: includes mutual places and high-risk places. 
Eligible contact: Includes (i) household contacts, (ii) close contacts, (iii) mutual contacts, (iv) 
people who frequently visited the eligible places during 3 months leading up to MDR-TB 
diagnosis and found to be TB suspects by primary interview. 
5.2.4 Sample size 
It was estimated that one index MDR-TB case would have approximately 3 eligible contacts. It 
was expected that 75% of contacts will be screened. It was assumed that 10% of the contacts will 
be symptomatic of which 15% will have TB and 60% of TB will be MDR. Therefore, the yield 
of contact tracing by SNA to MDR-TB case detection for 100 index cases was estimated to be 
2.0% (2 cases per 100 index cases). The minimum sample size we needed in order to detect the 
estimated yield of active case fi~ding of 2 cases per 100 index cases with 95% CI significantly 
different from 0 is 100 as shown in table 5.1 
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Table 5-1. Sample size calculation. 
Index Estimated Contacts Expected point Estimated 95% confidence 
, 
patients eligible contacts with active estimate for limits 
recruited (n) enrolled (n)* TB (n)** proportion of lower Upper 
contacts with TB 
(%) *** 
200 600 4 2.0 0.6 5.0 
200 600 3 1.5 0.3 4.3 
100 300 3 3.0 0.6 8.5 
100 300 2 2.0 0.2 7.0 
100 300 1 1.0 0 5.5 
50 150 3 6.0 1.3 16.5 
50 150 2 4.0 0.4 l3.7 
50 150 1 2.0 0 10.6 
*Based on assumption of 3 contacts screened per index patient: ** Assumption for number of 
contacts diagnosed as active TB. *** Number of patients detected by SNA divided by number of 
index cases 
5.2.5 Data analysis 
All CRFs were collected, screened and entered into data entry platform using MS Access 
software (Microsoft Inc, USA). Data were then transferred to SPSS 16.0 for statistical analysis. 
MDR-TB detected among close contacts was calculated to compare to that from current passive 
case finding strategy. Descriptive statistics, including frequency, median, interquartile range 
(lQR), proportion and 95% confidence intervals (95% CIs), were performed where appropriate. 
The comparisons were tested statistically using Chi-Square test to' compare proportion. P-values 
(2-sided) below 0.05 were considered significant. 
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5.2.6 Qualitative assessment 
In July 2015, a one- day workshop was conducted among 26 key staff members who were 
involved in the study in order to obtain information on their experience in implementation of 
investigation among contacts of MDR-TB patients in Viet Nam. These include 18 doctors and 
assistant doctors at 18 district TB units, 5 study coordinators working at provincial TB 
programme who were involved in interviewing MDR-TB patients, supervisions for study 
implementation at district level, and 3 staff from the National TB Control Programme. All staff 
were invited to the workshop and were given a semi-structured questionnaire to be self-
completed by them. District TB staff were asked about the project progress at their location, list 
down key steps in the SOP on contact investigation of the research, identify challenges and 
propose solutions in contact investigation. After a break the moderator summarized key findings 
from the questionnaire, followed by an open discussion among all 26 staff to understand the 
problem they had when conducting contact investigation. After the workshop, the moderator 
reviewed and summarized key findings noted form the questionnaires. 
5.3 Results 
5.3.1 Characteristic of MDR-TB pMients (index cases) and their contacts. 
Characteristic of MDR-TB patients 
A total of 99 MDR-TB index cases were enrolled into the study including 77 and 22 patients 
diagnosed by Xpert MTBIRIF and Hain test, respectively. The majority of MDR-TB patients .. 
belong to the age group 35-54 years old. Male to female ratio was 3.5:1, and 4% (95% CI: 0.2%-
7.9%) ofMDR-TB cases were HIV positive. 
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Table 5-2. Characteristic of patients at baseline 
Characteristic n % 
, 
Total patients 
Age group 0- 14 years 0 0.0 
15 - 24 years 14 14.0 
25 - 34 years 15 15.0 
35 - 44·years 29 29.0 
45 - 54 years 23 23.0 
55 - 64 years 14 14.0 
65 year and above 5 5.0 
Median age 43 
. 
Mean age (sd) 42.3 (13.9) 
Gender Male 78 78.0 
Female 22 22.0 
. , .. 
HIV (+). 4 4.0 
Test results of patients at baseline 
Sp~hIm smear and chest X-ray were performed for 99 MDR-TB patients: 76/99 (76.8%; 95% 
CI:68.5%-85.1 %) had a smear- positive result. Approximately 30% of MDR-TB patients had 
evidence of cavity manifestation on chest X-ray (Table 5-3). 
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Table 5-3. Test results microscopic smear and chest Xray of MDR-TB index patients at 
enrollment. 
n 0/0 
Total smear taken 99 100.0 
Sputum smear 
Negative 23 23.2 
Positive 76 76.8 
Scatter 20 26.3 
Grade among 
smear positivea 1+ 33 43.4 
2+ 13 17.1 
3+ 10 13.2 
Total chest Xray taken 99 
Chest X-ray Cavity 32 32.3 
aBased on the International Union Against Tuberculosis and Lung Disease (IUATLD)-recommended 
grading of sputum smear microscopy results 
Ca~egories of MDR-TB patients 
More than 70% of MDR-TB patients were previously treated cases and non-converters of 
retreatment regimen with first line anti TB drugs. Only 14% of patients belonged to neW 
category (Table 5-4). 
Table 5-4. Categories of MDR-TB patients 
Patient category n 0/0 
New 14 14.1% 
Non-converters of first line drug for new cases 11 11.1% 
Non-converters of first line drug for retreatment cases 1 1.0% 
Previously treated cases 69 69.7% 
Others 4 4.0% 
Total 99 100.0% 
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5.3.2 Characteristics of contacts 
There were a total of 496 contacts of the 99 index MDR-TB patients. The number of contacts 
excluded from the study before conducting social network analysis was 79 (15.9%). Most 
excluded contacts composed of contacts who were not living in Hanoi and/or not met the index 
patients during 3 months up to the time of MDR-TB diagnosis. Characteristics of eligible 
contacts are described in Table 5-5. The identified 417 (84.1 %) contacts were eligible to enter 
the study, including: 292 (70%) household contacts and 125 (30%) non- household contacts. Of 
125 outside household contacts, one contact came from a high-risk places. The male-to-female 
ratio was approximately 1:0.8. Of 417 eligible contacts, 86 (20.6%) were children under 14 
years of age at the time of the identification. 
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Table 5-5. Characteristics of MDR-TB eligible contacts 
Characteristic n % 
Total contacts 417 
Age group 0- 14 years 86 20.6 
15 - 24 years 65 15.6 
25 - 34 years 65 15.6 
35 -44 years 67 16.1 
45 - 54 years 49 11.8 
55 - 64 years 50 12 
65 year and above 27 6.5 
Missing 8 1.9 
. 
Median age 32 
Mean age (sd) 34.0 (20.0) 
Gender Male 189 45.3 
Female 223 53.5 
Missing 5 1.2 
Type of contact Household contact 292 70 
Outside household contacts 125 30 
138 
Figure 5-2. Contacts of MDR-TB identified and participated in the screening 
I Total contacts, n=496 I 
, 
_I I Excluded contact, n=79 (15.9%) I 
I eligible contacts, n=417 (84.1%) 
Household Outside 
contacts, household 
n=292 (70%) contacts, 
n=125 (30%) 
I n=248 (84.9%) ! First n=77 (61.6%) 
screening 
n=325 (77.9%) 
I n=127 (43.5%) I Second n=33 (26.4%) 
screening 
n=160 (38.4%) 
5.3.3 Screening practices 
Of the recruited 417 contacts, 325 (77.9%) contacts participated in the first screening. The 
household contacts and non-household contacts that participated in the first screening 
were248/292 (84.9%; 95%CI:80.8%-89.0%) and 77/125 (61.6%; 95%CI:53.1%-70.1%), 
respectively. Participation in the second screening among eligible contacts, household and 
outside household contacts was only 160/417(38.4%), 127/292 (43.5%; 95%CI: 37.8%-49.2%), 
and 33/125 (26.4%; 95%CI:18.7%-34.1 %), respectively (Figure 5-2). Among 412 eligible 
contacts, the participation of female contacts in the first screening was higher than for males, 
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186/223 (83.4%; 95%CI:78.5%-88.3%) versus135/189 (71.4%; 95%CI:65.0%-77.9%; Table 5· 
6). The proportion of contacts participating in the screening was significantly different between 
household contacts and non-household contacts (p-value =0.0001), as well as between female 
and male contacts (p-value=0.003). However, there was no difference (p-value =0.139)in the 
proportion of contacts participating in the screening by age groups (table 5·7). Results from the 
first screening showed that 36/325 (11.1 %) contacts interviewed were clinically assessed as 
presumed TB. 299 chest X-rays were performed and 12/299 (4.0%) contacts had an abnormal 
chest X-ray suggestive for TB. Xpert testing was provided to 48 presumed TB cases identified 
either by clinical assessment or by chest X-ray. We detected one TB case but not MDR-TB from 
the first active screening of contacts. 
We were able to assess 160 contacts during the second active screening (table 5-8). 11.3% were 
presumed TB by interview and 9/158 (5.7%) of chest X-rays taken had signs of TB. Xpert 
MTBIRIF testing detected one susceptible TB case. In addition, a two-year old baby, contact 
with his father, was diagnosed as TB meningitis but not by our study. This baby was not 
identified as presumed TB in the first screening. She was taken by her parents to the national 
pediatric hospital and not to the district coordinator when having fever, cough and loss of 
consciousness. She was diagnosed as meningitis combined with pulmonary TB and put on 
treatment regimen containing rifampicin (her parents described her red urine after drugs taken). 
She died after 1 month of admission. 
Table 5-6. Screening among contacts by gender 
Eligible Second 
contacts First screening screenmg 
Number 189 135 69 
Male % within gender 71.4% 36.5% 
Number 223 186 90 
Gender Female % within gender 83.4% 40.4% 
total 412 321 159 
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Table 5-7. Screening among contacts by age group 
Eligible First , Second 
contacts screening screening 
Age 0-14 Number 86 75 45 
group % within age 
group 87.2% 52.3% 
15-24 Number 65 53 16 
% within age 
group 81.5% 24.6% 
25-34 Number 65 51 27 
% within age 
group 78.5% 41.5% 
35-44 Number 67 51 31 
% within age 
group 76.1% 46.3% 
45-54 Number 49 32 14 
% within age 
group 65.3% 28.6% 
55-64 Number 50 40 18 
% within age ' , ' 
group 80.0% 36.0% 
65 Number 27 21 7 
above % within age 
group 77.8% 25.9% 
Total '409 323 158 
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Table 5-8. Screening among contacts by steps 
First active Second active Passive case 
Screening steps screening screening detection 
n % n % n % 
Interview N=325 N= 160 N=25 
Presumed TB by interview 36 11.1% 18 11.3% 6 24.0% 
CXR taken N=299 N= 158 N=4 
Abnormal CXR 12 4.0% 9 5.7% 0 0.0% 
GeneXpert taken N=48 N=27 N=6 
MTB, rifampicin susceptible 1 2.1% 0 0.0% 0 0.0% 
Rifampicin resistance 0 0.0% 0 0.0% 0 0.0% 
. 
MTB, unknown resistance (*) 0 0.0%· 0 0.0% 1 16.7% 
(*) Two -year old baby diagnosed as meningitis combined with pulmonary TB 
5.3.4 Social network analysis 
The median number of eligible contacts per index patient was 3· (lQR: 3-6). These median 
numbers among household and outside household contacts were 3 (IQR: 2--4) and 2 (lQR: 14), 
respectively. There were 35 places named by patients, of which 17 high-risk places identified to 
be screened. Only 1117 (5.9%) high-risk places had participation with the owners or employers to 
be investigated. There was one presumed MDR-TB case identified among 15 people screened 
who frequented the high-risk place. We found no mutual contact and no mutual place among 
MDR-TB cases. There were two TB cases detected among household contact (lD 19-00-03 and 
ID 77-00-01) and two pairs of index cases were found to be contacts of each other (diagnosed 
before study started: ID 03 and 04; ID 09 and 13) (Figure 5-3). 
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Figure 5-3. Social network of MDR-TB cases with identified links among index cases and 
TB cases detected among contacts . 
• 
e 
Index MDR-TB cases 
Contact case (with TB) 
Household contacts 
Contacts outside household 
.. High risk places: An internet cafe identified from index case 1004. Patients spent about 10 hours 
Per week during 3 months ,prior to MOR-TB diagnosis; Two beer restaurants (in-house condition) named 
by index case 1009. Patient spent about 1-2 hour per day per each restaurant for every day during 2 
rnonths prior to MOR-TB diagnosis 
5.3.5 Challenges and solutions for a successful.implementation of contact investigation 
among MDR-TB patients in Vietnam 
The questionnaire and discussion with healthcare workers involved in social network analysis 
revealed that patients' were often hesitant on being interviewed to give the information regarding 
their contacts. MDR-TB patients seemed not to want to reveal their contact's infonnation 
because they were afraid of being noticed as MDR-TB patients. Other issues were that some 
districts call contacts to come to the facility rather than going to the address themselves which 
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lead to a higher drop out rate. Also registering and managing many contacts was administratively 
a challenge for centers. Another finding was that often centers did make an appointment for the 
second screening at the first visit. Contacts were contacted later by telephone to make an 
appointment. However, this practice of indirect communication may have caused that contacts 
were not well informed about the message and resulted in drop outs for the second screening. 
Most of these issues occurred at the start of implementation and were resolved. Furthermore, it 
was often difficult to track the contacts as they were often 'too busy'. The most appropriate time 
to approach contacts was in the evening after work. Contacts were generally too busy to 
participate in the screening, probably as they already felt comforted by a negative result from the 
first screening. This was also considered by health staff as one reason that contacts were lost to 
follow up for the second screening. Additionally, many contacts could not found as wrong 
telephone number, inadequate or incorrect addresses were provided by the MDR-TB patients or 
some contacts moved to another place or changed their phone numbers. However, it waS 
mentioned by some health staff that some MDR-TB patients did help to find the correct contact 
details. 
It was also perceived there was a low awareness among contacts about TB and its transmission. 
Especially it was difficult to instruct for contacts with low level of education such as jobless 
people, or contacts belong to vulnerable groups such as drug users. Even information waS 
provided about the risk of being infected with MDR-TB, some contacts refused to be involved in 
the study due to still feeling healthy and did not believe there was a need for a health check. 
Others were afraid of being considered as a TB patients if they would go to a TB health clinic. 
Regarding high-risk places: generally restaurants did not agree or support to find contacts in their 
facilities. This was improved by the support from local authorities, involvement of local health 
facilities including staff working for food and hygiene programme to explain and persuade them 
to collaborate. It was then followed by local speaker to broadcast to call people who frequently 
visited the place during specific period to come for screening. The final issue was that 40% of 
the discussion participants found that social network analysis increased their workload. They 
regularly need to work after working hours or even in the weekend as health staff needed to 
spend extra time to go to the contact's home. 
5.4 Discussion 
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We implemented social network analysis to detect more MDR-TB cases. Enrolling 99 MDR-TB 
cases and their contacts did not reveal any new MDR-TB case. Links between MDR-TB cases 
were found in two instances but did not lead to detection of new cases. One potential case was 
missed (resistance testing pending) as the patient's parents did not report to the district 
coordinators when the child had symptoms suggestive for TB and they also did not inform the 
hospital doctor about the risk of MDR-TB. As a result, the child was treated as a susceptible TB 
case for one month until death. Utilization of Xpert MTBIRIF to early diagnose TB in children, 
especially diagnose meningitis and MDR-TB in health facility outside the NTP is highly 
recommended. This approach would be implemented either by setting up Xpert machine in those 
health facilities or by establishment a specimen referral mechanism to the NTP for diagnosis. 
Similar to TB patients in general, MDR-TB patients in this study were mainly distributed in 
working age category. The male-to-female ratio among MDR-TB patients in this study of 3.5:1 
was similar to the ratio among TB cases notified in Vietnam (3: 1), but lower than the ratio 
among TB cases detected in prevalence survey (5:1) [6]. The proportion MDR-TB with HIV 
positive was 4% which is less than that proportion (6%) in the whole country of Vietnam. 
However, the differeJ)ce was not statistically significant[3](Table 5-2). The proportion of smear 
positive among MDR-TB in the study (76.8%) was higher than that proportion (72.9%) among 
pulmonary TB patients notified in Vietnam in 2014. This may be explained by ~he current case 
finding strategy for MDR-TB that mainly focuses on smear positive TB cases (refer to chapter 2 
for more detail)[5]. The distribution of positivity grade among MDR-TB patients was similar to 
that proportion among TB cases detected in prevalence survey in Vietnam (unpublished data). 
While more than 50% of estimated MDR-TB patients among notified TB cases in Vietnam are 
new TB cases [3][19], the low proportion ofMDR-TB among new cases in this study reflect the 
limitation of current policy of Vietnam to focus on screening for MDR-TB among previously 
treated cases (refer to chapter 2 in this thesis for more detail). 
There was a drop out rate of 20.1 % of contact at the first screening more than 60% at the second 
screening. The participation rate among household contacts was higher than that among contacts 
outside the household, and also female contacts had a higher participation rate as compared to 
males. Participation of contacts outside the household was challenging to realize as they often 
refused to participate as was also revealed during the discussion. Health education about TB and 
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MDR-TB among the general population, especially for transmission among contacts ofMDR-TB 
should be more focused. Good communication skills of health staff is needed to improve the 
participant's participation. Better awareness and communication may also help to improve the 
participation of high-risk places to find potential contacts. 
Health education for MDR-TB patients on MDR-TB transmission among contacts would raise 
patient's awareness of protecting their relatives and friends or colleagues from being infected. As 
result, they may become willing to provide contact's information correctly and adequately. In 
our study, it was better to trace contacts by going to their home for the first time to provide 
necessary information and obtain informed consent, rather than do by telephone. This approach 
would expect to decrease the proportion of contacts lost to follow up. 
The fact that we found one potential pediatric case with TB meningitis who died reveals that a 
more awareness is needed among caregivers. In addition, there is a need to develop a system to 
record and manage the contacts of MDR-TB so that they would be well informed by the doctor 
to provide appropriate diagnostic testing and management. Regarding the preventive therapy for 
household ~ontacts or close contacts of TB who are under five years old, the WHO recommends 
to treat them as presumed latent TB infection (LTBI) according to WHO's guidelines in case 
active TB is excluded[20). However, at the moment, there is still controversy about whether 
preventive therapy should be provided to close contacts ofMDR-TB and it is not recommended 
to routinely treat them with second-line anti-TB drugs [2]. Due to the poor outcomes of existing 
treatment regimen for active MDR-TB, an effective preventive therapy forLTBI ofMDR-TB is 
considered as an important intervention to be explored, especially for children under five and 
HIV infected people[2]. 
Even though we did not find any new MDR-TB case through our social network analysis, this 
approach may still be worth consideration. Early detection and treatment of MDR-TB cases 
would prevent MDR-TB transmission from patients to others. Contacts of MDR-TB patients 
have high risk of getting TB infection from source patients~ therefore, investigation of TB among 
contacts ofa known or suspected cases ofMDR-TB is crucial to reduce the ongoing transmission 
of drug-resistant strains ofM. tuberculosis in a community[15][21]. Particularly family members 
of MDR-TB cases have been in close contacts with a highly infectious MDR-TB patient for a 
long duration due to long delays in MDR-TB treatment initiation. As such, the MDR-TB 
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prevalence among household contacts of MDR-TB patients is considered to be higher than TB 
prevalence among household contacts of drug-susceptible TB cases [2]. 
At this stage of the epidemic, when number of MDR-TB cases is still less than number of drug-
susceptible TB patients, it is possible to carry out contact investigation. However, it requires the 
program to build capacity for staff and make staff available for this task. 
Several studies have shown that active case finding among MDR-TB contacts face many 
challenges. MDR-TB patients may lost trust in TB treatment due to their experience in many 
failed TB treatment courses. Family member, learning from the experience, would likely to 
disagree to participate in screen and diagnosis program. They may even refuse to take MDR-TB 
treatment after being notified diagnosis result. While MDR-TB is curable, social barriers to 
MDR-TB treatment could be an important factor that needs to be taken into account when 
designing and implementing PMDT program[2]. 
Home visit by contact investigator is an effective method to interview and encourage household 
contacts to go under TB evaluation. By.visiting index patients and their household contacts, the 
investigator would be ~ble to observe, perform an environmental assessment, discuss and 
evaluate the risk of exposure, as well as to provide counseling to household contacts on 
symptoms suggestive of TB and when and where to seek for healthcare, and to provide social 
support [15]. 
The possible reason to explain why we found no new MDR-TB cases is that there could be a 
reduced fitness ofMDR-TB, which is an important aspect to consider in the risk of transmission. 
There have been number of studies on the fitness of MDR-TB conducted in animal models 
[22][23] or in laboratory using competitive fitness assays [24]. As such, these studies did not 
take into account the potential clinical, environmental, and socio-economic factors that influence 
the possibility to cause a second case of TB 'from an index patient. A prospective cohort 
household follow-up study in South Lima and Callao, Peru suggests that during the first 3 years 
of exposure, MDR-TB patients are less likely to transmit the disease to their contacts than drug-
susceptible tuberculosis patients[25]. This study implemented during 3 years following up 
household contacts, the TB incidence in household contacts of an MDR-TB index case is only 
about half that in household contacts of a drug-susceptible TB index case [25]. This finding 
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suggests a possible intervention to control MDR-TB. Additionally, in our study, the relative short 
time to follow up of 6 months may also explain why we did not detect any new case. It would 
take two-year follow up to find new cases due to the slow reactivation of latent tuberculosis 
infection after infection [26]. 
5.5 Conclusions 
In this study of nearly 100 MDR-TB index cases we were not able to find new MDR-TB cases 
using social network analysis within a follow-up period of 6 months. More staff resources may 
be needed and better communication skills and community awareness, collaboration of non NTP 
health facilities is needed to enhance participation and improve MDR-TB case detection. 
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Chapter 6. CONCLUSION 
Nearly half a million multi-drug resistant tuberculosis (MDR-TB and XDR-TB) cases emerge 
globally every year as a result of under investment in TB control, poor management of supply 
and quality of second line TB drugs, improper treatment, and the transmission of disease in 
crowded settings [1]. The Global Stop TB strategy (2006-2015) has identified MDR-TB as one 
challenge and therefore the framework for drug resistance is organized around five 
comprehensive components of DOTS strategy including sustained political commitment, rational 
case finding strategy, appropriate treatment strategy, uninterrupted supply of quality-assured 
anti-tuberculosis drugs, standardized recording and reporting system [2]. 
Vietnam is 14th among 27 MDR-TB high burden countries with an estimated about 5,100 MDR-
TB cases among notified TB cases per year [1]. Vietnam is also a country with confirmed XDR 
cases [3]. According to the result of the 4th National Drug resistance Survey (2005-2006), the 
proportion of MDR-TB in Vietnam is 4.0% among new cases and 23 % among previously 
treated cases [4]. Based on this result, the number ofMDR-TB estimated among new cases and 
previously treated cases are 3,000 and 2,100, respectively. The majority of MDR-TB founq 
among new cases in Viet Nam suggests an important source of tran·smission from MDR-TB to 
their contacts in the community. 
This thesis provides an understanding of the current situation ofMDRlXDR-TB in Vietnam and 
its control policies focusing on case finding strategy, targeting groups for MDR-TB screening. 
MDR-TB contacts, one of the high risk groups recommended by the WHO is also prioritized by 
studies to demonstrate the screening practice of household contacts, feasibility of contact 
investigation, and to identify challenges and solutions for a successful implementation of contact 
investigation among MDR-TB patients in Viet Nam. Below the key findings are presented. 
MDR-TB control policies and practices 
The first guideline initiated by WHO on Programmatic Management of Drug Resistant 
Tuberculosis was issued in 2006, following by three revision versions in 2008, 2011 and 
2014[1][5][6]. The guideline is intended as a useful tool to guide public health professionals to 
effectively manage MDR-TB program in country. These documents cover guidance on 
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implementation of case-finding, treatment regimens, monitoring the response to treatment, and 
selecting models of care for drug resistance tuberculosis. 
Since 2009, the programmatic management of drug resistant tuberculosis (PMDT) was piloted in 
Vietnam following the development of 2009 country MDR TB guideline. A year after WHO 
updated guideline disseminated, the country revised its guideline to be in line with WHO's 
recommendations and took into consideration the availability of capacity and resources. SOPs 
were developed following the issuance of national PMDT policies and a consultation with 
PMDT staff after a piloting period. The National TB Control Program has provided to provincial 
and district TB programme guidance and conducted training for their staff on policy and SOP 
implementation. PMDT has been rapidly scaled up in Viet Nam. Xpert MTB/RIF to test 
presumptive MDR-TB cases was introduced to the country one year after the 2011 WHO 
recommendation. However, lack of resources posed significant challenges for the NTP to 
implement their policy. Furthermore, often new guidelines or SOPs were not communicated well 
to the TB units and relevant staff resulting that staff do not which risk groups should be screened. 
Currently, the focus of MDR-TB screening is on certain high-risk groups rather than on new TB 
cases. There was delay in management of MDR-TB contacts, diagnosis of mono and poly 
resistant TB, as well as inadequate perfonnance of second-line DST to diagnose XDR-TB. 
Expansion of risk groups for MDR-TB screening is key to increasing the detection of MDR-TB 
cases. 
Detection of muItidrug resistant tuberculosis 
In 2013, among 5,065 estimated MDR-TB cases, only about 30 % was detected through the 
PMDT system. The possible reasons we identified were: (1) delay in fully rolling out PMDT 
policies and limited capacity of the system, mostly due to inadequate resources, (2) operational 
factors, and (3) neglecting high risk groups during' MDR-TB screening. 
The PMDT is more complex than for susceptible TB as it requires greater human, financial and 
technical resources. Viet Nam does not have a nation-wide PMDT coverage. Due to limited 
resources, Viet Nam PMDT policy gives priority to screen for MDR-TB among previou~ly 
treated patients. Additionally, PDMT staff was often not w~ll trained on the national policies 
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updated over time which have led to inadequate knowledge on policy implementation. There is a 
considerable delay in the development of SOPs, which took three years since implementing 
PMDT. Management of MDR-TB contacts and diagnosis of mono and poly resistant TB were 
delayed because of limited resources. Performance of second-line DST to diagnose XDR-TB has 
not been adequate. 
Our study found that only one third of MDR-TB presumptive cases are screened by Xpert 
MTBIRIF in Vietnam. Although Xpert MTBIRIF testing was available in PMDT provinces, the 
system for transferring specimens for Xpert MTBIRIF testing generally was not adequate. For 
some periods, Xpert MTBIRIF test kits were stocked out. Distribution of Xpert MTBIRIF 
instruments has not yet based on workload of the health facilities. 
The program has neglected to screen MDR-TB among new TB patients whose sputum had not 
converted after 2 or 3 months of treatment and TB patients with HIV. Those tested for MDR-TB 
were 340/3,224 (10.5%) ofTB-HIV co-infected patients and 290/2,214 (13.1%) of patients who 
remained sputum smear-positive after 2 and 3 months of category I TB regimen. These groupS 
account for the majority of presumptive MDR-TB cases. 
In order to be able to detect more MDR-TB cases, Xpert MTBIRIF should be more easily 
accessible for those at risk of MDR-TB. Currently, Xpert machines are located in provincial 
levels and the instrument's capacity is considered to be sufficient. Stock outs of testing kits have 
resulted in not being able to test for a period of time. An appropriate test kit procurement-supply 
management should be in place. Also the lack of a well functioning specimen referral system to 
send samples from district to provincial level has contributed to the low numbers of suspects 
being actually tested. This can be improved by involving a shipping agency in sample referral 
with good safety standards. This approach is considered not too costly and feasible to implement 
in Vietnam. Another way of increasing the accessibility of MDR-TB presumptive to Xpert 
testing is to provide more Xpert machines further down to district level. This approach can 
address the problem of sample referral system; However, it requires a huge resource to procure, 
operate and maintain for a large quantity of machines and not considered as suitable for Vietnam. 
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Enrollment for MDR-TB treatment 
Among 5,100 estimated MDR-TB cases, only 18.7% was diagnosed and provided with second-
line treatment. However, among those who were tested and detected WIth MDR-TB, it is 
encouraging that 95% of the patients were enrolled for treatment. 
One of the challenges we found in the regions with relatively high MDR-TB testing coverage 
(such as, North-East, North-West, Northern Central and Southern Central Coast) is the low 
treatment enrollment rate (0% - 27.3%) was still found where there was relative high testing 
proportion. This is partly due to insufficient hospitalization capacity to provide service to 
patients in their locality. Our qualitative study suggested that many patients refused to be 
referred to another treatment centre in another province either due to distance from hometown or 
additional costs without getting health insurance reimbursement. There was also a poor link 
between public and private sectors in regards to MDR-TB treatment. Temporary MDR-TB drug 
stock-out due to procurement and distribution delay resulted in patients either not enrolled for 
treatment or a delay in treatment 
Screening practices of household contacts of tuberculosis patients 
For most oJ the Vietnamese population, the NTP strategy relies on "passive case finding". 
Passive case finding needs people to self-report with TB symptoms to primary health centers, 
and are then screened by sputum smear. Our survey on screening practices of household contacts 
of smear positive TB patients (chapter 3) showed that the proportion of household contacts of 
smear-positive tuberculosis· patients screened for TB under the current passive screening 
approach of the Vietnam National TB program is very low compared with prevalence of TB 
among contacts in high burden countries, particularly for contacts under 5 years of age [7]. Of 
the 4,118 household contacts, 474 (11.5%) self-referred for TB screening, while this screening 
proportion was only 5.5% among contacts under 5 years old (16/293). Therefore, contact 
investigation should be conducted more actively and systematically, especially for close contacts 
of newly diagnosed TB patients, young children and contacts of drug-resistant TB. There is a 
need to establish a management system to follow up and screen for TB among close contacts of 
MDR-TB. Interestingly we found (chapter 4) that most TB cases from MDR household contacts 
are not MDR (they were screened within 1 year after MDR-TB patients diagnosed). This finding 
suggests that most MDR-TB is not easily transmitted and that contacts rather get TB from other 
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sources. We can not rule out that due to the relative short follow up time we may have missed 
MDR-TB cases. 
Actively tracing of close contacts of MDR-TB cases 
Although close contacts ofMDR-TB patients are recommended by the NTP of Viet Nam to be 
screened for MDR-TB [8], there is not yet a clear mechanism for contact tracing in Viet Nam. 
Household contacts are classified as a risk group but currently undergo a passive case finding 
approach. Data from our prevalence survey conducted in 2006-2007 showed that this existing 
passive case finding approach can only detect about 60% of patients, leading to the 
recommendation to conduct an active case finding approach in risk groups [9]. Our study on 
household contact investigation also shows a low proportion of contacts screened with a passive 
approach (Chapter 3) [10]. 
Traditional contact investigation of only household members is not sufficient to identify the 
transmission of MDR-TB and additional approaches are needed. Additional infonnation should 
be collected from MDR-TB patients regarding their contacts outside household and their 
residence and other sites where transmission might have occurred [11]. Social network Analysis 
(SNA) is a more comprehensive approach than traditional contact tracing which includes a set of 
persons (nodes) and the connections (ties) among them for analysis of structure of disease 
transmission[12]. Our study of SNA of nearly 100 MDR-TB index cases were not able to find 
new MDR-TB cases among 417 close contacts within a follow-up period of 6 months. The fact 
we found no new MDR-TB cases may be explained by reduced fitness of MDR-TB[13],' high 
drop out proportion and the short follow up time of our study of 6 months. Fitness of an 
organism refers to its ability to survive, reproduce and transmit from one host to the other. It is 
assumed that resistance can affect the essential function of an organism and cause a metabolic 
cost resulting in fitness cost. In this case, the resistant strain may be less fit than its sensitive 
ancestor organism [14][15]. However, fitness of some strains were not reduced after becoming 
resistant[l4][16]. This may be explained by adaptive mechanisms making the resistant variant 
maintain its fitness [17]. Bacterial fitness varies among members of species and depends on 
numerous factors. Some fitness characteristics of mycobacterium tuberculosis are measurable in 
the laboratory such as the culture growth rates [18][19], infectivity in animal experiments 
[20][21]. The ability to be disseminated can be ascertained by the prevalence of these strains in 
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the community. Although fitness cost is likely a result of MDR-TB [13][22], our study has no 
data on the strain characteristics of recruited MDR-TB patients, it is impossible to measure its 
fitness compared to susceptible isolates and warrants further investigations. ' 
Even though we did not find any new MDR-TB cases through our social network analysis, this 
approach may still be worth consideration. MDR-TB detected and treated early may prevent 
further transmission. Our study also revealed many difficulties to contact investigation. MDR-
TB patients' were often hesitant on being interviewed to give the information regarding their 
contacts. Participation of contacts outside the household was challenging to realize as they often 
refused to participate. Health education about TB and MDR-TB among the general population, 
especially for transmission among contacts of MDR-TB should be more focused. Good 
communication skills of health staffis needed to improve the participant's participation. 
Recommendations 
Based on this thesis we recommend the following: 
Standardize and decentralize training on PMDT; 
Provide NTP staff with updated inf9rmation on policy change and ensure this is received; 
Expand·capacity on MDR-TB treatment; this should also increase MDR-TB case finding; 
Expand ambulatory care of MDR-TB treatment; 
Expand risk group for MDR-TB screening; 
Strengthen case findings of MDR-TB by: 
o Provide information, educate close contacts ofMDR-TB patients, with special 
attention to children; 
o Conducting more research on how active contact investigations should be done to 
have the best yield. 
Allocate more resources to MDR-TB contr,ol, particularly well-trained staff. 
157 
References 
1. World Health Organization. Companion handbook to the WHO guidelines for the 
programmatic management of drug-resistant tuberculosis. Geneva, Switzerland:World Health 
Organization Document. 2014; WHOIHTMITB/20 14.11: 1-403 .. 
2. World Health Organization. The Global Plan to stop TB, 2011-2015, Transforming the Fight 
towards elimination of tuberculosis. Geneva, Switzerland: WHO, 2010 
3. World Health Organization. Multidrug and extensively drug-resistant TB (MIXDR-TB). 2010 
Global report on surveillance and response. Geneva, Switzerland:World Health Organization 
Document. 20 IO;WHOIHTMlTB/20 10.3. 
4. Nhung. N. V, Hoa.N. B, Sy.D. N, Hennig.C. M, Dean.A. S. The Fourth National Anti-
Tuberculosis Drug Resistance Survey in Viet Nam. Int J tuber Lung dis. 2015; 19(6): 670-5 
5. World Health Organization. Guidelines for the programmatic management of drug-resistant 
tuberculosis. Emergency update 2008. World Health Organization Document. 
2008; WHOIHTM/TB/2008.402: 1-247. 
6. W orId Health Organization. Guidelines for the programmatic management of drug-resistant 
tuberculosis. 2011 update. World Health Organization Document. 
... 
2011;WHOIHTMITB/2011.6:1-33. 
7. Rieder H L. Contacts of tuberculosis patients in high-incidence countries. Int J Tuberc Lung 
Dis 2003;7(suppI3):S333-S336 
8. National Tuberculosis Control Program of Vietnam: National Guidelines for ProgrammatiC 
Management of Drug Resistance Tuberculosis. Hanoi: Ministry of Health; 2009: 1-142. 
9. Hoa NB, Sy DN, Nhung NY, Tiermersma EW, Borgdorff MW, Cobelens FGJ. National 
survey of tuberculosis prevalence in Viet Nam. Bull World Health Organ. 2010;88:273-80. 
158 
10.Thuy Hoang Thi Thanh, Sy Dinh Ngoc, Nhung Nguyen Viet, Hung Nguyen Van, Peter 
Horby, Frank GJ Cobelens and Heiman FL Wertheim. A household survey on screening 
practices of household contacts of smear positive tuberculosis patients' in Vietnam. BMC 
Public Health 2014, 14:713 
11. World Health Organization. Recommendations for investigating contacts of persons with 
infectious tuberculosis in low- and middle-income countries. Geneva, Switzerland: World 
Health Organization Document. 2012.WHOIHTMlTB/2012.9 
12. V. J. Cook, L. Shah, M. Sc, E. Brodkin, S. Rempel, R. Moore, D. Ph, Y. Zhao, R. Holt, R. 
Varhol, I. Birol, M. Lem, M. K. Sharma, K. Elwood, S. J. M. Jones, F. S. L. Brinkman, R. C. 
Brunham, and P. Tang.Whole-Genome Sequencing and Social- Network Analysis of a 
Tuberculosis Outbreak. N. Engl. J. Med. 2011; 364:730-9. 
13. Gagneux S. Fitness cost of drug resistance in Mycobacterium tuberculosis. Clin Microbiol 
Infect. 2009; 15 (Suppll):6~8. doi: 1O.11111j.1469-0691.2008.02685. 
14. Gillespie, S. H,. McHugh, T. D .. The biological cost of antimicrobial resistance. ·Trends 
Microbiol., 1997; 5(9): 337-39. 
15. R. J. Shorten. The molecular epidemiology of Mycobacterium tuberculosis in north London. 
2011. http://discovery.ucl.ac.ukl1310448/ 
16. Bjorkman, J., Samuelsson, P., Andersson, D. I., Hughes, D. Novel ribosomal mutations 
affecting translational accuracy, antibiotic resistance and virulence of Salmonella 
typhimurium. Mo1.Microbiol; 1999.31 (1): 53-58. 
17. Andersson, D. I. Levin, B. R. The biological cost of antibiotic resistance. 
Curr.Opin.Microbiol; 1999; 2 (5): 489-93. 
18. Billington, O. 1., McHugh, T. D., Gillespie, S. H. Physiological cost ofrifampin resistance 
induced in vitro in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy; 
1999; 43 (8): 1866-69. 
19. Gagneux, S., Long, C. D., Small, P. M., Van, T;, Schoolnik, G. K., Bohannan, B. J. The 
competitive cost of antibiotic resistance in Mycobacterium tuberculosis. Science, 2006; 312 
159 
(5782): 1944-46. 
20. Heym, B., Stavropoulos, E., Honore, N., Domenech, P., Saint-Joanis, B., Wilson, T. M., 
Collins, D. M., Colston, M. J., Cole, S. T. Effects of overexpression of the alkyl 
hydroperoxide reductase AhpC on the virulence and isoniazid resistance of Mycobacterium 
tuberculosis. Infect.Immun. 1997.65 (4): 1395-1401. 
21. Li, Z., Kelley, C., Collins, F., Rouse, D., Morris, S. Expression ofkatG in Mycobacterium 
tuberculosis is associated with its growth and persistence in mice and guinea pigs. 
J.Infect.Dis., 1998; 177 (4): 1030-35. 
22. Grandjean, R. H. Gilman, L. Martin, E. Soto, B. Castro, S. Lopez, J. Coronel, E. Castillo, V. 
Alarcon, V. Lopez, A. San Miguel, N. Quispe, L. Asencios, C. Dye, and D. a 1. Moore. 
Transmission of Multidrug-Resistant and Drug-Susceptible Tuberculosis within Households: 
A Prospective Cohort Study. PLoS Med, 2015;12(6): elO01843. 
160 
Appendix 1. DEFINITION AND INTERVIE\V GUIDE 
Definition of presumptive MDR-TB case: 
Presumptive MDR-TB cases are individuals who are considered to be at high risk for MDR-
TB. Various MDR-TB risk groups are defined by the National Tubercl:llosis Programme. In 
2012, with the introduction of the Xpert MTBIRIF for MDR-TB diagnosis, the case findi,ng 
strategy was extensively discussed by the central PMDT task force. It was decided that MDR-
TB risk groups should include: retreatment cases (including relapse), treatment failure, 
treatment after default, HIV positive TB patients, and household contacts of MDR-TB cases, 
individuals who have a history of using TB drugs for more than 1 month. The following groups 
are considered as MDR-TB presumptive case: 
o Treatment after failure of Category I (for new TB cases) and/or Category II (for 
retreatment cases). Failure is defined as sputum smear positive at five months or 
later during treatment. 
o Relapse of Category I and/or Category II. Relapse is defined as a patient whose 
most recent treatment outcome was "cured" or "treatment completed", and who is 
subsequently diagnosed with bacteriologically positive TB by sputum smear 
microscopy or culture individuals that shares the same house with index TB cases 
including anyone staying in the house for at least 3 months leading up to the time of 
diagnosis of the index cases 
o Treatment after default of Category I and/or Category II. Default is defined as a 
patient who returns to treatment, bacteriologically positive by sputum smear 
microscopy or culture, following interruption of treatment for two or more 
consecutive months. 
o Other TB patients, including TB patients who were previously treated for TB in the 
private sector with unknown outcome, and/or patients who were diagnosed as smear 
negative in previous TB treatment course, but are currently smear positive. 
o TB patients whose sputum did not convert after 2 and 3 months of Category I 
regImen. 
o TB patients whose sputum did not convert after 3 months of Category II regimen. 
o Symptomatic individual who have contacts with a confirmed MDR-TB 
o A new TB patient (either smear positive or negative) who are infected with HIV 
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o TB suspects with history of using TB drugs for more than 1 month (not diagnosed 
as TB neither by the NTP nor by private sector and use any TB drugs for diseases 
other than TB) . 
Estimation of presumptive MDR-TB cases for special risk groups who are not notified to 
the NTP: 
o The number of symptomatic contacts: This estimation is applied for household 
contacts only. Currently, there is no clear mechanism for contact management in 
Vietnam and household contacts undergo a passive case finding approach; they are 
advised to seek help if symptomatic. It is estimated that one MDR-TB patients will 
have 4 household contacts on average [8]. Percentage of TB suspects among 
contacts (symptomatic contacts) is estimated at about 10% in the first year based on 
results from studies which showed about 5-12 % of suspects need to be examined to 
detect one TB case [9], and the TB prevalence among contacts at baseline waS 
734/100.000, incidence rate among contacts in the first year of exposure is about 
180/1 00.000[8] . 
o TB suspects with a history of using TB drugs for more than 1 month: Currently, 
there is no data on the number of individuals who have previously taken TB drugs 
for more than one mont~ to treat disease other than TB. However, this number is 
expected to be limited and estimated to be -2% of retreatment cases. 
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Calculation for the estimate number of MDR-TB cases to be detected per instrument per 
year 
Number of 
Estimated number Number of 
Ser. No Region MDR-TB/ 
ofMDR-TB GeneXpert 
machine/year 
1 Red river delta 627 9 
2 North-East 189 2 
3 North-West 9 1 
4 Northern Central 338 1 
5 Southern Central coast 304 3 
6 Central highland 21 
° 
NA 
7 South East 1,408 11 
8 Mekong delta 1,086 5 
Total 3,982 32 
Calculation of testing capacity for Xpert MTBIRIF instrument: 
Calculation is made based on the following assumptions: 
• One instrument has 4 modules, and 1 module can perform one test. 
• A test requires 2 hours for testing by Xpert MTB/RIF. 
• The machine can only be operated during working hours, which is about 7 working 
hours per 24 hours. It will not be operated in the weekend. 
70 
95 
9 
338 
101 
128 
217 
124 
• Therefore there can be a maximum 3 testing rounds per day. With 22 days per month 
the annual testing capacity is thus 3,168 tests. 
Assumed that the proportion of rifampicin resistance among tested MDR-TB presumptive 
cases is 17.6% (as shown in this study), it is estimated that there will be approximately 557 
rifampicin resistance TB patients among 3,168 MDR-TB presumptive cases tested. 
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. PMDT provinces participated in focus group discussion and in-depth interview 
N arne of PMDT province by region Number Focus In-depth 
of group interview 
provinces discussion 
Red River Delta region (Ha Noi, Hai 7 Group 1 1 province (Hai 
Phong, Vinh Phuc, Hai Duong, Hung Yen, Duong) 
Nam Dinh, Thai Binh 
North-East region (Thai Nguyen, Quang 3 Group 2 1 province 
Ninh, Bac Giang) (Quang Ninh) 
North-West regions (Dien Bien). 1 
Northern Central region (Thanh Hoa, 3 
Nghe An, Thua Thien Hue: 3 provinces) 
Southern Central Coast (Da Nang, Quang 4 Group 3 2 provinces (Da 
Nam, Binh Dinh, Khanh Hoa) Nang, Quang 
Central Highland (Lam Dong) 1 Nam) 
South-east (Ba ria Vung tau, Binh Thuan, 6 Group 4 4 provinces (Ba 
Dong Nai, Ninh Thuan, Tay Ninh, HCMC) ria Vung Tau, 
. 
Binh Thuan, 
Ninh Thuan, 
HCMC) 
Mekong River delta regions (An Giang, 10 Group 5 No 
Bac Lieu, Ben Tre, Ca Mau, Can Tho, 
Dong Thap, Kien Giang, Long An, Soc 
Trang, Tien Giang) 
Total 
35 5 4 
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INTERVIEW GUIDE 
1. Does your TB unit belong to a hospital or health center? 
2. If your TB unit belongs to health center, does the provincial TB program provide 
training for district hospital staff? If not, do you know why not? 
3. Can you name the MDR-TB risk groups (as many as you can)? 
4. Can you tell us why do you think they are at high risk for MDR-TB infection? How do' 
you define MDR-TB presumptives by risk group in your setting? What did you do 
when a MDR-TB presumptive defined? Probe for the following steps: 
(ii) Referring presumptive cases for diagnosis 
(iii) Drug resistance testing, 
(iv) Obtaining informed consent from patients for treatment, and 
(v) Enrollment of diagnosed MDR-TB patients to treatment. 
5. Can you describe the role of your unit in PMDT implementation, probe for the 
following steps: 
(i) Identification of presumptive MDR-TB cases (individuals considered at high risk for 
MDR- TB) according to case definitions 
(ii) Referring presumptive cases for diagnosis. 
(iii) Drug resistance testing 
(iv) Obtaining informed consent from patients for treatment, and 
(v) Enrollment of diagnosed MDR-TB patients to treatment. 
6. What are difficulties and challenges encountered for PMDT implementation in your 
setting? Probe for the following steps: 
(i) Identification of presumptive MDR-TB cases (individuals considered at high risk for 
MDR- TB) according to case definitions 
(ii) Referring presumptive cases for diagnosis 
(iii) Drug resistance testing 
(iv) Obtaining informed consent from patients for treatment, and 
(v) Enrollment of diagnosed MDR-TB patients to treatment. 
165 
7. How are policy changes infonned to you (by whom and by which way?) Did you get 
these changes infonned adequately? If not, what obstacles to get the policy changes 
infonned? 
8. What training topics provided? What was the quality of the training? What kind of 
training material was used? Do you think the trainings were adequate (fulfilled your 
needs) or not? If not, Why? 
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Appendix 2. OPERATIONAL DEFINITIONS 
MDR-TB presumptive: In this study, the MDR-TB presumptive referred to (i) any MDR-
TB contact (adults and adolescents) with clinical symptom suggested for TB orabnormal 
findings consistent with TB on the Chest X-ray (CXR). The most common symptom is a 
, 
productive cough for more than 2 weeks, which may be accompanied by other 
symptoms(shortness of breath, chest pains, haemoptysis) and/or constitutional symptoms (loss 
of appetite, weight loss, fever, night sweats, and fatigue), (ii) any children who was MDR-TB 
contact with one of the following: poor weight gain (failure to thrive), 2 weeks of fever or 
cough, abnormal findings consistent with TB on CXR, recent poor consciousness, enlarged 
cervical lymphadenopathy iii) any TB patients who were on current first line anti TB 
treatment. 
Confirmed tuberculosis. In this investigation, a case of tuberculosis includes (i) sputum smear 
examination positive for acid-fast bacilli (AFB), (ii)any specimen positive for Mycobacterium 
tuberculosis complex by either culture or molecular methods. 
MuItidrug-resistant tuberculosis (MDR-TB case): defined as TB caused by strains of 
Mycobacterium tuberculosis that are resistant to at least isoniazid and rifampicin. In this study, 
patients who are tested by Gene-X-pe~ and are positive for rifampicin resistant TB will be also 
classified as MDR-TB (because more than 96% of rifa,mpicin resistance in Vietnam is also 
resistant to isoniazid). 
Active case finding or active screening: Active effort by health workers to find TB cases III 
the community (among identified eligible contacts in this study) who do not seek consultations 
in health facilities. 
Passive case finding: Finding a case of tuberculosis from symptomatic patients who present 
themselves at the health facilities. 
Index MDR-TB case: the rifampicine resistant or MDR-TB patient who was diagnosed and 
enrolled to treatment by routine system. 
Household: includes all the persons who occupy a housing unit as their usual place of 
residence. A housing unit is a house, an apartment, a group of rooms, or a single room that is 
occupied by a single family, one person living alone, two or more families living together, or 
any other persons who share living arrangements. 
MDR-TB contact: anyone who spend time with MDR-TB patients either in household or in 
other in-house environment. 
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Household contact: all household members of the MDR-TB patients, including children who 
should have been in the household at least 4 hours a day, for at least 14 days, or a cumulative 
total average exposure of at least 8 hours per week for at least 8 weeks during 3 months leading 
up to the time of TB diagnosis. 
Close contact: any individual apart from household members who also have frequent and 
prolonged contact with the MDR-TB patients in in-house environment during 3 months leading 
up to the time of TB diagnosis. This may include friends, frequent visitors, work colleague, 
school/class mate, team club member who spend at least 4 hours a day, for at least 14 days, or 
a cumulative total average exposure of at least 8 hours per week for at least 8 weeks together 
with the patient in in-house environment. 
Mutual contact: a contact that is named by at least 2 confirmed MDR-TB patients. 
Mutual place: a place that is named by at least 2 confirmed MDR-TB patients. 
High risk place: The in-house condition place where the MDR-TB index case spend an 
average of at spend at least 4 hours a day for at least 14 days, or a cumulative total average 
exposure of at least 8 hours per week for at least 8 weeks in3 months prior MDR-TB diagnosis. 
Eligible place: includes mutual places and high risk places. 
Eligible contact: Includes (i) household contacts, (ii) close contacts, (iii) mutual contacts who 
have contact during 3 months leading up to the time of TB diagnosis for at least I patient (iv) 
people who frequently visited the eligible places during 3 months leading up to MDR-TB 
diagno~is and found to be TB suspects by primary interview. These contacts are eligible for 
both active screening and passive case detection. 
Categories of patients: 
• New: Patients who received no TB drugs or used them for less than one month 
• Non-converters of first line anti TB drugs for new cases: Patients whose sputum was 
not converted after 2 months of first line anti TB drugs treatment among new TB cases 
• Non-converters of first line anti TB drugs for retreatment cases: Patients whose sputum 
was not converted after 2 and/or 3 months of first line anti TB drugs treatment among 
retreatment TB cases 
• Previously treated cases: Includes relapsed cases, treatment failed cases, treatment after 
loss to follow-up cases 
• Others: includes TB patients who were previously treated for TB in the private sector 
with unknown outcome, and/or patients who were diagnosed as smear negative in 
previous TB treatment course, but are currently smear positive. 
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